US20230340091A1 - Antibodies for the treatment of synucleinopathies and neuroinflammation - Google Patents
Antibodies for the treatment of synucleinopathies and neuroinflammation Download PDFInfo
- Publication number
- US20230340091A1 US20230340091A1 US18/054,457 US202218054457A US2023340091A1 US 20230340091 A1 US20230340091 A1 US 20230340091A1 US 202218054457 A US202218054457 A US 202218054457A US 2023340091 A1 US2023340091 A1 US 2023340091A1
- Authority
- US
- United States
- Prior art keywords
- seq
- nucleotides
- antibody
- antigen
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000036110 Neuroinflammatory disease Diseases 0.000 title claims description 43
- 230000003959 neuroinflammation Effects 0.000 title claims description 39
- 238000011282 treatment Methods 0.000 title description 33
- 208000032859 Synucleinopathies Diseases 0.000 title description 20
- 230000027455 binding Effects 0.000 claims abstract description 197
- 239000000427 antigen Substances 0.000 claims abstract description 170
- 108091007433 antigens Proteins 0.000 claims abstract description 169
- 102000036639 antigens Human genes 0.000 claims abstract description 169
- 239000012634 fragment Substances 0.000 claims abstract description 168
- 238000000034 method Methods 0.000 claims abstract description 95
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 133
- 208000018737 Parkinson disease Diseases 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 61
- 125000003729 nucleotide group Chemical group 0.000 claims description 61
- 150000007523 nucleic acids Chemical group 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 102000040430 polynucleotide Human genes 0.000 claims description 30
- 239000000178 monomer Substances 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 28
- 201000002832 Lewy body dementia Diseases 0.000 claims description 21
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 230000004807 localization Effects 0.000 claims description 12
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 5
- 208000009144 Pure autonomic failure Diseases 0.000 claims description 4
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000003802 alpha-Synuclein Human genes 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 133
- 241000282414 Homo sapiens Species 0.000 description 93
- 150000001413 amino acids Chemical class 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 77
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 68
- 108090000623 proteins and genes Proteins 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 53
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 36
- 210000004556 brain Anatomy 0.000 description 36
- 239000013598 vector Substances 0.000 description 35
- 239000007924 injection Substances 0.000 description 33
- 238000002347 injection Methods 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 210000002569 neuron Anatomy 0.000 description 29
- 102000004127 Cytokines Human genes 0.000 description 27
- 108090000695 Cytokines Proteins 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 210000000274 microglia Anatomy 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 24
- 230000000770 proinflammatory effect Effects 0.000 description 24
- 229940080817 rotenone Drugs 0.000 description 24
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- 230000002776 aggregation Effects 0.000 description 16
- 238000004220 aggregation Methods 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
- 210000004558 lewy body Anatomy 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 108010002616 Interleukin-5 Proteins 0.000 description 14
- 102000000743 Interleukin-5 Human genes 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 229940100602 interleukin-5 Drugs 0.000 description 14
- 230000004770 neurodegeneration Effects 0.000 description 14
- 238000010899 nucleation Methods 0.000 description 14
- 230000007170 pathology Effects 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 230000006399 behavior Effects 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 238000004811 liquid chromatography Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 210000001577 neostriatum Anatomy 0.000 description 11
- 230000008506 pathogenesis Effects 0.000 description 11
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000007480 spreading Effects 0.000 description 10
- 238000003892 spreading Methods 0.000 description 10
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 10
- 210000001364 upper extremity Anatomy 0.000 description 10
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 102000019355 Synuclein Human genes 0.000 description 8
- 108050006783 Synuclein Proteins 0.000 description 8
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 8
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 8
- 230000006472 autoimmune response Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229960003130 interferon gamma Drugs 0.000 description 7
- 230000002232 neuromuscular Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010061296 Motor dysfunction Diseases 0.000 description 6
- 101000834887 Mus musculus Alpha-synuclein Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004700 cellular uptake Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000000384 rearing effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000012103 Alexa Fluor 488 Substances 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000003291 dopaminomimetic effect Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- -1 INFγ Proteins 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 101150088826 arg1 gene Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 230000004973 motor coordination Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 210000002243 primary neuron Anatomy 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241001573498 Compacta Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000003570 cell viability assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006720 chronic neuroinflammation Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000006999 cognitive decline Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 101100167135 Mus musculus Chil3 gene Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000021824 exploration behavior Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- 101000973239 Mus musculus Neurogranin Proteins 0.000 description 1
- 101500028998 Mus musculus Secretoneurin Proteins 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010052057 Neuroborreliosis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150110423 SNCA gene Proteins 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000005716 Subacute Combined Degeneration Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000033699 familial Guillain-Barre syndrome Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000017482 infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000007388 microgliosis Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000007642 neuronal ceroid lipofuscinosis 1 Diseases 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention in some embodiments thereof, relates to antibodies for the treatment of synucleinopathies and neuroinflammation.
- ⁇ -synucleinopathies Several neurodegenerative diseases, including Parkinson disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are associated with abnormal accumulation of ⁇ -synuclein ( ⁇ -syn) in the brain and hence are collectively termed “ ⁇ -synucleinopathies.” These diseases have distinct, as well as overlapping, features that seem to fall along a spectrum.
- PD the most common neurodegenerative movement disorder and the most common ⁇ -synucleinopathy
- PD has an estimated worldwide prevalence of 570 per 100,000 among people aged 50 and older, increasing with age.
- PD is clinically characterized by parkinsonism (i.e., bradykinesia, muscular rigidity, rest tremor, and postural and gait impairment), as well as non-motor features, including cognitive impairment, autonomic dysfunction, and rapid eye movement (REM) sleep behaviour disorder (RBD).
- parkinsonism i.e., bradykinesia, muscular rigidity, rest tremor, and postural and gait impairment
- non-motor features including cognitive impairment, autonomic dysfunction, and rapid eye movement (REM) sleep behaviour disorder (RBD).
- REM rapid eye movement
- Single gene mutations are a rare cause of PD.
- the etiology of sporadic PD remains unknown but probably involves the complex interplay of genetic and environmental factors.
- the pathology of PDD and DLB can be pure Lewy pathology with cortical Lewy bodies, or a mixed pathology with Lewy bodies, as well as amyloid- ⁇ plaques and neurofibrillary tangles.
- MSA is clinically characterized by autonomic dysfunction with parkinsonism or cerebellar symptoms.
- Lewy bodies can be seen in MSA, but the presence of ⁇ -syn aggregates in oligodendrocytes, called glial cytoplasmic inclusions, is a prerequisite for a definitive pathological diagnosis.
- There are additional neurodegenerative diseases with evident Lewy pathology including Gaucher disease and additional lysosomal storage disorders, a subset of neurodegeneration with brain iron accumulation (NBIA) disorders and AD.
- NBIA brain iron accumulation
- ⁇ -synuclein a protein of 140 amino acids that is ubiquitously expressed in neurons (Jakes et al. FEBS Lett.345:27-32(1994)).
- ⁇ -synuclein is intrinsically disordered in the cytosol; however it adopts an alpha-helical conformation when it becomes bound to cellular membranes (Burre et al.Nature.498:E4-E6(2013)).
- ⁇ -synuclein The normal function of ⁇ -synuclein is yet to be fully determined; however, it is thought to regulate neurotransmitter release (Burre et al.Science 329:1663-1667 (2010)) and can also be found in the cytosol and mitochondria (Chinta et al.Neurosci. Lett.486:235-239 (2010)). It has also been shown that ⁇ -synuclein can be secreted and transferred to nearby cells (Hansen et al.J. Clin. Invest.121:715-725(2011)), thus potentially facilitating spreading of Lewy pathology within the central nervous system (CNS) (Braak et al.Neurobiol Aging.24:197-211(2003)).
- CNS central nervous system
- ⁇ -synuclein presumably starts with a conformational shift of the monomeric protein, followed by the step-wise formation of larger multimeric protein species comprising toxic soluble oligomers and preformed fibrils (PFF).
- PFF toxic soluble oligomers and preformed fibrils
- Microglia are one of the major cell types involved in the inflammatory responses in the CNS that appear to contribute to neuroinflammation in PD pathogenesis.
- Positron emission tomography (PET) studies also suggest that there is significant activation of microglia in various regions of PD brains. This proinflammatory local state is evident by expression of tumor necrosis factor- ⁇ (TNF- ⁇ or TNFa), interleukin-1 ⁇ (IL-1 ⁇ ), and interferon-gamma (IFN- ⁇ ) in the midbrain of PD patients (Colonna and Butovsky, Annu Rev Immunol.35:441-468 (2017)). These findings strongly suggest the involvement of immune components in PD pathogenesis.
- TNF- ⁇ or TNFa tumor necrosis factor- ⁇
- IL-1 ⁇ interleukin-1 ⁇
- IFN- ⁇ interferon-gamma
- ⁇ -synuclein aggregates Activation of microglia by dying neurons or by various forms of ⁇ -syn as well as T cells could result in a vicious circle of neuroinflammation and neurodegeneration that is self-perpetuating and drives the progression of PD.
- Some of the substances liberated by degenerating neurons include ⁇ -synuclein aggregates, neuromelanin, adenosine triphosphate (ATP), and matrix metalloproteinase-3 (MMP-3) (Colonna and Butovsky 2017, supra).
- antibodies and antigen-binding fragments thereof that are capable of binding to alpha-synuclein and methods of making and using the same.
- an isolated antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a complementary determining region (CDR) H1 comprising the amino acid sequence set forth in SEQ ID NO:1 (GGSISSHY), a CDR H2 comprising the amino acid sequence set forth in SEQ ID NO:2 (IYDSGST), a CDR H3 comprising the amino acid sequence set forth in SEQ ID NO:3 (ARGAGWYRF), a CDR L1 comprising the amino acid sequence set forth in SEQ ID NO:4 (QSVLYSSNNKNY), a CDR2 L2 comprising the amino acid sequence set forth in SEQ ID NO:5 (WAS), and a CDR3 L3 comprising the amino acid sequence set forth in SEQ ID NO:6 (QQYYSTPRT).
- CDR H1 comprising the amino acid sequence set forth in SEQ ID NO:1
- IYDSGST amino acid sequence set forth in
- an isolated antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a CDR H1 comprising the amino acid sequence set forth in SEQ ID NO:50 (SHYWS), a CDR H2 comprising the amino acid sequence set forth in SEQ ID NO:51 (YIYDSGSTNYNPSLKS), a CDR H3 comprising the amino acid sequence set forth in SEQ ID NO:52 (GAGWYRF), a CDR L1 comprising the amino acid sequence set forth in SEQ ID NO:53 (KSSQSVLYSSNNKNYLA), a CDR2 L2 comprising the amino acid sequence set forth in SEQ ID NO:54 (WASTRES), and a CDR3 L3 comprising the amino acid sequence set forth in SEQ ID NO:55 (QQYYSTPRT).
- the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), wherein the VH comprises the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004. In one aspect, the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL), wherein the VL comprises the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a VH and a VL, wherein the VH comprises the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a VH and a VL, wherein the VL comprises the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 comprising the CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 amino acid sequences encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 comprising the CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 amino acid sequences of PMS209, PMS210, PMS211, PMS212, or PMS213.
- the CDRs are the Kabat-defined CDRs, the Chothia-defined CDRs, the AbM-defined CDRs, or the IMGT-defined CDRs.
- the antibody or antigen binding fragment thereof comprises a VH and a VL, wherein the VH comprises the mature form of the amino acid sequence set forth in SEQ ID NOs:21, 25, 29, 33, or 37; wherein the VL comprises the mature form of the amino acid sequence set forth in SEQ ID NOs:22, 26, 30, 34, or 38; or wherein the VH and VL comprise the mature forms of SEQ ID NOs:21 and 22, respectively, SEQ ID NOs:25 and 26, respectively, SEQ ID NOs:29 and 30, respectively, SEQ ID NOs: 33 and 34, respectively, or SEQ ID NOs:37 and 38, respectively.
- the antibody or antigen-binding fragment thereof is capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein with an affinity below 10 nM as measured by surface plasmon resonance.
- the alpha-synuclein is human alpha-synuclein. In one aspect, the alpha-synuclein is mouse alpha-synuclein.
- the antibody or antigen-binding fragment thereof is human, humanized, or chimeric.
- the antibody or antigen-binding fragment thereof is an IgG antibody.
- the IgG is an IgG1 or IgG4.
- the antibody is an antigen-binding fragment of an antibody.
- the fragment is selected from the group consisting of Fab, F(ab′)2, Fv, scFv, scFv-Fc, dsFv and a single domain molecule.
- the fragment is an scFv.
- the fragment is a Fab.
- the fragment is an intrabody.
- antigen-binding fragment is devoid of an Fc region.
- the antibody or antigen-binding fragment thereof comprises a VH and a VL on the same polypeptide chain.
- the linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO:47).
- the antibody or antigen-binding fragment thereof comprises the amino acid sequence of the mature form of SEQ ID NO:42 or 44.
- the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.
- an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.
- the antibody or antigen-binding fragment thereof is capable of inhibiting expression and/or secretion of pro-inflammatory cytokines from microglia cells incubated with misfolded alpha synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting uptake of misfolded alpha synuclein by macrophages. In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting T cell activation by misfolded alpha synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of preventing aggregation of alpha-synuclein as determined by Thioflavin T (ThT).
- Thioflavin T Thioflavin T
- the antibody or antigen-binding fragment thereof is capable of inhibiting seeding and spreading of alpha-synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of penetrating neurons, colocalizing with misfolded alpha synuclein, and/or attenuating consequent cellular toxicity. In one aspect, the antibody or antigen-binding fragment thereof is capable of ameliorating a motorical or physiological phenotype in a synucleinopathy mouse model.
- compositions comprising any antibody or antigen-binding fragment thereof provided herein and a carrier.
- the composition is a diagnostic composition.
- the composition is a therapeutic composition.
- the composition is a vaccine.
- isolated polynucleotides comprising a nucleic acid molecule encoding the heavy chain variable region or heavy chain of any antibody or antigen-binding fragment thereof provided herein.
- the isolated polynucleotide further comprises a nucleic acid molecule encoding the light chain variable region or light chain of the antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment thereof provided herein.
- the nucleic acid molecule encodes a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of SEQ ID NOs:21, 25, 29, 33, or 37.
- the nucleic acid molecule comprises the VH-encoding polynucleotide sequence of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NOs: 19, 23, 27, 31, or35.
- isolated polynucleotides comprising a nucleic acid molecule encoding the light chain variable region or light chain of any antibody or antigen-binding fragment thereof provided herein.
- the nucleic acid molecule encodes a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of SEQ ID NOs:22, 26, 30, 34, or 28.
- the nucleic acid molecule comprises the VL-encoding polynucleotide sequence of ATCC Deposit Designation PTA-125004or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of any of SEQ ID NOs:20, 24, 28, 32, or 36.
- isolated vectors comprising any polynucleotide provided herein.
- the polynucleotide is operably linked to a cis-acting regulatory element.
- the vector comprises a promoter sequence for driving expression of the polynucleotide and/or an internal ribosome entry site (IRES).
- the vector is a viral vector.
- the viral vector is an adenoviral vector, an adeno associated viral vector (AAV), or a lentiviral vector.
- the AAV is AAV9, AAV8, AAV7, AAV6, AAV5, AAV2, or AAV8-DJ.
- host cells comprising any polynucleotide provided herein, any vector provided herein, or a combination of vectors comprising polynucleotides provided herein.
- compositions comprising any antibody or antigen-binding fragment provided herein, any vector provided herein, or any cell provided herein.
- Also provided herein are methods of producing an anti-alpha synuclein antibody or antigen-binding fragment thereof comprising(a) culturing a cell provided herein in a cell culture under conditions which allow expression of said an alpha-synuclein antibody or antigen-binding fragment thereof; and (b) recovering the antibody or antigen-binding fragment thereof from said cell culture.
- anti-alpha synuclein antibodies or antigen-binding fragments thereof obtainable by the methods provided herein.
- Also provided herein are methods of treating or preventing a synucleinopathic disease in a subject comprising administering to the subject a therapeutically effective amount of any antibody or antigen-binding fragment thereof, composition, polynucleotide, vector, or cell provided herein, thereby treating or preventing the synucleinopathic disease.
- Also provided herein are methods of treating or preventing neuroinflammation in a subject comprising administering to the subject a therapeutically effective amount of any antibody or antigen-binding fragment thereof, composition, polynucleotide, vector, or cell provided herein, thereby treating or preventing the neuroinflammation.
- the administering is via an administration route selected from the group consisting of intranasal, intravenous, subcutaneous, and intrathecal.
- Also provided herein are method of diagnosing a synucleinopathic disease in a subject comprising (a) assessing the level, localization, conformation, or a combination thereof of misfolded alpha-synuclein in a subject to be diagnosed with any antibody or antigen-binding fragment thereof or composition provided herein; and (b) comparing the level, localization, conformation, or combination thereof of misfolded alpha-synuclein in the subject to one or more reference standards derived from one or more control samples, wherein a difference or similarity between the level, localization, conformation, or combination thereof of ⁇ -synuclein in the subject and the reference standard indicates whether the subject has a synucleinopathic disease.
- the synucleinopathic disease is Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple systems atrophy (MSA), a neurodegenerative disease with cerebral deposits of misfolded alpha-synuclein, or a combination thereof, optionally wherein neurodegenerative disease with cerebral deposits of misfolded alpha-synuclein is Alzheimer’s disease or frontotemportal dementia.
- PD Parkinson’s disease
- DLB dementia with Lewy bodies
- MSA multiple systems atrophy
- a neurodegenerative disease with cerebral deposits of misfolded alpha-synuclein is Alzheimer’s disease or frontotemportal dementia.
- the level, localization, conformation, or combination thereof of misfolded and monomeric alpha-synuclein in the subject is measured by in vivo imaging.
- the in vivo imaging comprises positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging or magnetic resonance imaging (MM).
- the subject is a mammal, optionally wherein the mammal is a human.
- Also provided herein are methods of detecting misfolded alpha-synuclein comprising (a) contacting a biological sample with any antibody or antigen-binding fragment thereof provided herein or any composition provided herein under conditions which allow formation of immunocomplexes; and (b) determining the presence and/or level of the immunocomplexes.
- the antibody or antigen-binding fragment thereof is attached to a heterologous detectable moiety.
- FIG. 1 is a bar graph of alpha-synuclein 42 positive Fab clone binders selected from a human scFv library: repertoire from over 110 individuals, diversity of 1 ⁇ 10 11 .
- FIG. 2 is a graph showing alpha-synuclein binding analysis by ELISA assay for 6 unique clones (Fab forms).
- FIG. 3 A shows nucleic acid sequences of the variable regions from heavy (VH) and light (VL) chains in PMS209.
- the VH leader sequence (ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCC AGCCGGCCATGGCC; SEQ ID NO:48) corresponds to nucleotides 1-66 of SEQ ID NO:19.
- the VL leader sequence (GTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCCTTTCTATTCTCACAGT GCA; SEQ ID NO:49) corresponds to nucleotides 1-57 of SEQ ID NO:20.
- the 6xHis-tag (CATCATCATCACCATCAC; SEQ ID NO:46) corresponds to nucleotides 754-771 of SEQ ID NO:19.
- the myc-tag (GAACAAAAACTCATCTCAGAAGAGGATCTG; SEQ ID NO:45) corresponds to nucleotides 781-810 of SEQ ID NO:19. CDR sequences are underlined.
- FIG. 3 B shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS210.
- the VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:23.
- the VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:24.
- the 6xHis-tag corresponds to nucleotides 730-747 of SEQ ID NO:23.
- the myc-tag corresponds to nucleotides 757-786 of SEQ ID NO:23.
- CDR sequences are underlined.
- FIG. 3 C shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS211.
- the VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:27.
- the VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:28.
- the 6xHis-tag corresponds to nucleotides 733-750 of SEQ ID NO:27.
- the myc-tag corresponds to nucleotides 760-789 of SEQ ID NO:27.
- CDR sequences are underlined.
- FIG. 3 D shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS212.
- the VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:31.
- the VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:32.
- the 6xHis-tag corresponds to nucleotides 742-759 of SEQ ID NO:31.
- the myc-tag corresponds to nucleotides 769-798 of SEQ ID NO:31.
- CDR sequences are underlined.
- FIG. 3 E shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS213.
- the VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:35.
- the VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:36.
- the 6xHis-tag corresponds to nucleotides 742-759 of SEQ ID NO:35.
- the myc-tag corresponds to nucleotides 769-798 of SEQ ID NO:35.
- CDR sequences are underlined.
- FIG. 3 F shows VH and VL amino acid sequences of PMS209.
- the VH leader sequence (MKYLLPTAAAGLLLLAAQPAMA; SEQ ID NO:40) corresponds to amino acids 1-22 of SEQ ID NO:21.
- the VL leader sequence (VKKLLFAIPLVVPFYSHSA; SEQ ID NO:39) corresponds to amino acids 1-20 of SEQ ID NO:22.
- the 6xHis-tag (HHHHHH; SEQ ID NO:18) corresponds to amino acids 252-257 of SEQ ID NO:21.
- the myc-tag (EQKLISEEDL; SEQ ID NO:17) corresponds to amino acids 261-270 of SEQ ID NO:21.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 3 G shows VH and VL amino acid sequences of PMS210.
- the VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:25.
- the VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:26.
- the 6xHis- corresponds to amino acids 244-249 of SEQ ID NO:25.
- the myc-tag corresponds to amino acids 253-262 of SEQ ID NO:25.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 3 H shows VH and VL amino acid sequences of PMS211.
- the VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:29.
- the VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:30.
- the 6xHis-tag corresponds to amino acids 245-250 of SEQ ID NO:29.
- the myc-tag corresponds to amino acids 254-263 of SEQ ID NO:29.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 3 I shows VH and VL amino acid sequences of PMS212.
- the VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:33.
- the VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:34.
- the 6xHis-tag corresponds to amino acids 248-253 of SEQ ID NO:33.
- the myc-tag corresponds to amino acids 257-266 of SEQ ID NO:33.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 3 J shows VH and VL amino acid sequences of PMS213.
- the VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:37.
- the VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:38.
- the 6xHis-tag corresponds to amino acids 248-253 of SEQ ID NO:37.
- the myc-tag corresponds to amino acids 257-266 of SEQ ID NO:37.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 4 A shows the nucleic acids sequence of PMS210 in full scFv-Fc format.
- the leader sequence (ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCGGCCCAGC; SEQ ID NO:16) corresponds to nucleotides 1-46 of SEQ ID NO:41.
- the VH sequence corresponds to nucleotides 52-705 of SEQ ID NO:41.
- the VL sequence corresponds to nucleotides 741-1,401 of SEQ ID NO:41.
- the linker (GGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGTGGTGGCAGC; SEQ ID NO:15) corresponds to nucleotides 706-750 of SEQ ID NO:41.
- the human IgG1 Fc tag corresponds to nucleotides 1,414-2,106 of SEQ ID NO:41. CDR sequences are underlined.
- FIG. 4 B shows the nucleic acids sequence of PMS212 in full scFv-Fc format.
- the leader sequence corresponds to nucleotides 1-46 of SEQ ID NO:43.
- the VH sequence corresponds to nucleotides 52-717 of SEQ ID NO:43.
- the VL sequence corresponds to nucleotides 763-1,410 of SEQ ID NO:43.
- the linker corresponds to nucleotides 718-762 of SEQ ID NO:43.
- the human IgG1 Fc tag corresponds to nucleotides 1,423-2,115 of SEQ ID NO:43. CDR sequences are underlined.
- FIG. 4 C shows amino acid sequence of PMS210 in full scFv-Fc format.
- the leader sequence (MKHLWFFLLLVAAAQPA; SEQ ID NO:14) corresponds to amino acids 1-17 of SEQ ID NO:42.
- the VH sequence corresponds to amino acids 18-235 of SEQ ID NO:42.
- the VL sequence corresponds to amino acids 251-467 of SEQ ID NO:42.
- the linker (GGGGSGGGGSGGGGS; SEQ ID NO:47) corresponds to amino acids 236-250 of SEQ ID NO:42.
- the human IgG1 Fc tag corresponds to amino acids 471-702 of SEQ ID NO:42.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 4 D shows amino acid sequences of PMS212 in full scFv-Fc format.
- the leader sequence corresponds to amino acids 1-17 of SEQ ID NO:44.
- the VH sequence corresponds to amino acids 18-239 of SEQ ID NO:44.
- the VL sequence corresponds to amino acids 255-470 of SEQ ID NO:42.
- the linker corresponds to amino acids 240-254 of SEQ ID NO:44.
- the human IgG1 Fc tag corresponds to amino acids 474-705 of SEQ ID NO:44.
- CDR sequences are underlined. Asterisk stands for a stop codon.
- FIG. 5 shows high affinity binding of scFv-Fc PMS208 to PFF versus monomers in ELISA assay.
- FIG. 6 shows high affinity binding of PMS208 (scFv form) to PFF and oligomers alpha synuclein in Surface Plasmon Resonance (Biacore). Association rate constant (Ka), dissociation rate constant (Kd) and affinity constant (KD) data are provided.
- Ka Association rate constant
- Kd dissociation rate constant
- KD affinity constant
- FIGS. 7 A and 7 B are images showing that PMS208 (scFv-Fc for immunoprecipitation) immunoprecipitates aSyn from PD patients sera ( FIG. 7 A ) or PD/DLB patients CSF ( FIG. 7 B ).
- FIG. 7 A Left panel - human alpha-synuclein staining using mouse monoclonal anti-human alpha-synuclein antibody ( ⁇ -syn clone Syn 204 #838201, Biolegend (previously Covance catalog #MMS-530R));
- FIG. 7 A Right Panel and FIG.
- FIGS. 8 A-C are bar graphs showing neuronal increase in viability mediated by PMS208 (scFv).
- PMS208 protects neuronal SH—SY5Y human cell line from ⁇ -syn PFF ( FIG. 8 A ), oligomers ( FIG. 8 B ), and human PD patient brain extracts ( FIG. 8 C ).
- the y-axis represents the relative increase in cell viability compared to PFF/oligomers/human PD brain extracts with no treatment (PBS), PMS208 treatment, and 80R scFv isotype treatment (sham).
- FIGS. 9 A and 9 B show Western blots of PMS208 binding to human striatum extracts from PD/control group patients ( FIG. 9 A ) and PMS208 binding to human cortex (CTX) and striatum (STR - right panels) extracts of DLB and control group (Ctrl) patients ( FIG. 9 B ).
- GAPDH as “housekeeping” protein loading control is shown in lower panels ( FIGS. 9 A and 9 B ).
- FIGS. 10 A-F are graphs showing that PMS208 attenuates neuroinflammation in human PBMCs ( FIGS. 10 A-C ) and mouse microglia BV2 cells ( FIGS. 10 D and 10 F ) induced by PFF and oligomers.
- PBMCs were activated with PFF ( FIG. 10 A ) and oligomers ( FIG. 10 B ) for 2.5 hours or 12 hours to measure TNFa at the protein and mRNA ( FIG. 10 C ) levels.
- PMS208 attenuates IL-6 mRNA levels ( FIG. 10 F ) as well as TNFa protein levels compared to PMS208-Fc ( FIGS.
- FIGS. 11 A-F are graphs showing that PMS208 attenuates uptake of fluorescent PFF (PFF-488) in mouse peritoneal macrophages ( FIG. 11 A ) and human PBMCs ( FIG. 11 B ) in a dose dependent manner.
- PMS208 FIGS. 11 C and 11 D
- PMS208 attenuates both PFF ( FIGS. 11 C and 11 E ) and oligomers ( FIGS. 12 D and F ) compared to PMS208-Fc ( FIGS. 11 E and 11 F ) in microglia cells (BV2).
- the y-axis represents the relative geometric mean (gMFI) measured by flow cytometry.
- FIGS. 12 A-D are graphs showing that PMS208 attenuates neuroinflammation in murine cortex of animals injected (striatum) with PFF ( FIGS. 12 A and 12 C ) and oligomers ( FIGS. 12 B and 12 D ).
- Real-time PCR was done in brain cortexes homogenates.
- the expression of TNFa, IL-6, IL-12, INF ⁇ , Caspase 3, Arg1, Chi313, and Mrc1 was determined by TaqMan real-time PCR in brain homogenates.
- the y-axis represents the fold-change in expression after PFF intrastriatal injections (with and without PMS208 treatment).
- FIGS. 13 A-C are graphs showing reactivity to ⁇ -syn toxic forms in patients with Parkinson’s disease as measured by the magnitude of autoimmune responses against ⁇ -syn PFF and oligomers as SFC (spot forming cells) per 10 5 PBMCs.
- FIGS. 13 A and 13 B show IL-5 responses
- FIG. 13 C shows IFN ⁇ responses of different PD patients.
- PMS208 manages to tune down the autoimmune response of T cells to ⁇ -syn pff and oligomers. Images are representative of a number of repeats in different PD patients.
- FIG. 14 is a graph showing kinetics for the formation of ⁇ -sheet-rich assemblies: human ⁇ -syn PFF incubated with PMS208 (7.5 ug/ml or 15 ug/ml) versus PBS (black solid line). Monomers (dotted line marked with triangles) were measured as baseline.
- FIG. 15 shows a Western blot following sequential extraction of neurons in 1% (vol/vol) TX-100 followed by SDS. Immunoblotting was performed using rabbit anti-rodent alpha-synuclein, an antibody that recognizes endogenous total ⁇ -syn (upper panel) and mouse anti-GAPDH (lower panel). In PFF-treated neurons, there was an increase in SDS-soluble ⁇ -syn (2% SDS) compared to PBS or PFF+PMS208 treated neurons (arrow).
- FIGS. 16 A and 16 B show that daily intraperitoneal rotenone elicits moderate weight loss and a parkinsonian phenotype that is alleviated by intranasal PMS208.
- 16 B shows the number of rears in rats was quantified (Rotenone + Sham,; Rotenone + PMS208; Vehicle + Sham).
- the animal had to raise forelimbs above shoulder level and make contact with the cylinder wall with either one or both forelimbs in order to be classified as a rear. Removal of both forelimbs from the cylinder wall and contact with the table surface was required before another. Animals were euthanized when severe parkinsonian symptoms developed. Mortality occurring immediately after the injection (in the absence of parkinsonian symptoms and typically ⁇ 10%) was excluded from analysis. *p ⁇ 0.05. Error bars represent standard error of the mean.
- FIGS. 17 A and 17 B show that PMS208 given intranasally (IN) attenuates motor dysfunction induced by intracerebral injections of adeno associated virus expressing human aSyn (AAV-aSyn) in rats.
- rAAV2/DJ vector-mediated ⁇ -synuclein overexpression in mouse SN leads to motor behaviour impairments.
- FIG. 17 A Neuromuscular strength was tested with the two limb wire hang test 6 weeks after injection. Each rat was tested three times and the top two results were used for analysis.
- FIG. 17 B Performance in the cylinder test of rAAV2/DJ- ⁇ -synuclein VS sham mice at 5-6 weeks after injection.
- n 7. *p ⁇ 0.05, **p ⁇ 0.01. Error bars represent standard error of the mean.
- FIGS. 18 A-C show that mouse alpha-synuclein PFF intrastriatal injections in mice leads to motor behavior and cognitive impairments.
- FIG. 18 A shows a neuromuscular strength assessment using a wire hang test performed at 12 weeks after injection.
- Mouse PFF injected group compared to sham and intranasal treatment groups (16, 80, 320 ug/kg) showed a significant reduction in average time of animals latency to fall. Each mouse was tested three times, and the top two results were used for analysis.
- FIG. 18 B demonstrates that the rotarod test performed at 12 weeks after injection showed a significant reduction in average time on the rotating rod for the mouse PFF injected group compared to the sham and intranasal treatment groups (16, 80, 320 ug/kg).
- FIG. 19 shows brain sections of animals injected with adeno-associated virus expressing human aSyn (AAV-aSyn) that develop extensive and significantly greater loss of TH + and dopaminergic (DA)neurons and the effect of PMS208 thereon.
- AAV-aSyn adeno-associated virus expressing human aSyn
- the present invention in some embodiments thereof, relates to antibodies and antigen-binding fragments thereof for the treatment of synucleinopathies and neuroinflammation.
- Alpha-synuclein plays a pivotal role in the pathogenesis of Parkinson’s Disease (PD) and other synucleinopathies.
- PD Parkinson’s Disease
- Two forms of ⁇ -syn are believed to promote neurotoxicity, spreading, and neuroinflammation; these are small molecular oligomers and preformed fibrils (PFF).
- the present inventors have searched for a biological agent that would target the small molecular oligomers and preformed fibrils of alpha-synuclein and be sufficiently small to facilitate effective entry to the brain without requiring high systemic dosages and avoiding non specific Fc portion-related immune-mediated effects.
- the present inventors have isolated from human phage display libraries of healthy individuals, a panel of Fabs, of which PMS208, was cloned into a single chain Fv.
- a plasmid encoding PMS208 was deposited with the American Type Culture Collection (ATCC), located at 10801 University Boulevard, Manassas, VA 20110 on March14, 2018, under the terms of the Budapest Treaty and has the ATCC® Deposit Designation PTA-125004.
- ATCC American Type Culture Collection
- This antibody fragment was selected based on a complex screening that included the following selection criteria: binding to native alpha-synuclein in patients’ sera, binding the denatured form of the protein as well as the native form (rendering it superior for both clinic and research), preventing recruitment of the immune system to the damaged area, reduction of neuro-inflammation, prevention of seeding and spreading, prevention of immune cells activation, prevention of alpha-synuclein aggregation (as determined by Thioflavin T (ThT), as well as disintegration of preformed aggregates and efficacy in vivo in animal models.
- Thioflavin T Thioflavin T
- the Fab was cloned into a smaller scFv format with successful retention of its affinity.
- PMS208 binds with high affinity both ⁇ -syn oligomers and PFF.
- PMS208 attenuates toxicity induced by both oligomers and PFF to human and murine neuronal cells and binds avidly to ⁇ -syn in brain extracts from PD patients.
- the scFv form of PMS208 down-regulates a panel of pro-inflammatory cytokines produced by microglia after exposure to oligomers and PFF, whereas Fc containing anti- ⁇ -syn antibodies up-regulate this same panel of proteins.
- Intranasal PMS208 administration attenuates motor dysfunction in a number of PD animal models in vivo, demonstrating that relatively low doses of PMS208 are required.
- the size of the scFv that still retains the high affinity is one sixth the size of an IgG, which explains its bioavailability and efficacy via the intranasal route (mainly via the olfactory nerve). This delivery mode reduces the need to achieve high systemic levels as is currently attempted with immunotherapy for neurodegenerative diseases.
- an isolated antibody comprising an antigen binding domain comprising CDR sequences which are N—C ordered:
- said antibody is capable of binding to soluble monomers, oligomers, and/ or preformed fibrils (PFF) of alpha-synuclein in an affinity that is below 10 nM, as determined by surface plasmon resonance.
- PFF preformed fibrils
- an isolated antibody comprising an antigen binding domain comprising CDR sequences which are N-C ordered:
- said antibody is capable of binding to soluble monomers, oligomers, and/or preformed fibrils (PFF) of alpha-synuclein in an affinity that is below 10 nM, as determined by surface plasmon resonance.
- PFF preformed fibrils
- the CDR sequences can be encoded by the following polynucleotide sequences.
- alpha-synuclein alpha-synuclein
- ⁇ -synuclein a-synuclein
- aSyn ⁇ Syn
- a-Syn a-Syn
- ⁇ -Syn ⁇ -Syn
- ⁇ -Syn alpha-synuclein
- ⁇ -Syn alpha-synuclein alpha
- alpha-synuclein include, e.g., SNCA, NACP, PARK1, PARK4, PD1, synuclein alpha. These terms include human alpha-synuclein as well as non-human alpha-synuclein. These terms also include soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein.
- human alpha-synuclein refers to the protein product of the SNCA gene with the UniProt identification P37840:
- non-human forms of the “alpha-synuclein” e.g., mouse alpha-synuclein to which an antibody or antigen-binding fragment thereof according to some embodiments of the invention (e.g., PMS208) can bind rendering it a pan-species antibody antigen-binding fragment that is very useful in research and pre-clinical studies.
- the molecular weight of human alpha-synuclein monomers is 14 kDa.
- Two or more alpha-synuclein monomers can aggregate and form soluble alpha-synuclein protofibrils/oligomers with a wide range of molecular weights.
- a dominating oligomer typically has a molecular weight of 28 kDa.
- Higher weight forms, e.g., 2000 kDa, are typically referred to as a preformed protofibril (PFF).
- PFF preformed protofibril
- oligomers are round and small, while PFFs are fibril shaped
- the weight can be determined by size exclusion chromatography and SDS-PAGE analysis (non-reduced or native).
- the oligomer is of the molecular weight of 14-84 kDa, as determined by electron microscopy and/or size exclusion chromatography.
- Preparation of higher orders of alpha-synuclein can be done by aldehyde induction for the preparation of oligomers.
- PFF can be induced by incubating monomers at 37° C. for 7 days at 1000 rpm.
- ⁇ -syn monomer in PBS, pH 7.4
- HNE 4-Hydroxynonenal 20 mg/ml
- DMSO DMSO
- Samples are incubated at 37° C. for 18 hours (h) and analyzed in SDS-PAGE, silver stain (manufacture protocol).
- Alpha-Syn adopts an extended conformation oligomeric form (spherical - monomers to hexamers), with dimers being the major species (SDS resistant).
- oligomers and PFF can overlap in the size but not in the structure (round vs. fibril)
- Each form can be produced by a different reaction (HNE or incubation in 37° C. for 7 days at 1000 rpm), which was verified with electron microscope and SDS-PAGE analysis.
- the antibody or antigen-binding fragment thereof binds the PFF in a higher affinity than to a-synuclein oligomers or even monomers. e.g., 0.67 nM PFF compared to 3.46 nM ( ⁇ 5 fold) oligomers as determined by SPA.
- higher affinity refers to an affinity which is at least 2-fold (e.g., 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9 and even 10 and above fold) higher (lower K D ).
- binding refers to an antibody-antigen mode of binding, which is generally, in the case of clinically relevant antibodies or antigen-binding fragments thereof, and in this case in the range of K D below 10 nM e.g., about 0.5-0.7 nM, e.g., 0.67 nM at the conditions described in the Examples section, as determined by Surface Plasmon Resonance assay (SPR), when binding to PFF, or 2-5 nM, e.g., 3.46 nM, when binding to the oligomers.
- SPR Surface Plasmon Resonance assay
- the affinity of the antibody or antigen-binding fragment to its antigen is determined by Surface Plasmon Resonance (SPR) using a captured or immobilized antigen.
- SPR Surface Plasmon Resonance
- the antigen is immobilized when the antibody or antigen-binding fragment (e.g., scFv) (table) is tested and in another embodiment the antibody or antigen-binding fragment (e.g., scFv-Fc) is immobilized and the antigen is in the solution.
- K D refers to the equilibrium dissociation constant between the antigen binding domain or the antibody or antigen-binding fragment thereof and its respective antigen.
- antibody means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
- a target such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
- the term “antibody” encompasses intact polyclonal antibodies, intact monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antibody, and any other modified immunoglobulin molecule so long as the antibodies exhibit the desired biological activity.
- An antibody can be of any the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively.
- the different classes of immunoglobulins have different and well known subunit structures and three-dimensional configurations.
- Antibodies can be naked or conjugated to other molecules such as toxins, radioisotopes, etc.
- antibody fragment refers to a portion of an intact antibody.
- An “antigen-binding fragment,” “antigen-binding domain,” or “antigen-binding region,” refers to a portion of an intact antibody that binds to an antigen.
- An antigen-binding fragment can contain an antigen recognition site of an intact antibody (e.g., complementarity determining regions (CDRs) sufficient to bind antigen).
- CDRs complementarity determining regions
- antigen-binding fragments of antibodies include, but are not limited to Fab, Fab′, F(ab′)2, and Fv fragments, linear antibodies, and single chain antibodies.
- An antigen-binding fragment of an antibody can be derived from any animal species, such as rodents (e.g., mouse, rat, or hamster) and humans or can be artificially produced.
- alpha-synuclein antibody and “antibody that binds to alpha-synuclein” refer to an antibody that is capable of binding alpha-synuclein (in soluble monomer, oligomer, and/or preformed fibril forms) with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting alpha-synuclein.
- the extent of binding of an alpha-synuclein antibody to an unrelated, non-alpha-synuclein protein can be less than about 10% of the binding of the antibody to alpha-synuclein as measured, e.g., by a radioimmunoassay (RIA).
- RIA radioimmunoassay
- the isotype of an antibody or antigen-binding fragment thereof is selected from IgG1, IgG2, IgG3, and IgG4, more particularly, IgG1 or IgG4. According to a specific embodiment, the isotype is IgG1.
- variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids or 110 to 125 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen.
- the variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR).
- CDRs complementarity determining regions
- FR framework regions
- VH and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody or antigen-binding fragment thereof.
- VL and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody or antigen-binding fragment thereof.
- polypeptides of an antibody or antigen-binding fragment thereof can be expressed with a leader sequence or signal sequence, which is cleaved during intracellular processing to produce a “mature” polypeptide.
- the “mature” forms of the polypeptides do not contain the leader or signal sequences.
- the “mature form” of the polypeptide of SEQ ID NO:21 comprises amino acids 23-274 of SEQ ID NO:21.
- CDR complementarity-determining region
- VH VH
- CDR H2 or H2 CDR H3 or H3
- VL VL
- the identity of the amino acid residues in a particular antibody or antigen-binding fragment thereof that make up a variable region or a CDR can be determined using methods well known in the art and include methods such as sequence variability as defined by Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C.), location of the structural loop regions as defined by Chothia et al.
- variable regions and “CDRs” may refer to variable regions and CDRs defined by any approach known in the art, including combinations of approaches.
- the antibody fragment is selected from the group consisting of single chain, F ab , F ab’ and F (ab’)2 fragments, Fv, dsFv, scFvs, diabodies, minibodies, nanobodies, F ab expression library or single domain molecules such as VH and VL that are capable of binding the antigen as described hereinabove.
- the antibody fragment is an intrabody.
- the intrabody can comprise an scFv and an intracellular trafficking signal.
- the antibody fragment is devoid of an Fc, which as shown in the Examples section attenuates (scFv) microglia cellular uptake of PFF ( FIG. 11 C ) and oligomers ( FIG. 11 D ) conjugated to Alexa fluor 488 ( FIGS. 12 C and 12 D ) in a dose dependent manner, whereas Fc containing antibodies do not ( FIGS. 12 E and 12 F ).
- the antibody fragment is a single chain Fv (scFv).
- the scFv comprises the amino acid sequence of the mature form of SEQ ID NO:42 or 44.
- the scFv comprises the scFv amino acid sequence encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof comprises six CDRs comprising the same amino acid sequences as the six CDRs encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof comprises a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof comprises a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- an antibody or antigen-binding fragment thereof comprises a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 and a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- the antibody fragment is a Fab.
- Antibody fragments according to some embodiments of the invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
- Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
- antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2.
- This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab’ monovalent fragments.
- a thiol reducing agent optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages
- an enzymatic cleavage using pepsin produces two monovalent Fab’ fragments and an Fc fragment directly.
- cleaving antibodies such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
- Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al., Proc. Nat′l Acad. Sci. USA 69:2659-62 (19720). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker.
- sFv single-chain antigen binding proteins
- the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
- a host cell such as E. coli.
- the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
- Methods for producing sFvs are described, for example, by Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, each of which is hereby incorporated by reference in its entirety.
- the antibody fragment is isolated from a library, e.g., a human library and hence no need for further humanization for therapeutic uses as further described herein below.
- the antibody is a fully human antibody.
- Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F (ab’)2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
- Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
- Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature , 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. , 2:593-596 (1992)).
- Fc immunoglobulin constant region
- a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and coworkers (Jones et al., Nature , 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science , 239:1534-1536 (1988)), by substituting rodent CDRs or other CDR sequences for the corresponding sequences of a human antibody.
- humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol. , 227:381 (1991); and Marks et al., J. Mol. Biol. , 222:581 (1991); see also the Examples section ).
- the techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol. , 147(1):86-95 (1991)).
- human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos.
- the antibody or an antigen-binding fragment thereof is an isolated antibody or antigen-binding fragment, i.e., not part of a library, or isolated from the physiological environment e.g., the human body.
- An antibody or antigen-binding fragment according to some embodiments of the invention is produced by recombinant DNA technology.
- an isolated polynucleotide comprising a nucleic acid sequence encoding the antibodies or antigen-binding fragments thereof as described herein (e.g., PMS208).
- the nucleic acid sequences encoding the CDRs are as set forth in SEQ ID NOs:7-12.
- Such CDRs can be cloned into suitable antibody or antigen-binding fragment configurations, while the encoded proteins (i.e., antibodies or antigen-binding fragments thereof) maintain their functions as described herein.
- nucleic acid sequences encoding the antibody or antigen-binding fragment thereof e.g., PMS208 are as set forth in SEQ ID NOs:7-12.
- the nucleic acid sequences encoding the CDRs encode CDRs with the same amino acid sequences as the CDRs encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- the nucleic acid sequences encoding the CDRs comprise the CDR-encoding nucleic acid sequences of the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VH encodes a VH with the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VL encodes a VL with the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VH and a VL encodes a VH with the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 and a VL with the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VH comprises the VH-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VL comprises the VL-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid sequence encoding a VH and VL comprises the VH-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004 and the VL-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- a nucleic acid encoding an scFv comprises the scFv-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- an expression vector comprising the polynucleotide operably linked to a cis- acting regulatory element.
- the nucleic acid construct (also referred to herein as an “expression vector”) of some embodiments of the invention includes additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors).
- typical cloning vectors may also contain a transcription and translation initiation sequence, transcription and translation terminator, and a polyadenylation signal.
- such constructs will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof.
- the nucleic acid construct of some embodiments of the invention typically includes a signal sequence for secretion or presentation of antibody or antigen-binding fragment thereof from a host cell in which it is placed.
- the signal sequence for this purpose is a mammalian signal sequence.
- the signal sequence can be cleaved to form a mature protein.
- a vector provided herein can contain a promoter (e.g., eukaryotic promoter), an enhancer, and/or a polyadenylation site.
- a promoter e.g., eukaryotic promoter
- the vector may or may not include a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the recombinant DNA integrates into the genome of the engineered cell, where the promoter directs expression of the desired nucleic acid.
- an anti-alpha-synuclein antibody or antigen-binding fragment thereof obtainable by the method, optionally wherein the antibody or antigen-binding fragment thereof has biological activities of some embodiments described herein.
- cells which comprise the polynucleotides/expression vectors as described herein.
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
- antibodies or antigen-binding fragments thereof may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N. J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli. After expression, the antibody or antigen-binding fragment thereof may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody or antigen-binding fragment-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody or antigen-binding fragment thereof with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
- Suitable host cells for the expression of glycosylated antibody or antigen-binding fragment thereof are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES.TM. technology for producing antibodies or antigen-binding fragments thereof in transgenic plants).
- Vertebrate cells may also be used as hosts.
- mammalian cell lines that are adapted to grow in suspension may be useful.
- Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
- monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells.
- Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR - CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
- the antibody or antigen-binding fragment thereof (e.g., scFv) can be isolated from the host cell or conditioned medium using methods which are well known in the art.
- the antibodies or antigen-binding fragments thereof e.g., scFvs
- scFvs antigen-binding fragments thereof described herein may be screened, selected or evaluated for their biological activity and optionally therapeutic potential in cell culture models and/or transgenic animal models for alpha-synuclein pathology.
- the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting expression and secretion of pro-inflammatory cytokines from microglia cells incubated with PFF.
- a “pro-inflammatory cytokine” refers to a type of signaling molecule (a cytokine) that is excreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation. They include interleukin-1 (IL-1), IL-5, IL-12, and IL-18, tumor necrosis factor (TNF), interferon gamma (IFN-gamma), and granulocyte-macrophage colony stimulating factor and play an important role in mediating the innate immune response. Inflammatory cytokines are predominately produced by and involved in the upregulation of inflammatory reactions. Dysregulation of pro-inflammatory and anti-inflammatory cytokines has also been linked to depression and other neurological diseases. A balance between proinflammatory and anti-inflammatory cytokines is necessary to maintain health.
- IL-1 interleukin-1
- TNF tumor necrosis factor
- IFN-gamma interferon gamma
- Pro-inflammatory cytokines and neuroinflammation are important not only in inflammatory responses but also in neurogenesis and neuroprotection. Sustained stress and the subsequent release of pro-inflammatory cytokines lead to chronic neuroinflammation, which contributes to a variety of medical conditions including but not limited to schizophrenia, depression and other medical conditions that are described herein below (under “Neuroinflammation”). Hippocampal glucocorticoid receptors (GRs) and the associated hypothalamus-pituitary-adrenal (HPA) axis have close interactions with pro-inflammatory cytokines and neuroinflammation. Elevated pro-inflammatory cytokine levels and GR functional resistance create a vicious cycle.
- GRs Hippocampal glucocorticoid receptors
- HPA hypothalamus-pituitary-adrenal
- chronic neuroinflammation inhibits GR function, which in turn exacerbates pro-inflammatory cytokine activity and aggravates chronic neuroinflammation.
- neuroinflammation causes an imbalance between oxidative stress and the antioxidant system, which is also associated with a variety of medical conditions.
- AD Alzheimer’s disease
- a ⁇ ⁇ -amyliod
- Activated microglia may play a potentially detrimental role by eliciting the expression of pro-inflammatory cytokines such as interleukin (IL)-1 ⁇ , IL-6, and tumor necrosis factor- ⁇ (TNF- ⁇ ; TNFa) influencing the surrounding brain tissue.
- pro-inflammatory cytokines such as interleukin (IL)-1 ⁇ , IL-6, and tumor necrosis factor- ⁇ (TNF- ⁇ ; TNFa) influencing the surrounding brain tissue.
- IL-1 ⁇ interleukin-1 ⁇
- IL-6 tumor necrosis factor- ⁇
- TNF- ⁇ tumor necrosis factor- ⁇
- the Examples section which follows describes an embodiment for analyzing the effect of an antibody or antigen-binding fragment thereof (e.g., scFv) on secretion of pro-inflammatory cytokines from microglia cells incubated with PFF, e.g., and Interferon- ⁇ (IFN ⁇ ) or interleukin-5 (IL-5) responses are measured by colour enzyme-linked immunospot (ELISPOT) assay, enabling quantification of responsive T cells.
- an antibody or antigen-binding fragment thereof e.g., scFv
- IFN ⁇ Interferon- ⁇
- IL-5 interleukin-5
- pro-inflammatory cytokines can be measured in vitro (Example 7 and Example 10) at the RNA or protein level and optionally or alternatively evaluated functionally in vivo in a relevant animal model (see e.g., Example 9).
- inhibiting refers to at least 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or complete inhibition in a biological function (e.g., in pro-inflammatory cytokines expression (e.g., mRNA) or secretion), as compared to a cell (e.g., microglia cell or a blood cell (e.g., PBMC)) untreated with the antibody or antigen-binding fragment thereof (e.g., scFv).
- a biological function e.g., in pro-inflammatory cytokines expression (e.g., mRNA) or secretion
- a cell e.g., microglia cell or a blood cell (e.g., PBMC)
- PBMC blood cell
- analysis or protein expression can be done at the RNA or protein level. Examples include, but are not limited to, RT-PCR, chromatography, electrophoretic methods, and immunodet
- inhibition of neuroinflammation is manifested by attenuating secretion of TNFa, IL6, IFN-gamma by microglia and PBMC and/or by reducing uptake of PFF to microglia and PBMC.
- inhibition of neuroinflammation is manifested by tuning down the autoimmune response of T cells to oligomers/PFF as evidenced by IL-5 and IFNg by e,g., Elispot.
- the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting uptake of PFF by macrophages or PBMC.
- the antibody or antigen-binding fragment thereof is capable of inhibiting alpha-synuclein oligo/PFF-specific helper T cell activation by PFF.
- IFN ⁇ was used as a representative cytokine to detect CD4 + T helper 1 (Th1) class II T cells, and IL-5 as a representative cytokine secreted by CD4 + T helper 2 (Th2) class II T cells.
- the antibody or antigen-binding fragment thereof e.g., scFv
- scFv is capable of inhibiting seeding and spreading of alpha-synuclein.
- ⁇ -synuclein presumably starts with a conformational shift of the monomeric protein, followed by the step-wise formation of larger multimeric protein species comprising toxic soluble oligomers and preformed fibrils (PFF).
- PFF toxic soluble oligomers and preformed fibrils
- the antibody or antigen-binding fragment thereof is capable of preventing aggregation of alpha-synuclein as determined by Thioflavin T (ThT).
- PFF monomeric protein or oligomers to high order aggregates
- the antibody or antigen-binding fragment thereof is capable of ameliorating a motorical or physiological phenotype in a synucleinopathy mouse model.
- Relevant disease models include, but are not limited to, the mouse synuclein PFF induced Parkinson’s disease, Adeno Associated Virus (AAV) transduced rats expressing human synuclein induced Parkinson’s disease and Rotenone induced Parkinson’s disease.
- AAV Adeno Associated Virus
- the clinical parameters include, but are not limited to, motoric functions: e.g., neuromuscular strength, forelimb asymmetry assessment, motor coordination and balance; behavioral functions e.g., exploratory behavior e.g., rearing; physiological parameters: e.g., body weight; and cognitive parameters: e.g., novel object recognition.
- motoric functions e.g., neuromuscular strength, forelimb asymmetry assessment, motor coordination and balance
- behavioral functions e.g., exploratory behavior e.g., rearing
- physiological parameters e.g., body weight
- cognitive parameters e.g., novel object recognition.
- the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG, e.g., by the covalent attachment of any type of molecule to the antibody or antigen-binding fragment thereof (e.g., scFv) such that covalent attachment does not prevent the antibody or antigen-binding fragment thereof (e.g., scFv) from specifically binding to its cognate epitope.
- an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG, e.g., by the covalent attachment of any type of molecule to the antibody or antigen-binding fragment thereof (e.g., scFv) such that co
- antibodies and antigen-binding fragments thereof can be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids. Methods of conjugation are further described herein below.
- antibodies or antigen-binding fragments thereof e.g., scFvs
- scFvs pathological forms of the alpha-synuclein
- PFF polypeptide-binding fragment-binding fragment-binding fragment-binding fragment-binding fragment-binding fragment-binding fragment-binding fragment-binding fragment-binding fragments thereof
- a method of detecting alpha-synuclein comprising:
- the antibody or antigen-binding fragment thereof e.g., scFv
- a detectable moiety or another antibody or antigen-binding fragment thereof or a secondary antibody or antigen-binding fragment thereof can be used dependent on the immunoassay that is being implemented e.g., ELISA, sandwich ELISA, immunohistochemistry e.g., on sections and more as the skilled artisan sees fit.
- detecting refers to the act of detecting, perceiving, uncovering, exposing, visualizing or identifying an aggregation state of alpha-synuclein.
- the precise method of detecting is dependent on the detectable moiety (also referred to herein as identifiable moiety) to which the antibody or antigen-binding fragment thereof (e.g., scFv) is attached.
- the above-mentioned detection method can be harnessed to the diagnosis of synucleinopathies.
- diagnosis refers to classifying a disease, determining a severity of a disease (grade or stage), monitoring progression, forecasting an outcome of the disease and/or prospects of recovery.
- the subject may be a healthy subject (e.g., human) undergoing a routine well-being check up.
- the subject may be at risk of the disease.
- the method can be used to monitor treatment efficacy.
- the method of the present invention is effected under conditions sufficient to form an immunocomplex (e.g. a complex between the antibodies or antigen-binding fragments (e.g., scFvs) of the present invention and the alpha-synuclein oligomers/PFF); such conditions (e.g., appropriate concentrations, buffers, temperatures, reaction times) as well as methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein.
- an immunocomplex e.g. a complex between the antibodies or antigen-binding fragments (e.g., scFvs) of the present invention and the alpha-synuclein oligomers/PFF
- such conditions e.g., appropriate concentrations, buffers, temperatures, reaction times
- methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein.
- a method of diagnosing a synucleinopathic disease in a subject comprising:
- the detection/diagnosis can be effected in-vitro on a biological sample.
- detection/diagnosis can be effected in-vivo.
- biological samples examples include, but are not limited to, blood, serum, plasma, CSF, brain tissue from biopsies/ urine and sputum).
- the selection of the detection method will much depend on the detectable moiety.
- determining a presence or level of the immunocomplex of the present invention is dependent on the detectable moiety to which the antibody or antigen-binding fragment thereof (e.g., scFv) is attached.
- detectable moieties examples include but are not limited to radioactive isotopes, phosphorescent chemicals, chemiluminescent chemicals, fluorescent chemicals, enzymes, fluorescent polypeptides and epitope tags.
- the detectable moiety can be a member of a binding pair, which is identifiable via its interaction with an additional member of the binding pair, and a label which is directly visualized.
- the member of the binding pair is an antigen which is identified by a corresponding labeled antibody.
- the label is a fluorescent protein or an enzyme producing a colorimetric reaction.
- detectable moieties include those detectable by Positron Emission Tomagraphy (PET) and Magnetic Resonance Imaging (MRI), all of which are well known to those of skill in the art.
- PET Positron Emission Tomagraphy
- MRI Magnetic Resonance Imaging
- the immunolabel i.e. the antibody or antigen-binding fragment thereof (e.g., scFv) conjugated to the detectable moiety
- the immunolabel can be produced by recombinant means or may be chemically synthesized by, for example, the stepwise addition of one or more amino acid residues in defined order using solid phase peptide synthetic techniques.
- polypeptide detectable moieties that can be linked to the antibodies of the present invention using recombinant DNA technology (in which the polynucleotide encoding the antibody is translationally fused to the detectable moiety) include fluorescent polypeptides, phosphorescent polypeptides, enzymes and epitope tags.
- a detectable moiety to the antibodies or antigen-binding fragments thereof (e.g., scFvs) provided herein can be effected using any suitable chemical linkage, direct or indirect, as via a peptide bond (when the detectable moiety is a polypeptide), or via covalent bonding to an intervening linker element, such as a linker peptide or other chemical moiety, such as an organic polymer.
- linker element such as a linker peptide or other chemical moiety, such as an organic polymer.
- Such chimeric peptides can be linked via bonding at the carboxy (C) or amino (N) termini of the peptides, or via bonding to internal chemical groups such as straight, branched or cyclic side chains, internal carbon or nitrogen atoms, and the like.
- modified peptides can be easily identified and prepared by one of ordinary skill in the art, using well known methods of peptide synthesis and/or covalent linkage of peptides.
- Description of fluorescent labeling of antibodies is provided in details in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110.
- the conjugates described herein can be prepared by known methods of linking antibodies with lipids, carbohydrates, protein, toxins, drugs or other atoms and molecules.
- the conjugate is formed by site-specific conjugation using a suitable linkage or bond. Site-specific conjugation is more likely to preserve the binding activity of the antibody or antigen-binding fragment thereof (e.g., scFv).
- the substance can be conjugate or attached at the hinge region of a reduced antigen binding construct via thioether bond formation.
- tyrosine conjugation can be employed.
- linkages or bonds used to form the conjugate can include, but are not limited to, a covalent bond, a non-covalent bond, a disulfide linkage, a hydrazone linkage, an ester linkage, an amido linkage, and amino linkage, an imino linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage and a carbon-carbon linkage.
- no cysteine or other linking aspect need be included in antibody (Bioconjugate Techniques (Third Edition) Author(s): Greg T. Hermanson ISBN: 978-0-12-382239-0).
- alpha-synuclein can be assessed by any suitable method known in the art comprising, e.g., analyzing alpha-synuclein by one or more techniques chosen from Western blot, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent activated cell sorting (FACS), two-dimensional gel electrophoresis, mass spectroscopy (MS), matrix-assisted laser desorption/ionization-time of flight-MS (MALDI-TOF), surface-enhanced laser desorption ionization-time of flight (SELDI-TOF), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), multidimensional liquid chromatography (LC) followed by tandem mass spectrometry (MS/MS), and laser densitometry.
- ELISA enzyme-linked immunosorbent assay
- RIA radioimmunoassay
- FACS fluorescent activated cell sorting
- MS mass spectroscopy
- composition comprising a biological sample of a subject diagnosed with a synucleinopathy (or being suspected as having the disease) and the antibody or antigen-binding fragment thereof (e.g., scFv) as described herein.
- the present methods can be used to classify the disease determining responsiveness to treatment, selecting treatment and determining disease outcome.
- the method further comprises informing the subject of the predicted diagnosis, treatment and/or the predicted prognosis of the subject.
- antibodies or antigen-binding fragments thereof e.g., scFv
- scFv antibodies or antigen-binding fragments thereof
- One or more polynucleotides encoding the antibodies or antigen-binding fragments thereof can also be used in therapeutics.
- a method of treating or preventing a synucleinopathic disease in a subject comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) (optionally devoid of an Fc), thereby treating or preventing the synucleinopathic disease.
- a therapeutically effective amount of the antibody or antigen-binding fragment thereof e.g., scFv
- the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof e.g., scFv
- a method of treating or preventing neuroinflammation in a subject comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) (not necessarily devoid of an Fc), thereby treating or preventing the neuroinflammation.
- a therapeutically effective amount of the antibody or antigen-binding fragment thereof e.g., scFv
- the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof e.g., scFv
- the antibody or antigen-binding fragment thereof is administered to the subject.
- one or more polynucleotides encoding the antibody or antigen-binding fragment thereof (e.g., scFv) are administered to the subject.
- the one or more polynucleotides can be contained in one or more vectors.
- the vectors can be, for example, viral vectors such as adenoviral vectors or lentiviral vectors.
- Synucleinopathic diseases or synucleinopathies are a diverse group of neurodegenerative disorders that share a common pathologic lesion composed of aggregates of insoluble alpha-synuclein protein in selectively vulnerable populations of neurons and glia. Thus, the hallmark is accumulation and/or deposition of alpha-synuclein in the brain and the central nervous system.
- These disorders include, but are not limited to, Parkinson’s disease (PD), Parkinson’s Disease Dementia (PDD), dementia with Lewy bodies (DLB), juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease), pure autonomic failure (PAF), multiple system atrophy (MSA) and neurodegeneration with brain iron accumulation type-1 (NBIA-I).
- Parkinson’s disease is an age-dependent neurodegenerative disease with unknown etiology. It is believed that sporadic Parkinson’s disease results from a combination of genetic vulnerability and environmental insults. It is further believed that Parkinson’s disease (PD), while triggered by disparate mechanisms follows a shared pathophysiologic pathway. One shared node is the involvement of alpha-synuclein. Linkage of this protein with Parkinson’s disease pathogenesis has been established by the identification of both point mutations and triplication of the gene in familial cases, the localization of alpha-synuclein to Lewy bodies, one of the hallmark pathological features of Parkinson’s disease, and the correlation of alpha-synuclein expression and disease pathology in neurotoxic models of Parkinson’s disease. Further evidence indicates that particular forms of alpha-synuclein (e.g., misfolded and alpha-synuclein bonded dopamine) are involved in sporadic disease.
- alpha-synuclein e.g
- neuroinflammatory disease or disorder refers to a medical condition that is manifested by inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity.
- neuroinflammatory diseases or disorders include, but not limited to, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Alzheimer’s Disease (AD), Traumatic Brain Injury (TBI), irritable bowel syndrome, schizophrenia, bipolar disorder, depression, anxiety (generalized anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder, dementia, autism spectrum disorder (autism, asperger’s disorder, pervasive developmental disorder, childhood disintegrative disorder), ataxia telangiectasia, Coackayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, spinocerebellare ataxia type 3, neuroborreliosis, primary lateral sclerosis, progressive supranuclear palsy, Schilder’s disease, subacute combined degeneration of spinal cord secondary to pernicious anemia, drug-induced demyelination, radiation induced demyelination, spinal muscular atrophy, tabes dorsales, spinal cord injury, chronic inflammatory
- subject in need thereof includes mammals, preferably human beings at any age which suffer from the pathology, i.e., synucleinopathy or neuroinflammation. According to a specific embodiment, this term encompasses individuals who are at risk to develop the pathology.
- non-Fc containing fragment and smallest (with lowest molecular weight) as possible antibody fragments for therapeutic purposes.
- the antibody or antigen-binding fragment thereof e.g., scFv
- the composition, the polynucleotide, the vector,or the cell comprising the antibody or antigen-binding fragment thereof e.g., scFv
- scFv antigen-binding fragment thereof
- a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
- the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- active ingredient refers to the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein accountable for the biological effect.
- scFv the antibody or antigen-binding fragment thereof
- the composition the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein accountable for the biological effect.
- physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- An adjuvant is included under these phrases.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.
- the administration route is intranasal.
- neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
- molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB
- pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers)
- the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).
- each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
- tissue refers to part of an organism consisting of cells designed to perform a function or functions. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
- compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., synucleinopathy) or prolong the survival of the subject being treated.
- active ingredients antibody or antigen-binding fragment thereof (e.g., scFv)
- the composition the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein
- a disorder e.g., synucleinopathy
- a pharmaceutical composition can be formulated as a vaccine, for example, if the pharmaceutical composition of the invention comprises an anti-alpha-synuclein antibody or antigen-binding fragment thereof (e.g., scFv), as described herein, for passive immunization.
- an anti-alpha-synuclein antibody or antigen-binding fragment thereof e.g., scFv
- oligomeric species of alpha-synuclein have been reported extracellularly in plasma and CSF (El-Agnaf et al., FASEB J.
- compositions of some aspects provided herein may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
- the pack may, for example, comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
- Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- certain aspects provided herein relate to the use of the alpha-synuclein antibody or antigen-binding fragment thereof, the polynucleotide, the vector, or the cell provided herein for the preparation of a pharmaceutical or diagnostic composition for prophylactic and therapeutic treatment of a synucleinopathic disease or neuroinflammation, monitoring the progression of a synucleinopathic disease or neuroinflammation or a response to a synucleinopathic disease treatment or neuroinflammation treatment in a subject or for determining a subject’s risk for developing a synucleinopathic disease or neuroinflammation.
- compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
- a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
- the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.
- method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- treating includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
- Tube was placed in a closed thermomixer (QSR technologies, U.S.A) at 37° C. incubation for 7d at 1000 rpm (solution should appear turbid). The solution was divided into aliquots (10-20 ⁇ l) into sterile microcentrifuge tubes and stored at -80° C. Before use, PFF was centrifuged at 100,000 ⁇ g, 4° C. for 60 min. The supernatant was removed and PFF was sonicated in new sterile PBS (20 % power 1 sec on 1 sec off in 60 sec total on (30 sec net on time)).
- ⁇ -syn monomer (2 mg/ml Alexotech, Sweden) (in PBS, pH 7.4) was mixed together with HNE (4-Hydroxynonenal) 20 mg/ml (in DMSO) in a low binding tube (Protein LoBind Tube 1.5, Eppendorf tubes, Cat no.: 022431081) for a final concentration of 140 ⁇ M ⁇ -syn and 4200 ⁇ M HNE, respectively. Samples were incubated at 37° C. for 18 h and analyzed in SDS-PAGE, silver stain (manufacture protocol).
- a 14 KDa form is the oligomer (aSyn adopts extended conformation oligomeric form (spherical - monomers to hexamers), with dimers being the major species (SDS resistant) and PFF Fibril forms (dimers and above). Of note, there can be an overlap in the size but not in the structure (fibril vs. round oligomers).
- the toxicity of a-syn fibrils was assessed by the MTT cell viability assay on differentiated human neuroblastoma SH-SY5Y cells.
- MTT assay cells were plated at a density of 10,000 cells per well on 96-well plates in 100 ⁇ l of culture medium per well. Following 24 h, the medium was exchanged with 100 ⁇ l of fresh medium containing 10 ⁇ M of retinoic acid (RA) for neuronal differentiation.
- RA retinoic acid
- Human PBMC’s, BV-2 (mouse microglia, ICLC ATL03001) and peritoneal mouse macrophages were split into 12 well culture plates (Greiner CELLSTAR multiwell culture plates) on the day before the experiment.
- 0.3 ⁇ M synuclein fibrils or oligomers conjugated with Alexa 488 pre-incubated with either 0.1, 0.5, 1.5, 3, 4 and 5 ⁇ g/ml PMS208 or PMS208-Fc for 30 min at room temperature, were added to cells with culture media (RPMI 1640, 10% FBS, 2 mM L-Glutamine, 1% Pen/Strep).
- the conditioned medium was also pre-incubated with PMS208 (without pff/oligomers) for 30 min as control. Cells were then incubated at 37° C. for 24 h and harvested. Flow cytometry (FL1 - blue laser (488 nm) was used to measure fibrils/oligomers (conjugated to ALEXA fluor 488) uptake indicated as relative geomean fluorescence intensity (gMFI). Cytochalasin D (Cyto D) is an antibiotic which is used to inhibit cellular uptake (control).
- Membrane was blocked for 1 hour with TBST/5% (wt/vol) milk, stained with diluted primary antibodies (mouse anti-human aSyn (clone Syn204, BioLegend) 1:1000, rabbit anti-rodent synuclein (D37A6, CellSignal) 1:1000, anti-GAPDH (clone 6C5, Millipore) 1:2000followed by secondary antibodies peroxidase-AffiniPure goat anti-mouse IgG (Jackson) 1:10000, mouse anti-rabbit IgG (Jackson)) 1:10000 TBS/1 % (wt/vol) BSA, incubated for additional 1 hour (both primary and secondary separately) while shaking and rinsed ⁇ 3 times (5 minutes each rinse) before enhanced chemiluminescence development.
- primary antibodies mouse anti-human aSyn (clone Syn204, BioLegend) 1:1000, rabbit anti-rodent synuclein (D37A6, CellSignal) 1:1000, anti-GAPDH (clo
- Membranes were analyzed by immunoblot for alpha-synuclein using mouse anti-human aSyn (clone Syn204, BioLegend-BLG838201; 1:1000) and mouse anti-aSyn phospho (Ser129) (clone P-syn/81A, BioLegend-BLG825701; 1:500) following peroxidase-AffiniPure goat anti-mouse IgG (Jackson; 1:10,000) before enhanced chemiluminescence development. 100 ng of recombinant human aSyn PFF and PBS were immunoprecipitated with 50 ⁇ g of PMS208-Fc bound to Dynabeads as positive and negative control respectively.
- mice C57BL/6JRccHsd background
- Rats Rats (Sprague-Dawley) were purchased from Envigo RMS (Israel), Ltd. All housing, breeding, and procedures were performed according to the National Institute of Health (NIH) Guide for the Care and Use of Experimental Animals and approved by the Kaplan Medical Center Institutional Animal Care and Use Committee.
- NASH National Institute of Health
- Sprague-Dawley rats (225-250 g) were anesthetized with an intraperitoneal injection of ketamine hydrochloride (100 mg/kg) and xylazine (10 mg/kg), and stereotaxically injected with AAV- ⁇ Syn into the right hemisphere. Injections were made into the SN at the following coordinates: anteroposterior (AP), -5.3; mediolateral (ML), +1.7; dorsoventral (DV), -7.2;. Control animals received sterile PBS. Material was injected via a 10 ⁇ l Hamilton syringe at a rate of 0.3 ⁇ l per min with the needle in place (33G) for ⁇ 10 min at each target.
- AP anteroposterior
- ML mediolateral
- DV dorsoventral
- tissue were immediately frozen after removal and stored at -80° C. until used. CSF and blood serum was collected from all animals.
- the AAV2 vector was used to overexpress human wild-type ⁇ -syn, in which the expression of the transgene is driven by the human CMV promoter. A total of 8 ⁇ 10 8 IFU were injected per animal (6 ⁇ L per animal).
- the rotenone solution was first prepared as a 50 ⁇ stock in 100 % dimethylsulfoxide (DMSO) and diluted in olive oil, to obtain a final concentration of 1.5, 2, or 2.5 mg/mL rotenone in olive oil, 2 % DMSO. Vortexing the solution creates a stable emulsion of the DMSO containing rotenone and olive oil.
- the solution was made fresh 2-3 times/week and stored in an amber septa vial protected from light and inverted several times before each injection to eliminate the possibility of settling.
- the solution was administered at 1 mL/kg, and control animals received the vehicle only. Experimental groups were comprised of at least 4-10 animals. Rotenone was administered by increased doses (day 0, day 2, and day 6) once a day for 12 consecutive days.
- TH tyrosine hydroxylase
- pSyn phosphorylated ⁇ -syn
- PBMC Peripheral Blood Mononuclear Cells
- IL-6 and TNF-alpha (TNFa) protein levels in cells were detected using DuoSet Elisa assay (R&D System) following manufacturer protocol.
- the assay is done by culturing PBMCs for 14 days (dilution of 1:1 with medium supplemented with IL-2 each couple of days) with PFF/oligomers in order to stimulate helper and cytotoxic T cells and then to test whether a-Syn pff/oligomers were recognized by those cells.
- culturing of PBMCs for in vitro expansion was performed by incubating in RPMI (Biological Industries, Israel) supplemented with 5% human AB serum (Biological Industries, Israel), GlutaMAX (Gibco), and penicillin and streptomycin (Biological Industries, Israel) at 2 ⁇ 10 6 per ml in the presence of alpha-synuclein PFF/oligomers at 10 ⁇ g/ml. Every three days, 10 U/mlIL-2 in medium was added to the cultures. After 14 days, cultures were stimulated with 25 ⁇ g/ml fibrilized ⁇ -syn or 25 ⁇ g/ml oligomerized ⁇ -syn and the response was measured by IFN ⁇ and IL-5 ELISPOT.
- ELISPOT antibodies mouse anti- human IFN ⁇ (clone 1-D1K), mouse anti-human IL-5 (clone TRFK5), mouse anti-human IFN ⁇ -HRP (clone 7-B6-1), and mouse anti-human IL-5 biotinylated (clone 5A10) were all from Mabtech.
- mice 10-week old mice were injected with human a-syn PFF or oligomers into the striatum (with and without PMS208 treatment) to examine in vivo neuroinflammation.
- 72 hours post-intrastriatal injections animals were sacrificed, and brains were dissected and homogenized.
- RNA from whole brain and suspension cells was isolated using SV total RNA isolation system kit (Promega) or EZ-RNA Total RNA Isolation Kit (Biological Industries, Israel) respectively following the manufacturer’s protocol.
- Complementary DNA (cDNA) synthesis was carried out with qScript cDNA Synthesis Kit (Quanta bio) using 2 ⁇ g of total RNA as template.
- Cylinder test is a motor assessment of forelimb asymmetry. Rats were individually put into a glass cylinder (20 cm diameter, 34 cm height) and were video recorded for 5 minutes and until they touched the cylinder wall with their forelimbs 20 times. The recordings were analyzed by an investigator who was not aware of the identity of the rats. The data are presented as the following formula: (Left touch)/(Right touch+Left touch+Both touch).
- Neuromuscular strength was tested with a wire hang test. The mouse was placed on a wire mesh, waved gently so that the mouse gripped the wire, and then inverted. Latency to fall was recorded with a 15 minutes cut-off time.
- Neuromuscular strength was tested with a two limb wire hang test. The rat was placed on a wire string, waved gently so that the rat gripped the wire. Latency to fall was recorded with a 10 minutes cut-off time.
- the Ugo Basile 47650 - Mouse NG rotarod treadmill (Ugo Basile) was used to assess fine motor coordination and balance.
- Rotarod performance is measured on a rotating rod as the mice must walk forward to avoid falling off a continuously rotating cylinder (Carter et al. 1999; Jones and Roberts 1968).
- Pre-training consisted of 4 consecutive trials at low rotational speed of 20 rpm. Two trials were measured on a rod that accelerates from 0-50 rpm, and the average time on the rod for each mouse was used for data analysis. Time on the rod was used to assess fine motor coordination and balance.
- rats When placed in a clear cylinder, rats will engage in exploratory behavior, including rearing. During rearing behavior, the forelimbs will contact the wall of the cylinder.
- mice 24 hours before testing, all animals were habituated to the testing apparatus for 10 minutes (50 cm box, 40 cm high). The day after, animals were introduced to the objects: first, two identical objects were placed in the box, and mice were allowed to explore objects for 5 minutes. The same procedure continued until 5 mice were done. The entire phase for 5 mice lasted 30 minutes. Immediately after, these 5 mice were tested in the same order as before. Animals were introduced to two different objects, one familiar object and one novel object that the mice never encountered. Mice were allowed to explore objects for 5 minutes and then removed from the box. At all phases, after each mouse was removed from the box, the box was sterilized with alcohol. Sample and novel objects and their locations were counterbalanced across animals. Each trial was videotaped, and time and frequency spent with each object was measured using Noldus EthoVision XT 11.5 (Noldus information Technology, The Netherlands).
- a human Fab/scFv library with a repertoire from over 110 individuals and diversity of 1 ⁇ 10 11 was screened against recombinant modified human alpha-synuclein (PFF and oligomers). Use of this library allows for the identification of combinations of variable heavy and variable light chains that are not found together in any of the 110 individuals.
- High-affinity binders were selected by 3 rounds of bio-panning in which 42 positive clones were identified ( FIG. 1 ) and sequenced. From sequencing data, 6 clones were identified with unique variable regions. These 6 clones, named Fab 1 to Fab 6, were subsequently expressed in E. coli in large scale as a Fab antibody format (50 KDa). Following Nickel column purification, the Fabs were analyzed by SDS-gel, and their protein concentrations were determined.
- Fabs 1 (PMS208), 3 (PMS210), 4 (PMS211), and 5 (PMS212) bound to the coating protein in a concentration dependent manner.
- Fabs 2 (PMS209) and 6 (PMS213) did not show binding under these assay conditions.
- scFv-Fc Three selected unique clones (PMS208, PMS210 and PMS212) were cloned to a mammalian expression vector as a scFv conjugated to human IgG1 Fc format (scFv-Fc). GGGGS ⁇ 3(SEQ ID NO:47) linker was used to link between the variable regions from heavy (VH) and light (VL) chains ( FIG. 4 ).
- PMS208 showed high affinity binding to alpha-synuclein PFF’s and oligomers seen in surface Plasmon resonance (Biacore SPR system, GE Healthcare Life Sciences) and ELISA assays in scFv-Fc format ( FIGS. 6 and 7 ), to both human and mouse alpha-synuclein PFF/oligomers.
- surface Plasmon resonance Biacore SPR system, GE Healthcare Life Sciences
- ELISA assays in scFv-Fc format FIGS. 6 and 7
- mouse alpha-synuclein gene was cloned into a mammalian expression vector with his-tag, and HEK293T cells were transfected with the vector to express mouse synuclein his-tag protein and then purified in His-trap column (FPLC).
- FPLC His-trap column
- PMS208 was cloned and expressed as single chain variable fragments (scFv) with a molecular weight of 25 KDa.
- the GSSSS ⁇ 3 (SEQ ID NO:47) linker was used to link the variable regions from heavy (VH) and light (VL) chains.
- PMS208 was expressed with and without his-tag for tests.
- PD Parkinson’s Disease
- pS129 ⁇ -syn ⁇ -syn serine 129
- Phosphorylation at Ser129 can regulate ⁇ -syn fibril formation and enhance ⁇ -syn toxicity both in vitro and in vivo.
- trace levels of phosphorylated ⁇ -syn are detectable in normal brains, nearly all ⁇ -syn accumulated within Lewy bodies in Parkinson disease brains is phosphorylated on serine 129 (Ser-129).
- Phosphorylated ⁇ -syn can be secreted from neuronal cells and can be seen in the serum and CSF of PD patients.
- FIGS. 9 A-C The cytotoxicity of a-syn fibrils and oligomers was assessed on differentiated human neuroblastoma SH-SY5Y cells using the 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
- MTT 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide
- PMS208 scFv was able to bind avidly its target alpha-synuclein in a number of human brain (striatum, cortex) PD, DLB, and control extracts seen in Western blot staining ( FIGS. 10 A and 10 B ), demonstrating its ability to recognize modified forms of ⁇ -syn in multiple patients with synucleinopathies.
- PMS208 Attenuates Neuroinflammation Induced by Oligomers and PFF in Human PBMC’s and Microglia
- Microglia is one of the major cell types which are involved in the inflammatory responses in the central nervous system (CNS) that appear to contribute to neuroinflammation in PD pathogenesis.
- CNS central nervous system
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-1 ⁇ interleukin-1 ⁇
- IFN- ⁇ interferon-gamma
- the scFv form of PMS208 down-regulates (in a dose dependent manner) a panel of pro-inflammatory cytokines (TNF- ⁇ , IL-6) produced by microglia after exposure to PFF, whereas Fc containing anti-aSyn antibodies up-regulate these same panel of proteins ( FIGS. 11 E and 11 F ).
- Monocytes range from 10 - 30% of human PBMCs, these cells move into tissues throughout the body where they differentiate into macrophages and dendritic cells. They serve three main functions in the immune system: antigen presentation, phagocytosis, and cytokine production.
- FIGS. 11 A-C shows that PMS208 down-regulates (in a dose dependent manner) pro-inflammatory cytokine TNF- ⁇ produced by human peripheral blood macrophages after PFF or oligomers alpha-synuclein exposure compared to Fc containing anti-aSyn antibodies which up-regulate TNF- ⁇ mRNA and protein levels ( FIGS. 11 E and 11 F ).
- phagocytosis thereby facilitating clearance of debri. They can also serve as antigen presenting cells that promote T cell mediated cellular immunity. Recently, it has also been shown that PD patients exhibit a systemic autoimmune response to ⁇ -syn modified forms further attesting to the role of inflammation in the pathogenesis. Activation of microglia by dying neurons or by various forms of ⁇ -syn, as well as T cells, could result in a vicious circle of neuroinflammation and neurodegeneration that is self perpetuating and drives the progression of PD.
- FIGS. 11 A- 11 F Flow cytometry was used to measure PFF/oligomers conjugated to Alexa fluor 488 (PFF-488/Oligo-488) cellular uptake (calculated by relative geomean fluorescent intensity (gMFI)) ( FIGS. 11 A- 11 F ).
- FIGS. 11 C-F shows that PMS208 in scFv format attenuates mouse and human macrophages cellular uptake of PFF conjugated to Alexa fluor 488 (relative gMFI ⁇ 60) compared to cells with PBS treatment (relative gMFI ⁇ 590) seen in FIGS. 12 A and 12 B .
- FIGS. 11 C-F shows that PMS208 in scFv format attenuates mouse microglia cellular uptake of PFF ( FIG. 11 C ) and oligomers ( FIG. 11 D ) conjugated to Alexa fluor 488 ( FIGS. 11 C and 11 D ) in a dose dependent manner, whereas Fc containing antibodies does not ( FIGS. 11 E and 11 F ).
- mice were injected with human a-syn PFF into the striatum (with and without PMS208 treatment) to examine in vivo neuroinflammation.
- FIG. 12 A shows that PMS208 significantly down-regulates IL-6, IL-12, and INF ⁇ pro-inflammatory cytokines mRNA expression levels after PFF exposure.
- FIG. 12 B shows that PMS208 significantly down-regulates TNFa and INF ⁇ pro-inflammatory cytokines mRNA expression levels after oligomers exposure.
- FIG. 12 C shows that PMS208 significantly up-regulates Arg1 (Arginase 1) and Chi313 (Ym1) mRNA expression levels after PFF exposure.
- FIG. 12 D shows that PMS208 significantly up-regulates Arg1 and Chi313 mRNA expression levels after oligomers exposure.
- PMS208 Attenuates Neuroinflammation by Tuning Down the Autoimmune Response of T cells to Oligomers/PFF as Evident by IL-5 and IFN-g ELISpots.
- ⁇ -synuclein aggregated forms act as antigenic epitopes and drive helper and cytotoxic T cell responses in patients with Parkinson’s disease.
- HLA class I type and HLA class II responses were assayed.
- IFN ⁇ was used as a representative cytokine to detect CD8 + HLA class I and CD4 + T helper 1 (Th1) class II T cells
- IL-5 was used as a representative cytokine secreted by CD4 + T helper 2 (Th2) class II T cells.
- PBMCs Peripheral blood mononuclear cells
- PFF/oligomers at 10 ⁇ g/ml, diluted 1:1 every 3-4 days.
- ⁇ -synuclein PFF/oligomers 25 ⁇ g/ml
- PMS208 15 ⁇ g/ml
- IFN ⁇ Interferon- ⁇
- IL-5 interleukin-5
- Parkinson’s Disease is a progressive movement disorder which is characterized neuropathologically by the presence of intra-neuronal Lewy Bodies (LB) and Lewy Neurites (LN). Misfolded and aggregated alpha-synuclein (fibrillar alpha-synuclein) is major component of LB’s and LN’s.
- Misfolded proteins are rich in ⁇ -sheet structures with a high tendency to form long fibrillar aggregates known as amyloid deposits. ⁇ -structures are harder to degrade than ⁇ -helixes (main conformation of native proteins), which explains why amyloid deposits cannot be removed by the proteasome system.
- the aggregation of misfolded proteins is believed to occur when hydrophobic residues exposed at the surface of proteins interact with other misfolded proteins.
- Human recombinant alpha-synuclein monomers can be driven to aggregate by constant shaking (orbital shaker) 1000 rpm at 37′C for 7 days ( FIG. 14 ). As seen in FIG.
- PMS208 (aSyn+PMS208 7.5ug/ml and aSyn+PMS208 15ug/ml) has the ability to inhibit alpha-synuclein aggregation (measured by Thioflavin T aggregated protein staining assay), whereas alpha-synuclein without PMS208 (aSyn+PBS) aggregates.
- Alpha-synuclein monomers were measured at each time point for reference (monomer).
- Prion proteins propagate by auto-catalytic conversion of native, nonpathogenic forms of the protein expressed in several types of human cells, into misfolded pathological conformation.
- the pathological conformation is the primary infectious agent that propagates using a mechanism called “seeding/nucleation,” where misfolded pathological form of the protein acts like a seed that recruits and converts soluble protein into aggregates of native-nonpathogenic protein, which form polymers.
- seeding/nucleation a mechanism that recruits and converts soluble protein into aggregates of native-nonpathogenic protein, which form polymers.
- Synucleinopathies are typified by pathologically aggregated alpha-synuclein in specific neuronal (e.g., Parkinson’s Disease and Dementia with Lewy Bodies) or glial (e.g., Multiple System Atrophy) populations where cell loss occurs.
- neuronal e.g., Parkinson’s Disease and Dementia with Lewy Bodies
- glial e.g., Multiple System Atrophy
- rotenone administration affects many of the pathogenic pathways including: oxidative stress, alpha-synuclein phosphorylation and aggregation and Lewy pathology, DJ-1 acidification and translocation, proteasomal dysfunction and nigral iron accumulation.
- ⁇ -synuclein can be expressed in dopaminergic neurons of the SNpc for long periods of time (a cell population particularly vulnerable in PD).
- Expression of the human wild-type a-synuclein leads to progressive loss of dopaminergic neurons in the SNpc, and loss of dopamine terminals in the striatum. Showing significant defects in motor behavior.
- the rapid early loss of striatal dopamine function seen in the rAAV-a-synuclein model replicates the pattern seen in human disease.
- neuroinflammation is one of the most robust phenotypes found by rAAV-a-synuclein over-expression, and replicates many features seen in human PD. These changes include early activation of microglia, increased pro-inflammatory cytokine expression, increased adaptive and innate immune responses, and infiltration of lymphocytes before cell loss. This inflammatory induction is caused by over-expression of a-synuclein, and not the virus itself, because control mice injected with rAAV-green fluorescent protein (GFP) do not show neuroinflammatory responses. The increase in inflammation likely contributes to neurodegeneration. Thus, targeting signaling in the inflammatory pathway may provide a therapeutic target that can prevent the progression for PD.
- GFP rAAV-green fluorescent protein
- FIG. 17 A shows that 6-8 weeks post intra-striatal injections of rAAV-a-synuclein in rats, reduced their latency to fall (+ AAV-aSyn + PBS; ⁇ 3.5 sec) in a wire hang test compared to sham injected animals (- AAV-aSyn + PBS; ⁇ 15 sec).
- Intranasal repeated treatments of PMS208 (twice a week) in rats post intra-striatal injections of rAAV-a-synuclein were able to attenuate motor dysfunction by significantly increasing the animals latency to fall (+ AAV-aSyn + PMS208 (50 ug/kg); ⁇ 9:00sec).
- FIG. 17 B shows a decrease in left paw use of AAV-a-synuclein injected animals (+ AAV-aSyn + PBS) compared to sham (- AAV-aSyn + PBS; ⁇ 8% increase).
- PMS208 i.n. treatment (5ug/kg) was able to increase left paw use of AAV-a-synuclein injected animals (+ AAV-aSyn + PMS208; ⁇ 7%).
- Sonicated fibrils made from recombinant a-synuclein when added to primary cultured neurons or injected into the striatum or other brain areas, can produce robust formation of inclusions that resemble Lewy bodies and Lewy neurites found in diseased brains.
- this model of PFF injection allows investigation of the impact of misfolded ⁇ -synuclein on the neuronal function and consequent phenotypes, and determination of whether preventing inclusion formation can reverse these phenotypes.
- inducing inclusion formation with protein fibrils is advantageous because transgenic over-expression of human ⁇ -synuclein is not required.
- Inclusion formation occurs in neurons from hippocampus, cortex, and midbrain and other brain regions, and thus the impact of these aggregates on diverse neuronal populations can be examined. Regardless of the injection site, ⁇ -synuclein inclusions form at the injection site and appear in brain areas distant from the site of injection. In this model, defects occur well before any neuron death, suggesting that neuronal dysfunction emerges in response to abnormal ⁇ -synuclein very early before neurodegeneration begins. This is important in light of the development of novel techniques showing the presence of a-synuclein aggregates at a very early stage in brains of patients with PD and dementia with Lewy bodies.
- mice were evaluated for their latency to fall 12 weeks post intra-striatal mouse a-syn PFF injections. Wire hang was used to test neuromuscular strength. Animals injected with mouse PFF and i.n. treated with PBS ( FIG. 18 A ; + mouse PFF + PBS; ⁇ 8:30 min) had significantly lower latency than animals injected with PBS and treated i.n. with PBS used as control (- mouse PFF + PBS; ⁇ 12:00 min). PMS208 i.n.
- FIG. 18 C shows cognitive decline of mouse PFF injected animals (+ mouse PFF + PBS) compare to PBS injected controls (- mouse PFF + PBS) measured by their preference to a novel object. Above 50% ( FIG. 18 C ), animal preference is for the novel object (less cognitive decline).
- Intranasal treatment with PMS208 (+ mouse PFF + PMS208 (320 ug/kg); ⁇ 65%) significantly improved cognitive decline compare to untreated animals (+ mouse PFF + PBS; ⁇ 45%). The experiment was done in 50 animals, 10 animals per group (n 10).
- FIG. 19 shows that animals injected with adeno-associated virus expressing human aSyn (AAV-aSyn) develop extensive and significantly greater loss of TH + neurons in SN pars compacta (SNc) and striatum 6 weeks post injections as seen in tyrosine hydroxylase immunostaining of brain coronal slices ( FIG. 19 - middle panel; right hemisphere (RH)).
- PMS208 given intra-nassaly i.n. - twice a week
- decreases loss of TH + nigral neurons induced by AAV-aSyn in rats FIG. 19 - right panel.
- There is no loss of TH + neurons seen in sham injected animals 6 weeks post injections FIG. 19 - left panel.
- Human alpha-synuclein levels in coronal rat brain slices was confirmed by immunostaining.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application is a continuation of U.S. Application No. 17/255,776; § 371(c) Date: Dec. 23, 2020 which is a U.S. National Phase of International Application No. PCT/IB2019/055461, filed Jun. 27, 2019, which claims priority to U.S. Provisional Application No. 62/690,733, filed Jun. 27, 2018, each of which is herein incorporated by reference in its entirety.
- The content of the electronically submitted sequence listing (Name: 4143_0020002_Seqlisting_ST26; Size: 70,616 bytes; and Date of Creation: Nov. 4, 2022) is herein incorporated by reference in its entirety.
- The present invention, in some embodiments thereof, relates to antibodies for the treatment of synucleinopathies and neuroinflammation.
- Several neurodegenerative diseases, including Parkinson disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are associated with abnormal accumulation of α-synuclein (α-syn) in the brain and hence are collectively termed “α-synucleinopathies.” These diseases have distinct, as well as overlapping, features that seem to fall along a spectrum.
- PD, the most common neurodegenerative movement disorder and the most common α-synucleinopathy, has an estimated worldwide prevalence of 570 per 100,000 among people aged 50 and older, increasing with age. PD is clinically characterized by parkinsonism (i.e., bradykinesia, muscular rigidity, rest tremor, and postural and gait impairment), as well as non-motor features, including cognitive impairment, autonomic dysfunction, and rapid eye movement (REM) sleep behaviour disorder (RBD). Single gene mutations are a rare cause of PD. The etiology of sporadic PD remains unknown but probably involves the complex interplay of genetic and environmental factors. Irrespective of etiology, all cases of PD show loss of dopaminergic neurons in the substantia nigra pars compacta (SN), and most show Lewy pathology including Lewy bodies and Lewy neuritis. Histological examination of Lewy pathology shows that α-syn is the major component of the Lewy body. Thus, it has been suggested that downstream effects of α-syn are a principal factor in the pathogenesis.
- The pathology of PDD and DLB can be pure Lewy pathology with cortical Lewy bodies, or a mixed pathology with Lewy bodies, as well as amyloid-β plaques and neurofibrillary tangles. MSA is clinically characterized by autonomic dysfunction with parkinsonism or cerebellar symptoms. Lewy bodies can be seen in MSA, but the presence of α-syn aggregates in oligodendrocytes, called glial cytoplasmic inclusions, is a prerequisite for a definitive pathological diagnosis. There are additional neurodegenerative diseases with evident Lewy pathology including Gaucher disease and additional lysosomal storage disorders, a subset of neurodegeneration with brain iron accumulation (NBIA) disorders and AD.
- As mentioned, the principal component of the intracellular inclusions is α-synuclein, a protein of 140 amino acids that is ubiquitously expressed in neurons (Jakes et al. FEBS Lett.345:27-32(1994)). α-synuclein is intrinsically disordered in the cytosol; however it adopts an alpha-helical conformation when it becomes bound to cellular membranes (Burre et al.Nature.498:E4-E6(2013)). The normal function of α-synuclein is yet to be fully determined; however, it is thought to regulate neurotransmitter release (Burre et al.Science 329:1663-1667 (2010)) and can also be found in the cytosol and mitochondria (Chinta et al.Neurosci. Lett.486:235-239 (2010)). It has also been shown that α-synuclein can be secreted and transferred to nearby cells (Hansen et al.J. Clin. Invest.121:715-725(2011)), thus potentially facilitating spreading of Lewy pathology within the central nervous system (CNS) (Braak et al.Neurobiol Aging.24:197-211(2003)). The aggregation of α-synuclein presumably starts with a conformational shift of the monomeric protein, followed by the step-wise formation of larger multimeric protein species comprising toxic soluble oligomers and preformed fibrils (PFF). These forms are potential drivers of seeding of aggregated forms, which are taken up by neuronal cells and catalyze the conversion of alpha-synuclein soluble protein molecules into their aggregated forms and subsequent propagation culminating in widespread Lewy body pathology.
- Microglia are one of the major cell types involved in the inflammatory responses in the CNS that appear to contribute to neuroinflammation in PD pathogenesis. Positron emission tomography (PET) studies also suggest that there is significant activation of microglia in various regions of PD brains. This proinflammatory local state is evident by expression of tumor necrosis factor-α (TNF-α or TNFa), interleukin-1β (IL-1β), and interferon-gamma (IFN-γ) in the midbrain of PD patients (Colonna and Butovsky, Annu Rev Immunol.35:441-468 (2017)). These findings strongly suggest the involvement of immune components in PD pathogenesis.
- Recently, it has also been shown that PD patients exhibit a systemic autoimmune response to α-syn modified forms further attesting to the role of inflammation in the pathogenesis.
- Activation of microglia by dying neurons or by various forms of α-syn as well as T cells could result in a vicious circle of neuroinflammation and neurodegeneration that is self-perpetuating and drives the progression of PD. Some of the substances liberated by degenerating neurons include α-synuclein aggregates, neuromelanin, adenosine triphosphate (ATP), and matrix metalloproteinase-3 (MMP-3) (Colonna and Butovsky 2017, supra).
- The understanding that α-synuclein oligomers/PFF are responsible for the neurotoxicity in Lewy body pathology led to the development of several immunotherapy strategies (Brundin et al., Exp Neurol.298:225-235 (2017)). Animal models have supported the efficacy of active and passive immunotherapy with antibodies targeting modified forms of α-syn. Clinical trials with monoclonal antibodies are at their early stages, and the major hurdles to be overcome are the difficulty in achieving meaningful levels of the large molecular weight antibody (e.g., an IgG antibody) and the potentially deleterious effects of having to dose the antibody with very high quantities thus potentially increasing side effects. Also, the large size of a full antibody does not allow penetration into intraneuronal spaces that represent the bulk of lewy bodies.
- Provided herein are antibodies and antigen-binding fragments thereof that are capable of binding to alpha-synuclein and methods of making and using the same.
- In one aspect, an isolated antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a complementary determining region (CDR) H1 comprising the amino acid sequence set forth in SEQ ID NO:1 (GGSISSHY), a CDR H2 comprising the amino acid sequence set forth in SEQ ID NO:2 (IYDSGST), a CDR H3 comprising the amino acid sequence set forth in SEQ ID NO:3 (ARGAGWYRF), a CDR L1 comprising the amino acid sequence set forth in SEQ ID NO:4 (QSVLYSSNNKNY), a CDR2 L2 comprising the amino acid sequence set forth in SEQ ID NO:5 (WAS), and a CDR3 L3 comprising the amino acid sequence set forth in SEQ ID NO:6 (QQYYSTPRT). In one aspect, an isolated antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a CDR H1 comprising the amino acid sequence set forth in SEQ ID NO:50 (SHYWS), a CDR H2 comprising the amino acid sequence set forth in SEQ ID NO:51 (YIYDSGSTNYNPSLKS), a CDR H3 comprising the amino acid sequence set forth in SEQ ID NO:52 (GAGWYRF), a CDR L1 comprising the amino acid sequence set forth in SEQ ID NO:53 (KSSQSVLYSSNNKNYLA), a CDR2 L2 comprising the amino acid sequence set forth in SEQ ID NO:54 (WASTRES), and a CDR3 L3 comprising the amino acid sequence set forth in SEQ ID NO:55 (QQYYSTPRT).
- In one aspect, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), wherein the VH comprises the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004. In one aspect, the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL), wherein the VL comprises the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- In one aspect, an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a VH and a VL, wherein the VH comprises the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- In one aspect, an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises a VH and a VL, wherein the VL comprises the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- In one aspect, an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 comprising the CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 amino acid sequences encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- In one aspect, an antibody or antigen-binding fragment thereof capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein comprises CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 comprising the CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, and CDR L3 amino acid sequences of PMS209, PMS210, PMS211, PMS212, or PMS213.
- In one aspect, the CDRs are the Kabat-defined CDRs, the Chothia-defined CDRs, the AbM-defined CDRs, or the IMGT-defined CDRs.
- In one aspect, the antibody or antigen binding fragment thereof comprises a VH and a VL, wherein the VH comprises the mature form of the amino acid sequence set forth in SEQ ID NOs:21, 25, 29, 33, or 37; wherein the VL comprises the mature form of the amino acid sequence set forth in SEQ ID NOs:22, 26, 30, 34, or 38; or wherein the VH and VL comprise the mature forms of SEQ ID NOs:21 and 22, respectively, SEQ ID NOs:25 and 26, respectively, SEQ ID NOs:29 and 30, respectively, SEQ ID NOs: 33 and 34, respectively, or SEQ ID NOs:37 and 38, respectively.
- In one aspect, the antibody or antigen-binding fragment thereof is capable of binding to soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein with an affinity below 10 nM as measured by surface plasmon resonance.
- In one aspect, the alpha-synuclein is human alpha-synuclein. In one aspect, the alpha-synuclein is mouse alpha-synuclein.
- In one aspect, the antibody or antigen-binding fragment thereof is human, humanized, or chimeric.
- In one aspect, the antibody or antigen-binding fragment thereof is an IgG antibody. In one aspect, the IgG is an IgG1 or IgG4. In one aspect, the antibody is an antigen-binding fragment of an antibody. In one aspect, the fragment is selected from the group consisting of Fab, F(ab′)2, Fv, scFv, scFv-Fc, dsFv and a single domain molecule. In one aspect, the fragment is an scFv. In one aspect, the fragment is a Fab. In one aspect, the fragment is an intrabody. In one aspect, antigen-binding fragment is devoid of an Fc region. In one aspect, the antibody or antigen-binding fragment thereof comprises a VH and a VL on the same polypeptide chain. In one aspect, the linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO:47).
- In one aspect, the antibody or antigen-binding fragment thereof comprises the amino acid sequence of the mature form of SEQ ID NO:42 or 44.
- In one aspect, the antibody or antigen-binding fragment thereof is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.
- In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting expression and/or secretion of pro-inflammatory cytokines from microglia cells incubated with misfolded alpha synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting uptake of misfolded alpha synuclein by macrophages. In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting T cell activation by misfolded alpha synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of preventing aggregation of alpha-synuclein as determined by Thioflavin T (ThT). In one aspect, the antibody or antigen-binding fragment thereof is capable of inhibiting seeding and spreading of alpha-synuclein. In one aspect, the antibody or antigen-binding fragment thereof is capable of penetrating neurons, colocalizing with misfolded alpha synuclein, and/or attenuating consequent cellular toxicity. In one aspect, the antibody or antigen-binding fragment thereof is capable of ameliorating a motorical or physiological phenotype in a synucleinopathy mouse model.
- Also provided herein are compositions comprising any antibody or antigen-binding fragment thereof provided herein and a carrier. In one aspect, the composition is a diagnostic composition. In one aspect, the composition is a therapeutic composition. In one aspect, the composition is a vaccine.
- Also provided herein are isolated polynucleotides comprising a nucleic acid molecule encoding the heavy chain variable region or heavy chain of any antibody or antigen-binding fragment thereof provided herein. In one aspect, the isolated polynucleotide further comprises a nucleic acid molecule encoding the light chain variable region or light chain of the antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment thereof provided herein. In one aspect, the nucleic acid molecule encodes a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of SEQ ID NOs:21, 25, 29, 33, or 37. In one aspect, the nucleic acid molecule comprises the VH-encoding polynucleotide sequence of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NOs: 19, 23, 27, 31, or35.
- Also provided herein are isolated polynucleotides comprising a nucleic acid molecule encoding the light chain variable region or light chain of any antibody or antigen-binding fragment thereof provided herein.
- In one aspect, the nucleic acid molecule encodes a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004 or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of SEQ ID NOs:22, 26, 30, 34, or 28. In one aspect, the nucleic acid molecule comprises the VL-encoding polynucleotide sequence of ATCC Deposit Designation PTA-125004or wherein the nucleic acid molecule encodes a VH comprising the amino acid sequence of any of SEQ ID NOs:20, 24, 28, 32, or 36.
- Also provided herein are isolated vectors comprising any polynucleotide provided herein. In one aspect, the polynucleotide is operably linked to a cis-acting regulatory element. In one aspect, the vector comprises a promoter sequence for driving expression of the polynucleotide and/or an internal ribosome entry site (IRES). In one aspect, the vector is a viral vector. In one aspect, the viral vector is an adenoviral vector, an adeno associated viral vector (AAV), or a lentiviral vector. In one aspect, the AAV is AAV9, AAV8, AAV7, AAV6, AAV5, AAV2, or AAV8-DJ.
- Also provided herein are host cells comprising any polynucleotide provided herein, any vector provided herein, or a combination of vectors comprising polynucleotides provided herein.
- Also provided herein are pharmaceutical compositions comprising any antibody or antigen-binding fragment provided herein, any vector provided herein, or any cell provided herein.
- Also provided herein are methods of producing an anti-alpha synuclein antibody or antigen-binding fragment thereof comprising(a) culturing a cell provided herein in a cell culture under conditions which allow expression of said an alpha-synuclein antibody or antigen-binding fragment thereof; and (b) recovering the antibody or antigen-binding fragment thereof from said cell culture.
- Also provided herein are anti-alpha synuclein antibodies or antigen-binding fragments thereof obtainable by the methods provided herein.
- Also provided herein are methods of treating or preventing a synucleinopathic disease in a subject comprising administering to the subject a therapeutically effective amount of any antibody or antigen-binding fragment thereof, composition, polynucleotide, vector, or cell provided herein, thereby treating or preventing the synucleinopathic disease.
- Also provided herein are methods of treating or preventing neuroinflammation in a subject comprising administering to the subject a therapeutically effective amount of any antibody or antigen-binding fragment thereof, composition, polynucleotide, vector, or cell provided herein, thereby treating or preventing the neuroinflammation.
- In one aspect, the administering is via an administration route selected from the group consisting of intranasal, intravenous, subcutaneous, and intrathecal.
- Also provided herein are method of diagnosing a synucleinopathic disease in a subject comprising (a) assessing the level, localization, conformation, or a combination thereof of misfolded alpha-synuclein in a subject to be diagnosed with any antibody or antigen-binding fragment thereof or composition provided herein; and (b) comparing the level, localization, conformation, or combination thereof of misfolded alpha-synuclein in the subject to one or more reference standards derived from one or more control samples, wherein a difference or similarity between the level, localization, conformation, or combination thereof of α-synuclein in the subject and the reference standard indicates whether the subject has a synucleinopathic disease.
- In one aspect, the synucleinopathic disease is Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple systems atrophy (MSA), a neurodegenerative disease with cerebral deposits of misfolded alpha-synuclein, or a combination thereof, optionally wherein neurodegenerative disease with cerebral deposits of misfolded alpha-synuclein is Alzheimer’s disease or frontotemportal dementia.
- In one aspect, the level, localization, conformation, or combination thereof of misfolded and monomeric alpha-synuclein in the subject is measured by in vivo imaging. In one aspect, the in vivo imaging comprises positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging or magnetic resonance imaging (MM).
- In one aspect, the subject is a mammal, optionally wherein the mammal is a human.
- Also provided herein are methods of detecting misfolded alpha-synuclein comprising (a) contacting a biological sample with any antibody or antigen-binding fragment thereof provided herein or any composition provided herein under conditions which allow formation of immunocomplexes; and (b) determining the presence and/or level of the immunocomplexes. In one aspect, the antibody or antigen-binding fragment thereof is attached to a heterologous detectable moiety.
- Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
- Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
- In the drawings:
-
FIG. 1 is a bar graph of alpha-synuclein 42 positive Fab clone binders selected from a human scFv library: repertoire from over 110 individuals, diversity of 1×1011. -
FIG. 2 is a graph showing alpha-synuclein binding analysis by ELISA assay for 6 unique clones (Fab forms). -
FIG. 3A shows nucleic acid sequences of the variable regions from heavy (VH) and light (VL) chains in PMS209. The VH leader sequence (ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCC AGCCGGCCATGGCC; SEQ ID NO:48) corresponds to nucleotides 1-66 of SEQ ID NO:19. The VL leader sequence (GTGAAAAAATTATTATTCGCAATTCCTTTAGTTGTTCCTTTCTATTCTCACAGT GCA; SEQ ID NO:49) corresponds to nucleotides 1-57 of SEQ ID NO:20. The 6xHis-tag (CATCATCATCACCATCAC; SEQ ID NO:46) corresponds to nucleotides 754-771 of SEQ ID NO:19. The myc-tag (GAACAAAAACTCATCTCAGAAGAGGATCTG; SEQ ID NO:45) corresponds to nucleotides 781-810 of SEQ ID NO:19. CDR sequences are underlined. -
FIG. 3B shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS210. The VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:23. The VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:24. The 6xHis-tag corresponds to nucleotides 730-747 of SEQ ID NO:23. The myc-tag corresponds to nucleotides 757-786 of SEQ ID NO:23. CDR sequences are underlined. -
FIG. 3C shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS211. The VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:27. The VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:28. The 6xHis-tag corresponds to nucleotides 733-750 of SEQ ID NO:27. The myc-tag corresponds to nucleotides 760-789 of SEQ ID NO:27. CDR sequences are underlined. -
FIG. 3D shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS212. The VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:31. The VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:32. The 6xHis-tag corresponds to nucleotides 742-759 of SEQ ID NO:31. The myc-tag corresponds to nucleotides 769-798 of SEQ ID NO:31. CDR sequences are underlined. -
FIG. 3E shows nucleic acids sequences of the variable regions from heavy (VH) and light (VL) chains in PMS213. The VH leader sequence corresponds to nucleotides 1-66 of SEQ ID NO:35. The VL leader sequence corresponds to nucleotides 1-57 of SEQ ID NO:36. The 6xHis-tag corresponds to nucleotides 742-759 of SEQ ID NO:35. The myc-tag corresponds to nucleotides 769-798 of SEQ ID NO:35. CDR sequences are underlined. -
FIG. 3F shows VH and VL amino acid sequences of PMS209. The VH leader sequence (MKYLLPTAAAGLLLLAAQPAMA; SEQ ID NO:40) corresponds to amino acids 1-22 of SEQ ID NO:21. The VL leader sequence (VKKLLFAIPLVVPFYSHSA; SEQ ID NO:39) corresponds to amino acids 1-20 of SEQ ID NO:22. The 6xHis-tag (HHHHHH; SEQ ID NO:18) corresponds to amino acids 252-257 of SEQ ID NO:21. The myc-tag (EQKLISEEDL; SEQ ID NO:17) corresponds to amino acids 261-270 of SEQ ID NO:21. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 3G shows VH and VL amino acid sequences of PMS210. The VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:25. The VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:26. The 6xHis- corresponds to amino acids 244-249 of SEQ ID NO:25. The myc-tag corresponds to amino acids 253-262 of SEQ ID NO:25. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 3H shows VH and VL amino acid sequences of PMS211. The VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:29. The VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:30. The 6xHis-tag corresponds to amino acids 245-250 of SEQ ID NO:29. The myc-tag corresponds to amino acids 254-263 of SEQ ID NO:29. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 3I shows VH and VL amino acid sequences of PMS212. The VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:33. The VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:34. The 6xHis-tag corresponds to amino acids 248-253 of SEQ ID NO:33. The myc-tag corresponds to amino acids 257-266 of SEQ ID NO:33. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 3J shows VH and VL amino acid sequences of PMS213. The VH leader sequence corresponds to amino acids 1-22 of SEQ ID NO:37. The VL leader sequence corresponds to amino acids 1-20 of SEQ ID NO:38. The 6xHis-tag corresponds to amino acids 248-253 of SEQ ID NO:37. The myc-tag corresponds to amino acids 257-266 of SEQ ID NO:37. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 4A shows the nucleic acids sequence of PMS210 in full scFv-Fc format. The leader sequence (ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCGGCCCAGC; SEQ ID NO:16) corresponds to nucleotides 1-46 of SEQ ID NO:41. The VH sequence corresponds to nucleotides 52-705 of SEQ ID NO:41. The VL sequence corresponds to nucleotides 741-1,401 of SEQ ID NO:41. The linker (GGTGGCGGCGGTTCCGGAGGTGGTGGTTCTGGCGGTGGTGGCAGC; SEQ ID NO:15) corresponds to nucleotides 706-750 of SEQ ID NO:41. The human IgG1 Fc tag corresponds to nucleotides 1,414-2,106 of SEQ ID NO:41. CDR sequences are underlined. -
FIG. 4B shows the nucleic acids sequence of PMS212 in full scFv-Fc format. The leader sequence corresponds to nucleotides 1-46 of SEQ ID NO:43. The VH sequence corresponds to nucleotides 52-717 of SEQ ID NO:43. The VL sequence corresponds to nucleotides 763-1,410 of SEQ ID NO:43. The linker corresponds to nucleotides 718-762 of SEQ ID NO:43. The human IgG1 Fc tag corresponds to nucleotides 1,423-2,115 of SEQ ID NO:43. CDR sequences are underlined. -
FIG. 4C shows amino acid sequence of PMS210 in full scFv-Fc format. The leader sequence (MKHLWFFLLLVAAAQPA; SEQ ID NO:14) corresponds to amino acids 1-17 of SEQ ID NO:42. The VH sequence corresponds to amino acids 18-235 of SEQ ID NO:42. The VL sequence corresponds to amino acids 251-467 of SEQ ID NO:42. The linker (GGGGSGGGGSGGGGS; SEQ ID NO:47) corresponds to amino acids 236-250 of SEQ ID NO:42. The human IgG1 Fc tag corresponds to amino acids 471-702 of SEQ ID NO:42. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 4D shows amino acid sequences of PMS212 in full scFv-Fc format. The leader sequence corresponds to amino acids 1-17 of SEQ ID NO:44. The VH sequence corresponds to amino acids 18-239 of SEQ ID NO:44. The VL sequence corresponds to amino acids 255-470 of SEQ ID NO:42. The linker corresponds to amino acids 240-254 of SEQ ID NO:44. The human IgG1 Fc tag corresponds to amino acids 474-705 of SEQ ID NO:44. CDR sequences are underlined. Asterisk stands for a stop codon. -
FIG. 5 shows high affinity binding of scFv-Fc PMS208 to PFF versus monomers in ELISA assay. -
FIG. 6 shows high affinity binding of PMS208 (scFv form) to PFF and oligomers alpha synuclein in Surface Plasmon Resonance (Biacore). Association rate constant (Ka), dissociation rate constant (Kd) and affinity constant (KD) data are provided. -
FIGS. 7A and 7B are images showing that PMS208 (scFv-Fc for immunoprecipitation) immunoprecipitates aSyn from PD patients sera (FIG. 7A ) or PD/DLB patients CSF (FIG. 7B ).FIG. 7A , Left panel - human alpha-synuclein staining using mouse monoclonal anti-human alpha-synuclein antibody (α-syn clone Syn 204 #838201, Biolegend (previously Covance catalog #MMS-530R));FIG. 7A , Right Panel andFIG. 7B - phosphorylated human alpha-synuclein staining using mouse monoclonal anti-human phosphorylated alpha-synuclein in serine 129 (p-aSyn (ser129) (clone P-syn/81A #825701, Biolegend (previously Covance catalog #MMS-5091))). -
FIGS. 8A-C are bar graphs showing neuronal increase in viability mediated by PMS208 (scFv). PMS208 protects neuronal SH—SY5Y human cell line from α-syn PFF (FIG. 8A ), oligomers (FIG. 8B ), and human PD patient brain extracts (FIG. 8C ). The y-axis represents the relative increase in cell viability compared to PFF/oligomers/human PD brain extracts with no treatment (PBS), PMS208 treatment, and 80R scFv isotype treatment (sham). -
FIGS. 9A and 9B show Western blots of PMS208 binding to human striatum extracts from PD/control group patients (FIG. 9A ) and PMS208 binding to human cortex (CTX) and striatum (STR - right panels) extracts of DLB and control group (Ctrl) patients (FIG. 9B ). GAPDH as “housekeeping” protein loading control is shown in lower panels (FIGS. 9A and 9B ). -
FIGS. 10A-F are graphs showing that PMS208 attenuates neuroinflammation in human PBMCs (FIGS. 10A-C ) and mouse microglia BV2 cells (FIGS. 10D and 10F ) induced by PFF and oligomers. PBMCs were activated with PFF (FIG. 10A ) and oligomers (FIG. 10B ) for 2.5 hours or 12 hours to measure TNFa at the protein and mRNA (FIG. 10C ) levels. In mouse microglia BV2 cells, PMS208 attenuates IL-6 mRNA levels (FIG. 10F ) as well as TNFa protein levels compared to PMS208-Fc (FIGS. 10D and 10E ) which has the opposing effect (elevates TNFa protein levels). Real-time PCR was done in cell homogenates. TNFa and IL-6 underwent TaqMan real-time PCR in cell homogenates. The y-axis represents the fold-change in expression compared to no treatment (cells only). GAPDH was used as “housekeeping” gene. -
FIGS. 11A-F are graphs showing that PMS208 attenuates uptake of fluorescent PFF (PFF-488) in mouse peritoneal macrophages (FIG. 11A ) and human PBMCs (FIG. 11B ) in a dose dependent manner. PMS208 (FIGS. 11C and 11D ) attenuates both PFF (FIGS. 11C and 11E ) and oligomers (FIGS. 12D and F ) compared to PMS208-Fc (FIGS. 11E and 11F ) in microglia cells (BV2). The y-axis represents the relative geometric mean (gMFI) measured by flow cytometry. -
FIGS. 12A-D are graphs showing that PMS208 attenuates neuroinflammation in murine cortex of animals injected (striatum) with PFF (FIGS. 12A and 12C ) and oligomers (FIGS. 12B and 12D ). Real-time PCR was done in brain cortexes homogenates. The expression of TNFa, IL-6, IL-12, INFγ,Caspase 3, Arg1, Chi313, and Mrc1 was determined by TaqMan real-time PCR in brain homogenates. The y-axis represents the fold-change in expression after PFF intrastriatal injections (with and without PMS208 treatment). GAPDH was used as “housekeeping” gene. *p<0.05, n = 3. -
FIGS. 13A-C are graphs showing reactivity to α-syn toxic forms in patients with Parkinson’s disease as measured by the magnitude of autoimmune responses against α-syn PFF and oligomers as SFC (spot forming cells) per 105 PBMCs.FIGS. 13A and 13B show IL-5 responses, andFIG. 13C shows IFNγ responses of different PD patients. PMS208 manages to tune down the autoimmune response of T cells to α-syn pff and oligomers. Images are representative of a number of repeats in different PD patients. -
FIG. 14 is a graph showing kinetics for the formation of β-sheet-rich assemblies: human α-syn PFF incubated with PMS208 (7.5 ug/ml or 15 ug/ml) versus PBS (black solid line). Monomers (dotted line marked with triangles) were measured as baseline. -
FIG. 15 shows a Western blot following sequential extraction of neurons in 1% (vol/vol) TX-100 followed by SDS. Immunoblotting was performed using rabbit anti-rodent alpha-synuclein, an antibody that recognizes endogenous total α-syn (upper panel) and mouse anti-GAPDH (lower panel). In PFF-treated neurons, there was an increase in SDS-soluble α-syn (2% SDS) compared to PBS or PFF+PMS208 treated neurons (arrow). -
FIGS. 16A and 16B show that daily intraperitoneal rotenone elicits moderate weight loss and a parkinsonian phenotype that is alleviated by intranasal PMS208.FIG. 16A shows the percent change in mass fromday 0 in 2 months old rats treated with rotenone (Rotenone + Sham, n = 10), rotenone with PMS208 treatment (Rotenone + PMS208, n = 9), and control rats (Vehicle + Sham, n = 4). Rotenone was administrated at increasing concentrations (day 0 with 1.5 mg/kg/day,day 3 with 2 mg/kg/day andday 6 with 2.5 mg/kg/day).FIG. 16B shows the number of rears in rats was quantified (Rotenone + Sham,; Rotenone + PMS208; Vehicle + Sham). The animal had to raise forelimbs above shoulder level and make contact with the cylinder wall with either one or both forelimbs in order to be classified as a rear. Removal of both forelimbs from the cylinder wall and contact with the table surface was required before another. Animals were euthanized when severe parkinsonian symptoms developed. Mortality occurring immediately after the injection (in the absence of parkinsonian symptoms and typically <10%) was excluded from analysis. *p<0.05. Error bars represent standard error of the mean. -
FIGS. 17A and 17B show that PMS208 given intranasally (IN) attenuates motor dysfunction induced by intracerebral injections of adeno associated virus expressing human aSyn (AAV-aSyn) in rats. rAAV2/DJ vector-mediated α-synuclein overexpression in mouse SN leads to motor behaviour impairments. (FIG. 17A ) Neuromuscular strength was tested with the two limbwire hang test 6 weeks after injection. Each rat was tested three times and the top two results were used for analysis. (FIG. 17B ) Performance in the cylinder test of rAAV2/DJ-α-synuclein VS sham mice at 5-6 weeks after injection. At 5-6 weeks after injection, a significantly reduced use of the contralateral forepaw was observed for α-synuclein vector compared to the sham and intranasal treatment groups. For all tests: n = 7. *p<0.05, **p<0.01. Error bars represent standard error of the mean. -
FIGS. 18A-C show that mouse alpha-synuclein PFF intrastriatal injections in mice leads to motor behavior and cognitive impairments.FIG. 18A shows a neuromuscular strength assessment using a wire hang test performed at 12 weeks after injection. Mouse PFF injected group compared to sham and intranasal treatment groups (16, 80, 320 ug/kg) showed a significant reduction in average time of animals latency to fall. Each mouse was tested three times, and the top two results were used for analysis.FIG. 18B demonstrates that the rotarod test performed at 12 weeks after injection showed a significant reduction in average time on the rotating rod for the mouse PFF injected group compared to the sham and intranasal treatment groups (16, 80, 320 ug/kg).FIG. 18C shows the mean novel object preference for all mice groups during the testing phase when one familiar object and one novel object were presented to mice is shown. n = 9, 10, 9, 9, 9; *p<0.05, **p<0.002. Error bars represent standard error of the mean. -
FIG. 19 shows brain sections of animals injected with adeno-associated virus expressing human aSyn (AAV-aSyn) that develop extensive and significantly greater loss of TH+ and dopaminergic (DA)neurons and the effect of PMS208 thereon. - The present invention, in some embodiments thereof, relates to antibodies and antigen-binding fragments thereof for the treatment of synucleinopathies and neuroinflammation.
- Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
- Alpha-synuclein (α-syn) plays a pivotal role in the pathogenesis of Parkinson’s Disease (PD) and other synucleinopathies. Two forms of α-syn are believed to promote neurotoxicity, spreading, and neuroinflammation; these are small molecular oligomers and preformed fibrils (PFF).
- Whilst conceiving the invention, the present inventors have searched for a biological agent that would target the small molecular oligomers and preformed fibrils of alpha-synuclein and be sufficiently small to facilitate effective entry to the brain without requiring high systemic dosages and avoiding non specific Fc portion-related immune-mediated effects.
- Thus, the present inventors have isolated from human phage display libraries of healthy individuals, a panel of Fabs, of which PMS208, was cloned into a single chain Fv. A plasmid encoding PMS208 was deposited with the American Type Culture Collection (ATCC), located at 10801 University Boulevard, Manassas, VA 20110 on March14, 2018, under the terms of the Budapest Treaty and has the ATCC® Deposit Designation PTA-125004.
- This antibody fragment was selected based on a complex screening that included the following selection criteria: binding to native alpha-synuclein in patients’ sera, binding the denatured form of the protein as well as the native form (rendering it superior for both clinic and research), preventing recruitment of the immune system to the damaged area, reduction of neuro-inflammation, prevention of seeding and spreading, prevention of immune cells activation, prevention of alpha-synuclein aggregation (as determined by Thioflavin T (ThT), as well as disintegration of preformed aggregates and efficacy in vivo in animal models.
- The Fab was cloned into a smaller scFv format with successful retention of its affinity. Importantly and uniquely, PMS208 binds with high affinity both α-syn oligomers and PFF. PMS208 attenuates toxicity induced by both oligomers and PFF to human and murine neuronal cells and binds avidly to α-syn in brain extracts from PD patients. Importantly, the scFv form of PMS208 down-regulates a panel of pro-inflammatory cytokines produced by microglia after exposure to oligomers and PFF, whereas Fc containing anti-α-syn antibodies up-regulate this same panel of proteins. Intranasal PMS208 administration attenuates motor dysfunction in a number of PD animal models in vivo, demonstrating that relatively low doses of PMS208 are required.
- The size of the scFv that still retains the high affinity is one sixth the size of an IgG, which explains its bioavailability and efficacy via the intranasal route (mainly via the olfactory nerve). This delivery mode reduces the need to achieve high systemic levels as is currently attempted with immunotherapy for neurodegenerative diseases.
- Thus, according to an aspect of the invention there is provided an isolated antibody comprising an antigen binding domain comprising CDR sequences which are N—C ordered:
-
Heavy Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 HC 1 GGSISSHY CDR2 HC 2 IYDSGST CDR3 HC 3 ARGAGWYRF Light Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 LC 4 QSVLYSSNNKNY CDR2 LC 5 WAS CDR3 LC 6 QQYYSTPRT - wherein said antibody is capable of binding to soluble monomers, oligomers, and/ or preformed fibrils (PFF) of alpha-synuclein in an affinity that is below 10 nM, as determined by surface plasmon resonance.
- According to another aspect of the invention there is provided an isolated antibody comprising an antigen binding domain comprising CDR sequences which are N-C ordered:
-
Heavy Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 HC 50 SHYWS CDR2 HC 51 YIYDSGSTNYNPSLKS CDR3 HC 52 GAGWYRF Light Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 LC 53 KSSQSVLYSSNNKNYLA CDR2 LC 54 WASTRES CDR3 LC 55 QQYYSTPRT - wherein said antibody is capable of binding to soluble monomers, oligomers, and/or preformed fibrils (PFF) of alpha-synuclein in an affinity that is below 10 nM, as determined by surface plasmon resonance.
- The CDR sequences can be encoded by the following polynucleotide sequences.
-
Heavy Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 HC 7 GGCGGCTCTATCAGCAGCCACTAC CDR2 HC 8 ATCTACGACAGCGGCAGCACC CDR3 HC 9 GCTAGAGGCGCCGGATGGTACAGATTT Light Chain PMS208 SEQ ID NO: SEQUENCE: CDR1 LC 10 CAGAGCGTGCTGTACTCCAGCAACAACAAGAACTAC CDR2 LC 11 TGGGCCAGC CDR3 LC 12 CAGCAGTACTACAGCACCCCTCGGACC - The terms “alpha-synuclein,” “α-synuclein,” “a-synuclein,” “aSyn,” “αSyn,” “a-Syn,” and “α-Syn” are used interchangeably herein. Aliases for alpha-synuclein include, e.g., SNCA, NACP, PARK1, PARK4, PD1, synuclein alpha. These terms include human alpha-synuclein as well as non-human alpha-synuclein. These terms also include soluble monomers, oligomers, and/or preformed fibrils of alpha-synuclein.
- As used herein “human alpha-synuclein” refers to the protein product of the SNCA gene with the UniProt identification P37840:
-
MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVH GVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA (SEQ I D NO:13). - Also contemplated herein are non-human forms of the “alpha-synuclein” e.g., mouse alpha-synuclein to which an antibody or antigen-binding fragment thereof according to some embodiments of the invention (e.g., PMS208) can bind rendering it a pan-species antibody antigen-binding fragment that is very useful in research and pre-clinical studies.
- The molecular weight of human alpha-synuclein monomers is 14 kDa. Two or more alpha-synuclein monomers can aggregate and form soluble alpha-synuclein protofibrils/oligomers with a wide range of molecular weights. A dominating oligomer typically has a molecular weight of 28 kDa. Higher weight forms, e.g., 2000 kDa, are typically referred to as a preformed protofibril (PFF). The major difference between oligomers and PFF is in the morphology, which is visible under an electron microscope (oligomers are round and small, while PFFs are fibril shaped), and the weight can be determined by size exclusion chromatography and SDS-PAGE analysis (non-reduced or native).
- According to a specific embodiment, the oligomer is of the molecular weight of 14-84 kDa, as determined by electron microscopy and/or size exclusion chromatography.
- Purified α-syn monomers are available commercially such as from Alexotech, Sweden.
- Preparation of higher orders of alpha-synuclein can be done by aldehyde induction for the preparation of oligomers. PFF can be induced by incubating monomers at 37° C. for 7 days at 1000 rpm.
- Specifically, purified α-syn monomer (in PBS, pH 7.4) are mixed together with HNE (4-Hydroxynonenal) 20 mg/ml (in DMSO) in a low binding tube (e.g., Protein LoBind Tube 1.5, Eppendorf tubes, Cat no.: 022431081) for a final concentration of 140 µM α-syn and 4200 µM HNE. Samples are incubated at 37° C. for 18 hours (h) and analyzed in SDS-PAGE, silver stain (manufacture protocol). Alpha-Syn adopts an extended conformation oligomeric form (spherical - monomers to hexamers), with dimers being the major species (SDS resistant). Of note, oligomers and PFF can overlap in the size but not in the structure (round vs. fibril)
- Each form can be produced by a different reaction (HNE or incubation in 37° C. for 7 days at 1000 rpm), which was verified with electron microscope and SDS-PAGE analysis.
- According to a specific embodiment, the antibody or antigen-binding fragment thereof binds the PFF in a higher affinity than to a-synuclein oligomers or even monomers. e.g., 0.67 nM PFF compared to 3.46 nM (~5 fold) oligomers as determined by SPA.
- As used herein, “higher affinity” refers to an affinity which is at least 2-fold (e.g., 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9 and even 10 and above fold) higher (lower KD).
- As used herein “binding” or “binds” refers to an antibody-antigen mode of binding, which is generally, in the case of clinically relevant antibodies or antigen-binding fragments thereof, and in this case in the range of KD below 10 nM e.g., about 0.5-0.7 nM, e.g., 0.67 nM at the conditions described in the Examples section, as determined by Surface Plasmon Resonance assay (SPR), when binding to PFF, or 2-5 nM, e.g., 3.46 nM, when binding to the oligomers.
- The affinity of the antibody or antigen-binding fragment to its antigen is determined by Surface Plasmon Resonance (SPR) using a captured or immobilized antigen. For instance, in one embodiment the antigen is immobilized when the antibody or antigen-binding fragment (e.g., scFv) (table) is tested and in another embodiment the antibody or antigen-binding fragment (e.g., scFv-Fc) is immobilized and the antigen is in the solution.
- As used herein the term “KD” refers to the equilibrium dissociation constant between the antigen binding domain or the antibody or antigen-binding fragment thereof and its respective antigen.
- The term “antibody” means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term “antibody” encompasses intact polyclonal antibodies, intact monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antibody, and any other modified immunoglobulin molecule so long as the antibodies exhibit the desired biological activity. An antibody can be of any the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated to other molecules such as toxins, radioisotopes, etc.
- The term “antibody fragment” refers to a portion of an intact antibody. An “antigen-binding fragment,” “antigen-binding domain,” or “antigen-binding region,” refers to a portion of an intact antibody that binds to an antigen. An antigen-binding fragment can contain an antigen recognition site of an intact antibody (e.g., complementarity determining regions (CDRs) sufficient to bind antigen). Examples of antigen-binding fragments of antibodies include, but are not limited to Fab, Fab′, F(ab′)2, and Fv fragments, linear antibodies, and single chain antibodies. An antigen-binding fragment of an antibody can be derived from any animal species, such as rodents (e.g., mouse, rat, or hamster) and humans or can be artificially produced.
- The terms “alpha-synuclein antibody” and “antibody that binds to alpha-synuclein” refer to an antibody that is capable of binding alpha-synuclein (in soluble monomer, oligomer, and/or preformed fibril forms) with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting alpha-synuclein. The extent of binding of an alpha-synuclein antibody to an unrelated, non-alpha-synuclein protein can be less than about 10% of the binding of the antibody to alpha-synuclein as measured, e.g., by a radioimmunoassay (RIA).
- In some embodiments, the isotype of an antibody or antigen-binding fragment thereof is selected from IgG1, IgG2, IgG3, and IgG4, more particularly, IgG1 or IgG4. According to a specific embodiment, the isotype is IgG1.
- As used herein, the terms “variable region” or “variable domain” are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-
terminal 110 to 120 amino acids or 110 to 125 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen. In certain aspects, the variable region is a human variable region. - The terms “VH” and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody or antigen-binding fragment thereof.
- The terms “VL” and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody or antigen-binding fragment thereof.
- As provided herein, the polypeptides of an antibody or antigen-binding fragment thereof (e.g., a VH, VL, heavy chain, light chain, and/or scFv) can be expressed with a leader sequence or signal sequence, which is cleaved during intracellular processing to produce a “mature” polypeptide. The “mature” forms of the polypeptides do not contain the leader or signal sequences. For example, the “mature form” of the polypeptide of SEQ ID NO:21 comprises amino acids 23-274 of SEQ ID NO:21.
- As used herein, the terms “complementarity-determining region” or “CDR” are used interchangeably to refer to the antigen binding regions found within the variable region of the heavy and light chain polypeptides. Generally, antibodies or antigen-binding fragments thereof comprise three CDRs in each of the VH (CDR HI or HI; CDR H2 or H2; and CDR H3 or H3) and three in each of the VL (CDR LI or LI; CDR L2 or L2; and CDR L3 or L3).
- The identity of the amino acid residues in a particular antibody or antigen-binding fragment thereof that make up a variable region or a CDR can be determined using methods well known in the art and include methods such as sequence variability as defined by Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C.), location of the structural loop regions as defined by Chothia et al. (see, e.g., Chothia et al., Nature 342:877-883, 1989), a compromise between Kabat and Chothia using Oxford Molecular’s AbM antibody modeling software (now Accelrys®, see, Martin et al., 1989, Proc. Natl Acad Sci USA. 86:9268; and world wide web site www.bioinf-org.uk/abs), available complex crystal structures as defined by the contact definition (see MacCallum et al., J. Mol. Biol. 262:732-745, 1996) and the “conformational definition” (see, e.g., Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008; IMGT unique numbering for V-DOMAIN and V-LIKE-DOMAIN; lefranc numbering, Lefranc M.-P. et al., 1997).
- As used herein, the “variable regions” and “CDRs” may refer to variable regions and CDRs defined by any approach known in the art, including combinations of approaches.
- According to a specific embodiment, the antibody fragment is selected from the group consisting of single chain, Fab, Fab’ and F(ab’)2 fragments, Fv, dsFv, scFvs, diabodies, minibodies, nanobodies, Fab expression library or single domain molecules such as VH and VL that are capable of binding the antigen as described hereinabove.
- According to a specific embodiment, the antibody fragment is an intrabody. The intrabody can comprise an scFv and an intracellular trafficking signal.
- Functional antibody fragments comprising whole or essentially whole variable regions of both light and heavy chains some of which are defined as follows:
- (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains;
- (ii) single chain Fv (“scFv”), a genetically engineered single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
- (iii) disulfide-stabilized Fv (“dsFv”), a genetically engineered antibody including the variable region of the light chain and the variable region of the heavy chain, linked by a genetically engineered disulfide bond.
- (iv) Fab, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and CHI domains thereof;
- (v) Fab′, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule);
- (vi) F(ab′)2, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds); and
- (vii) Single domain antibodies or nanobodies are composed of a single VH or VL domains which exhibit sufficient affinity to the antigen.
- According to a specific embodiment, the antibody fragment is devoid of an Fc, which as shown in the Examples section attenuates (scFv) microglia cellular uptake of PFF (
FIG. 11C ) and oligomers (FIG. 11D ) conjugated to Alexa fluor 488 (FIGS. 12C and 12D ) in a dose dependent manner, whereas Fc containing antibodies do not (FIGS. 12E and 12F ). - According to a specific embodiment, the antibody fragment is a single chain Fv (scFv).
- According to a specific embodiment, the scFv comprises the amino acid sequence of the mature form of SEQ ID NO:42 or 44.
- According to a specific embodiment, the scFv comprises the scFv amino acid sequence encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, an antibody or antigen-binding fragment thereof (e.g., an scFv) comprises six CDRs comprising the same amino acid sequences as the six CDRs encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, an antibody or antigen-binding fragment thereof (e.g., an scFv) comprises a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, an antibody or antigen-binding fragment thereof (e.g., an scFv) comprises a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, an antibody or antigen-binding fragment thereof (e.g., an scFv) comprises a VH comprising the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 and a VL comprising the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, the antibody fragment is a Fab.
- Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).
- Antibody fragments according to some embodiments of the invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab’ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab’ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R., Biochem. J.73: 119-126 (1959). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
- Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al., Proc. Nat′l Acad. Sci. USA 69:2659-62 (19720). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, each of which is hereby incorporated by reference in its entirety.
- According to a specific embodiment, the antibody fragment is isolated from a library, e.g., a human library and hence no need for further humanization for therapeutic uses as further described herein below.
- According to a specific embodiment, the antibody is a fully human antibody.
- Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab’)2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).
- Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and coworkers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or other CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); and Marks et al., J. Mol. Biol., 222:581 (1991); see also the Examples section ). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)). Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/
Technology 10,: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al.,Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995). - According to a specific embodiment, the antibody or an antigen-binding fragment thereof is an isolated antibody or antigen-binding fragment, i.e., not part of a library, or isolated from the physiological environment e.g., the human body.
- An antibody or antigen-binding fragment according to some embodiments of the invention is produced by recombinant DNA technology.
- Thus, according to an aspect of the invention there is also provided an isolated polynucleotide comprising a nucleic acid sequence encoding the antibodies or antigen-binding fragments thereof as described herein (e.g., PMS208).
- According to a specific embodiment, the nucleic acid sequences encoding the CDRs are as set forth in SEQ ID NOs:7-12. Such CDRs can be cloned into suitable antibody or antigen-binding fragment configurations, while the encoded proteins (i.e., antibodies or antigen-binding fragments thereof) maintain their functions as described herein.
- According to a specific embodiment, the nucleic acid sequences encoding the antibody or antigen-binding fragment thereof e.g., PMS208 (SEQ ID NOs: 1-6) are as set forth in SEQ ID NOs:7-12.
- According to a specific embodiment, the nucleic acid sequences encoding the CDRs encode CDRs with the same amino acid sequences as the CDRs encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, the nucleic acid sequences encoding the CDRs comprise the CDR-encoding nucleic acid sequences of the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, a nucleic acid sequence encoding a VH encodes a VH with the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, a nucleic acid sequence encoding a VL encodes a VL with the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, a nucleic acid sequence encoding a VH and a VL encodes a VH with the same amino acid sequence as the VH encoded by the plasmid of ATCC Deposit Designation PTA-125004 and a VL with the same amino acid sequence as the VL encoded by the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, a nucleic acid sequence encoding a VH comprises the VH-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, a nucleic acid sequence encoding a VL comprises the VL-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004. According to a specific embodiment, a nucleic acid sequence encoding a VH and VL comprises the VH-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004 and the VL-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- According to a specific embodiment, a nucleic acid encoding an scFv comprises the scFv-encoding nucleic acid sequence of the plasmid of ATCC Deposit Designation PTA-125004.
- Also provided is an expression vector, comprising the polynucleotide operably linked to a cis- acting regulatory element.
- The nucleic acid construct (also referred to herein as an “expression vector”) of some embodiments of the invention includes additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors). In addition, typical cloning vectors may also contain a transcription and translation initiation sequence, transcription and translation terminator, and a polyadenylation signal. By way of example, such constructs will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof.
- The nucleic acid construct of some embodiments of the invention typically includes a signal sequence for secretion or presentation of antibody or antigen-binding fragment thereof from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence. The signal sequence can be cleaved to form a mature protein.
- In some aspects, a vector provided herein can contain a promoter (e.g., eukaryotic promoter), an enhancer, and/or a polyadenylation site.
- The vector may or may not include a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the recombinant DNA integrates into the genome of the engineered cell, where the promoter directs expression of the desired nucleic acid.
- According to an aspect of the invention there is provided a method of producing an alpha-synuclein antibody or antigen-binding fragment thereof, the method comprising:
- (a) culturing a host cell comprising a nucleic acid construct or a polynucleotide as described herein in a cell culture under conditions which allow expression of an alpha-synuclein antibody or antigen-binding fragment thereof; and
- (b) recovering the antibody or antigen-binding fragment thereof from said cell culture.
- Also provided is an anti-alpha-synuclein antibody or antigen-binding fragment thereof obtainable by the method, optionally wherein the antibody or antigen-binding fragment thereof has biological activities of some embodiments described herein.
- Also provided are cells which comprise the polynucleotides/expression vectors as described herein.
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies or antigen-binding fragments thereof may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N. J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli. After expression, the antibody or antigen-binding fragment thereof may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody or antigen-binding fragment-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody or antigen-binding fragment thereof with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
- Suitable host cells for the expression of glycosylated antibody or antigen-binding fragment thereof are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES.TM. technology for producing antibodies or antigen-binding fragments thereof in transgenic plants).
- Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982);
MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0, and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003). - The antibody or antigen-binding fragment thereof (e.g., scFv) can be isolated from the host cell or conditioned medium using methods which are well known in the art.
- In accordance with the methods and techniques described, the antibodies or antigen-binding fragments thereof (e.g., scFvs) described herein may be screened, selected or evaluated for their biological activity and optionally therapeutic potential in cell culture models and/or transgenic animal models for alpha-synuclein pathology.
- According to a specific embodiment, the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting expression and secretion of pro-inflammatory cytokines from microglia cells incubated with PFF.
- As used herein a “pro-inflammatory cytokine” refers to a type of signaling molecule (a cytokine) that is excreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation. They include interleukin-1 (IL-1), IL-5, IL-12, and IL-18, tumor necrosis factor (TNF), interferon gamma (IFN-gamma), and granulocyte-macrophage colony stimulating factor and play an important role in mediating the innate immune response. Inflammatory cytokines are predominately produced by and involved in the upregulation of inflammatory reactions. Dysregulation of pro-inflammatory and anti-inflammatory cytokines has also been linked to depression and other neurological diseases. A balance between proinflammatory and anti-inflammatory cytokines is necessary to maintain health.
- Pro-inflammatory cytokines and neuroinflammation are important not only in inflammatory responses but also in neurogenesis and neuroprotection. Sustained stress and the subsequent release of pro-inflammatory cytokines lead to chronic neuroinflammation, which contributes to a variety of medical conditions including but not limited to schizophrenia, depression and other medical conditions that are described herein below (under “Neuroinflammation”). Hippocampal glucocorticoid receptors (GRs) and the associated hypothalamus-pituitary-adrenal (HPA) axis have close interactions with pro-inflammatory cytokines and neuroinflammation. Elevated pro-inflammatory cytokine levels and GR functional resistance create a vicious cycle. In brief, chronic neuroinflammation inhibits GR function, which in turn exacerbates pro-inflammatory cytokine activity and aggravates chronic neuroinflammation. On the other hand, neuroinflammation causes an imbalance between oxidative stress and the antioxidant system, which is also associated with a variety of medical conditions.
- Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the brain, which is characterized by the formation of extracellular amyloid plaques (or senile plaques) and intracellular neurofibrillary tangles. However, increasing evidences demonstrated that neuroinflammatory changes, including chronic microgliosis are key pathological components of AD. Microglia, the resident immune cells of the brain, constantly survey the microenvironment under physiological conditions. In AD, deposition of β-amyliod (Aβ) peptide initiates a spectrum of cerebral neuroinflammation mediated by activating microglia. Activated microglia may play a potentially detrimental role by eliciting the expression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α; TNFa) influencing the surrounding brain tissue. Emerging studies have demonstrated that up-regulation of pro-inflammatory cytokines play multiple roles in both neurodegeneration and neuroprotection.
- The Examples section which follows describes an embodiment for analyzing the effect of an antibody or antigen-binding fragment thereof (e.g., scFv) on secretion of pro-inflammatory cytokines from microglia cells incubated with PFF, e.g., and Interferon-γ (IFNγ) or interleukin-5 (IL-5) responses are measured by colour enzyme-linked immunospot (ELISPOT) assay, enabling quantification of responsive T cells.
- Briefly, pro-inflammatory cytokines can be measured in vitro (Example 7 and Example 10) at the RNA or protein level and optionally or alternatively evaluated functionally in vivo in a relevant animal model (see e.g., Example 9).
- As used herein “inhibiting” refers to at least 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or complete inhibition in a biological function (e.g., in pro-inflammatory cytokines expression (e.g., mRNA) or secretion), as compared to a cell (e.g., microglia cell or a blood cell (e.g., PBMC)) untreated with the antibody or antigen-binding fragment thereof (e.g., scFv). Generally, analysis or protein expression can be done at the RNA or protein level. Examples include, but are not limited to, RT-PCR, chromatography, electrophoretic methods, and immunodetection assays such as ELISA, Western blot analysis, and immunohistochemistry.
- According to a specific embodiment, inhibition of neuroinflammation is manifested by attenuating secretion of TNFa, IL6, IFN-gamma by microglia and PBMC and/or by reducing uptake of PFF to microglia and PBMC.
- According to a specific embodiment, inhibition of neuroinflammation is manifested by tuning down the autoimmune response of T cells to oligomers/PFF as evidenced by IL-5 and IFNg by e,g., Elispot.
- According to a specific embodiment, the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting uptake of PFF by macrophages or PBMC.
- This can be analyzed as described in the Materials and Methods section of the Examples section which follows under “Uptake of alpha-synuclein fibrils and oligomers in cells” using FACS for detecting uptake indicated as relative geomean fluorescence intensity (gMFI).
- According to a specific embodiment, the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting alpha-synuclein oligo/PFF-specific helper T cell activation by PFF.As shown in the Examples section which follows, IFNγ was used as a representative cytokine to detect CD4+T helper 1 (Th1) class II T cells, and IL-5 as a representative cytokine secreted by CD4+ T helper 2 (Th2) class II T cells.
- According to a specific embodiment the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of inhibiting seeding and spreading of alpha-synuclein.
- The aggregation of α-synuclein presumably starts with a conformational shift of the monomeric protein, followed by the step-wise formation of larger multimeric protein species comprising toxic soluble oligomers and preformed fibrils (PFF). These forms are potential drivers of seeding of (aggregated forms which are taken up by neuronal cells and catalyze the conversion of alpha-synuclein soluble protein molecules into their aggregated forms) and subsequent propagation culminating in widespread Lewy body pathology.
- A seeding and spreading assay is described under the Materials and Methods section of the Examples section which follows under the header “Spreading and seeding determination of human PFF in vitro.”
- According to a specific embodiment, the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of preventing aggregation of alpha-synuclein as determined by Thioflavin T (ThT).
- The ability to prevent aggregation of monomeric protein or oligomers to high order aggregates (PFF) renders the antibody or antigen-binding fragment thereof (e.g., scFv) specifically applicable for both prevention and/or treatment at early and late stages of the disease (i.e., synucleinopathy) when different forms are evident.
- According to a specific embodiment of the invention, the antibody or antigen-binding fragment thereof (e.g., scFv) is capable of ameliorating a motorical or physiological phenotype in a synucleinopathy mouse model. Relevant disease models include, but are not limited to, the mouse synuclein PFF induced Parkinson’s disease, Adeno Associated Virus (AAV) transduced rats expressing human synuclein induced Parkinson’s disease and Rotenone induced Parkinson’s disease.
- The clinical parameters include, but are not limited to, motoric functions: e.g., neuromuscular strength, forelimb asymmetry assessment, motor coordination and balance; behavioral functions e.g., exploratory behavior e.g., rearing; physiological parameters: e.g., body weight; and cognitive parameters: e.g., novel object recognition.
- According to a specific embodiment, the antibody or antigen-binding fragment thereof (e.g., scFv) is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG, e.g., by the covalent attachment of any type of molecule to the antibody or antigen-binding fragment thereof (e.g., scFv) such that covalent attachment does not prevent the antibody or antigen-binding fragment thereof (e.g., scFv) from specifically binding to its cognate epitope. For example, but not by way of limitation, antibodies and antigen-binding fragments thereof (e.g., scFv) can be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids. Methods of conjugation are further described herein below.
- The ability of the antibodies or antigen-binding fragments thereof (e.g., scFvs) of some embodiments of the invention to bind the pathological forms of the alpha-synuclein (i.e., oligomers and PFF) with higher affinity than to the monomeric form, renders it particularly useful for detection of these forms and diagnosis of synucleinopathies.
- Thus, according to an aspect of the invention there is provided a method of detecting alpha-synuclein, the method comprising:
- (a) contacting a biological sample with the antibody or antigen-binding fragment thereof (e.g., scFv) as described herein under conditions which allow formation of immunocomplexes; and
- (b) determining presence and/or level of said immunocomplexes.
- For the purpose of detection of alpha-synuclein oligomers/PFF or diagnosis of synucleinopathies, the antibody or antigen-binding fragment thereof (e.g., scFv) can be bound to a detectable moiety or another antibody or antigen-binding fragment thereof or a secondary antibody or antigen-binding fragment thereof can be used dependent on the immunoassay that is being implemented e.g., ELISA, sandwich ELISA, immunohistochemistry e.g., on sections and more as the skilled artisan sees fit.
- The term “detecting”, as used herein, refers to the act of detecting, perceiving, uncovering, exposing, visualizing or identifying an aggregation state of alpha-synuclein. The precise method of detecting is dependent on the detectable moiety (also referred to herein as identifiable moiety) to which the antibody or antigen-binding fragment thereof (e.g., scFv) is attached.
- The above-mentioned detection method can be harnessed to the diagnosis of synucleinopathies.
- As used herein the term “diagnosing” refers to classifying a disease, determining a severity of a disease (grade or stage), monitoring progression, forecasting an outcome of the disease and/or prospects of recovery.
- The subject may be a healthy subject (e.g., human) undergoing a routine well-being check up. Alternatively, the subject may be at risk of the disease. Alternatively, the method can be used to monitor treatment efficacy.
- As mentioned, the method of the present invention is effected under conditions sufficient to form an immunocomplex (e.g. a complex between the antibodies or antigen-binding fragments (e.g., scFvs) of the present invention and the alpha-synuclein oligomers/PFF); such conditions (e.g., appropriate concentrations, buffers, temperatures, reaction times) as well as methods to optimize such conditions are known to those skilled in the art, and examples are disclosed herein.
- Accordingly there is provided a method of diagnosing a synucleinopathic disease in a subject, comprising:
- (a) assessing the level, localization, conformation or a combination thereof of alpha-synuclein in a subject to be diagnosed with the antibody or antigen-binding fragment thereof (e.g., scFv) as described herein, optionally attached to a detectable moiety;
- (b) comparing the level, localization, conformation or combination thereof of alpha-synuclein in the subject to one or more reference standards derived from one or more control samples,
- The detection/diagnosis can be effected in-vitro on a biological sample.
- Alternatively, detection/diagnosis can be effected in-vivo.
- Examples of biological samples that can be used in accordance with the present teachings include, but are not limited to, blood, serum, plasma, CSF, brain tissue from biopsies/ urine and sputum).
- The selection of the detection method will much depend on the detectable moiety.
- Thus, determining a presence or level of the immunocomplex of the present invention is dependent on the detectable moiety to which the antibody or antigen-binding fragment thereof (e.g., scFv) is attached.
- Examples of detectable moieties that can be used in the present invention include but are not limited to radioactive isotopes, phosphorescent chemicals, chemiluminescent chemicals, fluorescent chemicals, enzymes, fluorescent polypeptides and epitope tags. The detectable moiety can be a member of a binding pair, which is identifiable via its interaction with an additional member of the binding pair, and a label which is directly visualized. In one example, the member of the binding pair is an antigen which is identified by a corresponding labeled antibody. In one example, the label is a fluorescent protein or an enzyme producing a colorimetric reaction.
- Further examples of detectable moieties, include those detectable by Positron Emission Tomagraphy (PET) and Magnetic Resonance Imaging (MRI), all of which are well known to those of skill in the art.
- When the detectable moiety is a polypeptide, the immunolabel (i.e. the antibody or antigen-binding fragment thereof (e.g., scFv) conjugated to the detectable moiety) can be produced by recombinant means or may be chemically synthesized by, for example, the stepwise addition of one or more amino acid residues in defined order using solid phase peptide synthetic techniques. Examples of polypeptide detectable moieties that can be linked to the antibodies of the present invention using recombinant DNA technology (in which the polynucleotide encoding the antibody is translationally fused to the detectable moiety) include fluorescent polypeptides, phosphorescent polypeptides, enzymes and epitope tags.
- Alternatively, chemical attachment of a detectable moiety to the antibodies or antigen-binding fragments thereof (e.g., scFvs) provided herein can be effected using any suitable chemical linkage, direct or indirect, as via a peptide bond (when the detectable moiety is a polypeptide), or via covalent bonding to an intervening linker element, such as a linker peptide or other chemical moiety, such as an organic polymer. Such chimeric peptides can be linked via bonding at the carboxy (C) or amino (N) termini of the peptides, or via bonding to internal chemical groups such as straight, branched or cyclic side chains, internal carbon or nitrogen atoms, and the like. Such modified peptides can be easily identified and prepared by one of ordinary skill in the art, using well known methods of peptide synthesis and/or covalent linkage of peptides. Description of fluorescent labeling of antibodies is provided in details in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110.
- Thus, the conjugates described herein can be prepared by known methods of linking antibodies with lipids, carbohydrates, protein, toxins, drugs or other atoms and molecules. In some embodiments, the conjugate is formed by site-specific conjugation using a suitable linkage or bond. Site-specific conjugation is more likely to preserve the binding activity of the antibody or antigen-binding fragment thereof (e.g., scFv). The substance can be conjugate or attached at the hinge region of a reduced antigen binding construct via thioether bond formation. In some embodiments, tyrosine conjugation can be employed. Other linkages or bonds used to form the conjugate can include, but are not limited to, a covalent bond, a non-covalent bond, a disulfide linkage, a hydrazone linkage, an ester linkage, an amido linkage, and amino linkage, an imino linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage and a carbon-carbon linkage. In some embodiments, no cysteine or other linking aspect, need be included in antibody (Bioconjugate Techniques (Third Edition) Author(s): Greg T. Hermanson ISBN: 978-0-12-382239-0).
- Exemplary methods for conjugating moieties are described in WO2017/027325 and U.S. 9,078,931, each of which is hereby incorporated by reference in its entirety.
- The level, localization, and/or conformation of alpha-synuclein can be assessed by any suitable method known in the art comprising, e.g., analyzing alpha-synuclein by one or more techniques chosen from Western blot, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent activated cell sorting (FACS), two-dimensional gel electrophoresis, mass spectroscopy (MS), matrix-assisted laser desorption/ionization-time of flight-MS (MALDI-TOF), surface-enhanced laser desorption ionization-time of flight (SELDI-TOF), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), multidimensional liquid chromatography (LC) followed by tandem mass spectrometry (MS/MS), and laser densitometry. In vivo imaging of alpha-synuclein can comprise positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR) optical imaging, or magnetic resonance imaging (MRI).
- Also provided is a composition comprising a biological sample of a subject diagnosed with a synucleinopathy (or being suspected as having the disease) and the antibody or antigen-binding fragment thereof (e.g., scFv) as described herein.
- The present methods can be used to classify the disease determining responsiveness to treatment, selecting treatment and determining disease outcome.
- According to some embodiments of the invention, the method further comprises informing the subject of the predicted diagnosis, treatment and/or the predicted prognosis of the subject.
- As mentioned the antibodies or antigen-binding fragments thereof (e.g., scFv) provided herein can also be used in therapeutics. One or more polynucleotides encoding the antibodies or antigen-binding fragments thereof can also be used in therapeutics.
- Thus, according to an aspect of the invention there is provided a method of treating or preventing a synucleinopathic disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) (optionally devoid of an Fc), thereby treating or preventing the synucleinopathic disease.
- According to an aspect there is provided a method of treating or preventing neuroinflammation in a subject, the method comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) (not necessarily devoid of an Fc), thereby treating or preventing the neuroinflammation.
- According to a specific embodiment the antibody or antigen-binding fragment thereof (e.g., scFv) is administered to the subject. According to a specific embodiment one or more polynucleotides encoding the antibody or antigen-binding fragment thereof (e.g., scFv) are administered to the subject. The one or more polynucleotides can be contained in one or more vectors. The vectors can be, for example, viral vectors such as adenoviral vectors or lentiviral vectors.
- Synucleinopathic diseases or synucleinopathies are a diverse group of neurodegenerative disorders that share a common pathologic lesion composed of aggregates of insoluble alpha-synuclein protein in selectively vulnerable populations of neurons and glia. Thus, the hallmark is accumulation and/or deposition of alpha-synuclein in the brain and the central nervous system. These disorders include, but are not limited to, Parkinson’s disease (PD), Parkinson’s Disease Dementia (PDD), dementia with Lewy bodies (DLB), juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease), pure autonomic failure (PAF), multiple system atrophy (MSA) and neurodegeneration with brain iron accumulation type-1 (NBIA-I).
- They are characterized by a chronic and progressive decline in motor, cognitive, behavioral, and autonomic functions, depending on the distribution of the lesions.
- Parkinson’s disease is an age-dependent neurodegenerative disease with unknown etiology. It is believed that sporadic Parkinson’s disease results from a combination of genetic vulnerability and environmental insults. It is further believed that Parkinson’s disease (PD), while triggered by disparate mechanisms follows a shared pathophysiologic pathway. One shared node is the involvement of alpha-synuclein. Linkage of this protein with Parkinson’s disease pathogenesis has been established by the identification of both point mutations and triplication of the gene in familial cases, the localization of alpha-synuclein to Lewy bodies, one of the hallmark pathological features of Parkinson’s disease, and the correlation of alpha-synuclein expression and disease pathology in neurotoxic models of Parkinson’s disease. Further evidence indicates that particular forms of alpha-synuclein (e.g., misfolded and alpha-synuclein bonded dopamine) are involved in sporadic disease.
- As used herein, the term “neuroinflammatory disease or disorder” refers to a medical condition that is manifested by inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. Examples of neuroinflammatory diseases or disorders include, but not limited to, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Alzheimer’s Disease (AD), Traumatic Brain Injury (TBI), irritable bowel syndrome, schizophrenia, bipolar disorder, depression, anxiety (generalized anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder, dementia, autism spectrum disorder (autism, asperger’s disorder, pervasive developmental disorder, childhood disintegrative disorder), ataxia telangiectasia, Coackayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease,
spinocerebellare ataxia type 3, neuroborreliosis, primary lateral sclerosis, progressive supranuclear palsy, Schilder’s disease, subacute combined degeneration of spinal cord secondary to pernicious anemia, drug-induced demyelination, radiation induced demyelination, spinal muscular atrophy, tabes dorsales, spinal cord injury, chronic inflammatory demyelinating neuropathy, a congenital metabolic disorder, polymyositis, temporal arteritis, vasculitis, autism, and interstitial cystitis, Hurler’s Syndrome, Scheie’s Syndrome, Hunter’s Syndrome, San Fillipo’s Syndrome, Maroteaux-Lany Syndrome, Sly Syndrome, Fucosidosis, Alpha-mannosidosis, Beta-mannosidosis, Schindler’s Disease, Pompeii’s Disease, Woman’s Disease, and Infantile Neuronal Ceroid Lipofuscinosis. - As used herein “subject in need thereof” includes mammals, preferably human beings at any age which suffer from the pathology, i.e., synucleinopathy or neuroinflammation. According to a specific embodiment, this term encompasses individuals who are at risk to develop the pathology.
- As mentioned, it may be desirable to use the non-Fc containing fragment and smallest (with lowest molecular weight) as possible antibody fragments for therapeutic purposes.
- The antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector,or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein can be administered to an organism per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
- As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
- Herein the term “active ingredient” refers to the antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein accountable for the biological effect.
- Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.
- Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.
- According to some embodiments of the invention, the administration route is intranasal.
- Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
- Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.
- The term “tissue” refers to part of an organism consisting of cells designed to perform a function or functions. Examples include, but are not limited to, brain tissue, retina, skin tissue, hepatic tissue, pancreatic tissue, bone, cartilage, connective tissue, blood tissue, muscle tissue, cardiac tissue brain tissue, vascular tissue, renal tissue, pulmonary tissue, gonadal tissue, hematopoietic tissue.
- Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (antibody or antigen-binding fragment thereof (e.g., scFv), the composition, the polynucleotide, the vector, or the cell comprising the antibody or antigen-binding fragment thereof (e.g., scFv) of some aspects provided herein) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., synucleinopathy) or prolong the survival of the subject being treated.
- Furthermore, a pharmaceutical composition can be formulated as a vaccine, for example, if the pharmaceutical composition of the invention comprises an anti-alpha-synuclein antibody or antigen-binding fragment thereof (e.g., scFv), as described herein, for passive immunization. As mentioned in the background section, oligomeric species of alpha-synuclein have been reported extracellularly in plasma and CSF (El-Agnaf et al., FASEB J. 20 (2006), 419-425) and passive immunization studies in mouse models of Parkinson’s disease show that extracellular mouse monoclonal antibodies against alpha-synuclein can reduce accumulation of intracellular alpha-synuclein aggregates (Masliah et al., Neuron, 46 (2005), 857-868). Accordingly it is prudent to expect that the human anti-alpha-synuclein antibodies or antigen-binding fragment thereof (e.g., scFv) provided herein are particularly useful as a vaccine for the prevention or amelioration of the medical conditions described herein e.g., synucleinopathic diseases such as PD, DLB and MSA.
- Compositions of some aspects provided herein may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- Hence, certain aspects provided herein relate to the use of the alpha-synuclein antibody or antigen-binding fragment thereof, the polynucleotide, the vector, or the cell provided herein for the preparation of a pharmaceutical or diagnostic composition for prophylactic and therapeutic treatment of a synucleinopathic disease or neuroinflammation, monitoring the progression of a synucleinopathic disease or neuroinflammation or a response to a synucleinopathic disease treatment or neuroinflammation treatment in a subject or for determining a subject’s risk for developing a synucleinopathic disease or neuroinflammation.
- As used herein the term “about” refers to ± 10 %.
- The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
- The term “consisting of” means “including and limited to”.
- The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
- As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- Throughout this application, various aspects of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.
- As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
- It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
- Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
- Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
- Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Maryland (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., ed. (1994); “Current Protocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., Eds. (1984); “Animal Cell Culture” Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, CA (1990); Marshak et al., “Strategies for Protein Purification and Characterization - A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
- Purified α-syn monomer (1 mg Alexotech, Sweden) was thawed in a 1.5-ml microcentrifuge tube in a 37° C. water bath until complete thawing. The tube was centrifuged at 100,000 × g at 4° C. for 60 min to pellet any aggregated material. Supernatant was removed and diluted with PBS in a new, low binding sterile 1.5-ml micro centrifuge tube (Protein LoBind Tube 1.5, Eppendorf tubes, Cat no.: 022431081) for the use of generating PFFs in to a final volume of 200 µl and a final concentration of 5 mg/ml. Tube was placed in a closed thermomixer (QSR technologies, U.S.A) at 37° C. incubation for 7d at 1000 rpm (solution should appear turbid). The solution was divided into aliquots (10-20 µl) into sterile microcentrifuge tubes and stored at -80° C. Before use, PFF was centrifuged at 100,000 × g, 4° C. for 60 min. The supernatant was removed and PFF was sonicated in new sterile PBS (20
% power 1 sec on 1 sec off in 60 sec total on (30 sec net on time)). - Purified α-syn monomer (2 mg/ml Alexotech, Sweden) (in PBS, pH 7.4) was mixed together with HNE (4-Hydroxynonenal) 20 mg/ml (in DMSO) in a low binding tube (Protein LoBind Tube 1.5, Eppendorf tubes, Cat no.: 022431081) for a final concentration of 140 µM α-syn and 4200 µM HNE, respectively. Samples were incubated at 37° C. for 18 h and analyzed in SDS-PAGE, silver stain (manufacture protocol). A 14 KDa form is the oligomer (aSyn adopts extended conformation oligomeric form (spherical - monomers to hexamers), with dimers being the major species (SDS resistant) and PFF Fibril forms (dimers and above). Of note, there can be an overlap in the size but not in the structure (fibril vs. round oligomers).
- The toxicity of a-syn fibrils was assessed by the MTT cell viability assay on differentiated human neuroblastoma SH-SY5Y cells. For the MTT assay, cells were plated at a density of 10,000 cells per well on 96-well plates in 100 µl of culture medium per well. Following 24 h, the medium was exchanged with 100 µl of fresh medium containing 10 µM of retinoic acid (RA) for neuronal differentiation. After 96 additional hours, 0.0625 µM of alpha-syn fibrils, 0.0156 µM a-syn oligomers or human PD brain extracts (1:1000 in PBS) were incubated with PMS208 or sham scFv (80R a proprietary unspecific protein engineered clone) for additional 4 h at room temperature and added to the differentiated neuronal cells for 24 h at 37° C. Control samples were prepared with the addition of identical volumes of buffer. After 24 h of incubation, the cells were incubated for another 4 h with 100 µl of serum-free Dulbecco’s modified Eagle’s medium without phenol red, containing 0.5 mg/ml MTT. Then, 100 µl of cell lysis solution (20 % SDS, 50 % N,N- dimethylformamide) were added to each well, and the samples were incubated over night at 37° C. to allow complete lysis. The absorbance of the formazan was measured at 570 nm in a Tecan infinite 200 pro microplate reader (Tecan, Männedorf, Switzerland).
- Human PBMC’s, BV-2 (mouse microglia, ICLC ATL03001) and peritoneal mouse macrophages were split into 12 well culture plates (Greiner CELLSTAR multiwell culture plates) on the day before the experiment. 0.3 µM synuclein fibrils or oligomers conjugated with
Alexa 488, pre-incubated with either 0.1, 0.5, 1.5, 3, 4 and 5 µg/ml PMS208 or PMS208-Fc for 30 min at room temperature, were added to cells with culture media (RPMI 1640, 10% FBS, 2 mM L-Glutamine, 1% Pen/Strep). The conditioned medium was also pre-incubated with PMS208 (without pff/oligomers) for 30 min as control. Cells were then incubated at 37° C. for 24 h and harvested. Flow cytometry (FL1 - blue laser (488 nm) was used to measure fibrils/oligomers (conjugated to ALEXA fluor 488) uptake indicated as relative geomean fluorescence intensity (gMFI). Cytochalasin D (Cyto D) is an antibiotic which is used to inhibit cellular uptake (control). - α-Syn in 10 mM phosphate buffer, pH 7.4, was filtered to ensure removal of preformed aggregates and then incubated at 37° C. with shaking at 1000 rpm (Thermomixer, QSR technologies, U.S.A) for 6 days in the presence of 2 different PMS208 concentrations. Aliquots of the reactions were removed at each time point and added to a 10 µM Thioflavin T (ThT) (Sigma, T3516) solution (prepared from a stock dissolved in 10 mM phosphate buffer, pH 7.4) in a low-binding black 96-well plate (Corning).Fluorescent measurements were performed using a Tecan infinite 200 pro microplate fluorescent reader (Tecan, Männedorf, Switzerland) recording fluorescence measurements from 440 to 485 nm. All measurements were performed in triplicate.
- Aliquot of 5 mg/ml PFF were thawed at room temperature immediately before use. PFFs were added to sterile PBS to a final concentration of 0.1 mg/ml (minimal volume for use is 200 ul) and then sonicated with 60 pulses at 10% power (total of 30s, 0.5 sec on, 0.5 sec off). Sonicated PFFs or equivalent volume of PBS as a control were diluted with prewarmed neuronal medium in a 1:20 dilution (with and without PMS208 treatment (15 ug/ml)) and added to neurons (primary neurons derived from wild-type, nontransgenic p0 mouse pups, (M J Beaudoin et al; Nature protocols)) 7 days after plating for additional 7-10 days. About 50 % of the medium was changed once a week (the fresh medium does not need to contain more fibrils as the seeding takes place only once at the beginning of the experiment). Next, primary neuron culture cells were rinsed twice with PBS and each well was completely aspirated before adding ice cold RIPA lysis buffer with protease and phosphotase inhibitors. Neuronal cells were taken out from wells using a cell scraper and placed in a low binding 1.5ml tubes on ice. Next, cells were sonicated (1 sec on, 1 sec off,
time 5 sec -20%) and incubated on ice for 30 minutes. Samples were centrifuged at 17,000 × g at 4° C. for 60 min, and supernatants were removed to a new low-binding 1.5 ml tubes, retained on ice or in a -20° C. freezer while additional (same volume) ice-cold RIPA lysis buffer with protease and phosphatase inhibitors was added to the pellet. The pellet tube was sonicated (1 sec on, 1 sec off,time 5 sec -20%) and centrifuged at 17,000 × g at room temperature for additional 80 minutes, supernatant was discarded, and 2 % (wt/vol) of SDS/RIPA added to the pellet with protease and phosphatase inhibitors. Cells were sonicated (1 sec on, 1 sec off,time 16 sec -20%), and a BCA/protein assay was performed on TX-100 supernatant and SDS extract. Samples were diluted with 2 % (wt/vol) SDS extract intoLaemmli buffer 2× + beta mercaptoethanol and heated at 95° C. for 5 minutes before loading on a 10% (wt/vol) gel. Proteins were transferred from a gel to a nitrocellulose membrane according to the manufacturer’s instructions at 100 V for 75 minutes or overnight at 40 V. Membrane was blocked for 1 hour with TBST/5% (wt/vol) milk, stained with diluted primary antibodies (mouse anti-human aSyn (clone Syn204, BioLegend) 1:1000, rabbit anti-rodent synuclein (D37A6, CellSignal) 1:1000, anti-GAPDH (clone 6C5, Millipore) 1:2000followed by secondary antibodies peroxidase-AffiniPure goat anti-mouse IgG (Jackson) 1:10000, mouse anti-rabbit IgG (Jackson)) 1:10000 TBS/1 % (wt/vol) BSA, incubated for additional 1 hour (both primary and secondary separately) while shaking and rinsed × 3 times (5 minutes each rinse) before enhanced chemiluminescence development. - Human sera and human CSF obtained from PD patients were immunoprecipitated with different amounts of PMS208-Fc (5, 10 and 50 µg) bound to Dynabeads protein A (Dynabeads® Protein A for IP 1ml, Life technologies, Grand Island, NY, USA) following manufacturer’s instructions, then separated by SDS-PAGE (Bis-Tris 4-12% acrylamide) and transferred to protran nitrocellulose membranes. Membranes were analyzed by immunoblot for alpha-synuclein using mouse anti-human aSyn (clone Syn204, BioLegend-BLG838201; 1:1000) and mouse anti-aSyn phospho (Ser129) (clone P-syn/81A, BioLegend-BLG825701; 1:500) following peroxidase-AffiniPure goat anti-mouse IgG (Jackson; 1:10,000) before enhanced chemiluminescence development. 100 ng of recombinant human aSyn PFF and PBS were immunoprecipitated with 50 µg of PMS208-Fc bound to Dynabeads as positive and negative control respectively.
- WT mice (C57BL/6JRccHsd background) and Rats (Sprague-Dawley) were purchased from Envigo RMS (Israel), Ltd. All housing, breeding, and procedures were performed according to the National Institute of Health (NIH) Guide for the Care and Use of Experimental Animals and approved by the Kaplan Medical Center Institutional Animal Care and Use Committee.
- This study was performed at Kaplan Medical Centre in Rehovot, Israel under appropriate Institutional Review Board approval. Blood samples were obtained from the Israel National Blood Services (MDA) except for CSF and brain specimens included in the study which were collected at the Cambridge Brain Bank supported by the NIHR Cambridge Biomedical Research Centre.
- 50 Male (5 groups of n = 10) C57BL/6JRccHsd mice (2-4 months of age) were anesthetized by Isoflurane, and stereotaxically injected with recombinant aSyn fibrils (7 µg of PFF per brain) in PBS. Control C57BL/6JRccHsd animals received sterile PBS. A single needle insertion (coordinates: +0.2 mm relative to bregma, 2.0 mm from midline) into the right forebrain was used to target the inoculum to the dorsal neostriatum located at a depth of 2.6 mm below the dura. Material was injected via a 10µl Hamilton syringe at a rate of 0.5 µl per min (3.5 µl total volume) with the needle in place (33G) for ≥10 min at each target. Animals were inoculated at the right hemisphere unless otherwise indicated. After recovery from surgery, animals were treated by intranasal (IN) administration with 3 concentrations of PMS208 (16 ug/kg, 80 ug/kg and 320 ug/kg) twice a week, behavior tests (Grip test, Rota rod, Cylinder and NOR) were conducted at various predetermined time points before they were sacrificed at 9 weeks post injections by overdose with ketamine/xylazine and then transcardial perfusion with PBS (and additional perfusion with 4% formalin for histological studies). For histological studies the brain was removed and underwent overnight postfixation with neutral buffered formalin (Thermo Fisher Scientific), before being processed and embedded in O.C.T compound (Ref 4583, Tissue-Tek) - used for binding tissue to the specimen block and to surround and cover the tissue specimen. For biochemical studies, tissues were immediately frozen after removal and stored at -80° C. until used.
- 38 female (5 groups) Sprague-Dawley rats (225-250 g) were anesthetized with an intraperitoneal injection of ketamine hydrochloride (100 mg/kg) and xylazine (10 mg/kg), and stereotaxically injected with AAV-αSyn into the right hemisphere. Injections were made into the SN at the following coordinates: anteroposterior (AP), -5.3; mediolateral (ML), +1.7; dorsoventral (DV), -7.2;. Control animals received sterile PBS. Material was injected via a 10 µl Hamilton syringe at a rate of 0.3 µl per min with the needle in place (33G) for ≥10 min at each target. Animals were inoculated at the right hemisphere unless otherwise indicated. After recovery from surgery, animals were treated by intranasal (i.n.) administration with 3 concentrations of PMS208 (5 ug/kg, 50 ug/kg, and 250 ug/kg) 2 times/week, behavior tests (Two limb wire hang, Cylinder and Open Field) were conducted at various predetermined time points before they were sacrificed at 7 weeks post injections by overdose with ketamine/xylazine and then transcardial perfusion with PBS (and additional perfusion with 4% formalin for histological studies). For histological studies the brain was removed and underwent overnight postfixation with neutral buffered formalin (Thermo Fisher Scientific), before being processed and embedded in O.CT. For biochemical studies, tissues were immediately frozen after removal and stored at -80° C. until used. CSF and blood serum was collected from all animals. The AAV2 vector was used to overexpress human wild-type α-syn, in which the expression of the transgene is driven by the human CMV promoter. A total of 8 × 108 IFU were injected per animal (6 µL per animal).
- 24 adult male (3 groups) Sprague-Dawley rats (175-200 g) were anesthetized with an intraperitoneal (i.p.) injection of ketamine hydrochloride (100 mg/kg) and xylazine (10 mg/kg), and injected daily i.p. for 12 days with 1.5 mg/kg/d Rotenone (dissolved in DMSO/Olive oil), 2 mg/kg/d from
day 5 and 2.5 mg/kg/d fromday 9 prepared fresh twice a week. Animals were treated by intranasal (i.n.) administration with 10 µg (~40 µg/kg) of PMS208 (5 µg in each nozzle) and PBS as sham at the first and every 3 days after (4 total). Behavior tests (Cylinder and Postural instability) were conducted at various predetermined time points before they were sacrificed atday 12. Transcardial perfusion with PBS and 4 % formalin was done in all animals. For histological studies the brain was removed and underwent overnight postfixation with neutral buffered formalin (Thermo Fisher Scientific), before being processed and embedded in O.C.T. For biochemical studies, tissues were immediately frozen after removal and stored at -80° C. until used. CSF was collected from all animals. - The rotenone solution was first prepared as a 50× stock in 100 % dimethylsulfoxide (DMSO) and diluted in olive oil, to obtain a final concentration of 1.5, 2, or 2.5 mg/mL rotenone in olive oil, 2 % DMSO. Vortexing the solution creates a stable emulsion of the DMSO containing rotenone and olive oil. The solution was made fresh 2-3 times/week and stored in an amber septa vial protected from light and inverted several times before each injection to eliminate the possibility of settling. The solution was administered at 1 mL/kg, and control animals received the vehicle only. Experimental groups were comprised of at least 4-10 animals. Rotenone was administered by increased doses (
day 0,day 2, and day 6) once a day for 12 consecutive days. - Brains were extracted and post-fixed in 4% PFA for 24 h and sunk in 30% sucrose. Brains were frozen on a microtome platform and cut to generate 16 and 40 µm thick sections. A series of free-floating coronal sections was stained for either tyrosine hydroxylase (TH) or phosphorylated α-syn (pSyn). Tissue was incubated in 0.3% H2O2 for 45 min, rinsed, and blocked in 10% normal goat serum (1 h) and then incubated in primary mouse anti-pSyn (Ser129) (1:500, biolegend), mouse-anti-TH (1:200) antibodies overnight at 4° C. Then, sections were incubated in biotinylated secondary antisera against either mouse (1:400, Millipore, Temecula, CA) or rabbit IgG (1:400, Millipore, Temecula, CA) followed by the Vector ABC detection kit (Vector Labs, Burlingame, CA). Antibody labeling was visualized by exposure to 0.5 mg/
ml - Whole blood was diluted 1:1 ratio with PBS (Ca/Mg free), gently laid in ficoll (ratio 1:2), and centrifuged for 30 min, 1500 rpm (with slow acceleration and de-acceleration (0)). Buffy coat was collected into a new tube, washed with PBS, and centrifuged for 15 min in 1200 rpm. Additional wash with PBS was supplemented, and blood was centrifuged for 15 min in 1200 rpm before cells were resuspended in 10 ml PBS for counting.
- IL-6 and TNF-alpha (TNFa) protein levels in cells were detected using DuoSet Elisa assay (R&D System) following manufacturer protocol.
- The assay is done by culturing PBMCs for 14 days (dilution of 1:1 with medium supplemented with IL-2 each couple of days) with PFF/oligomers in order to stimulate helper and cytotoxic T cells and then to test whether a-Syn pff/oligomers were recognized by those cells.
- Specifically, culturing of PBMCs for in vitro expansion was performed by incubating in RPMI (Biological Industries, Israel) supplemented with 5% human AB serum (Biological Industries, Israel), GlutaMAX (Gibco), and penicillin and streptomycin (Biological Industries, Israel) at 2 × 106 per ml in the presence of alpha-synuclein PFF/oligomers at 10 µg/ml. Every three days, 10 U/mlIL-2 in medium was added to the cultures. After 14 days, cultures were stimulated with 25 µg/ml fibrilized α-syn or 25 µg/ml oligomerized α-syn and the response was measured by IFNγ and IL-5 ELISPOT. ELISPOT antibodies, mouse anti- human IFNγ (clone 1-D1K), mouse anti-human IL-5 (clone TRFK5), mouse anti-human IFNγ-HRP (clone 7-B6-1), and mouse anti-human IL-5 biotinylated (clone 5A10) were all from Mabtech.
- 10-week old mice were injected with human a-syn PFF or oligomers into the striatum (with and without PMS208 treatment) to examine in vivo neuroinflammation. 72 hours post-intrastriatal injections, animals were sacrificed, and brains were dissected and homogenized. RNA from whole brain and suspension cells was isolated using SV total RNA isolation system kit (Promega) or EZ-RNA Total RNA Isolation Kit (Biological Industries, Israel) respectively following the manufacturer’s protocol. Complementary DNA (cDNA) synthesis was carried out with qScript cDNA Synthesis Kit (Quanta bio) using 2 µg of total RNA as template. In order to examine neuroinflammation relative quantitation of gene expression was conducted by real time PCR carried out using TaqMan® Gene Expression Assay (Applied Biosystems). Fluorescent (FAM)-labeled IL-6, TNFa, INFγ, IL-12,
Caspase 3, Arg1, Chi3l3, and Mrc1 were normalized to a internal control, GAPDH. All comparisons refer to sham. Analysis was done using the Comparative Ct Method (ΔΔCT). - Cylinder test is a motor assessment of forelimb asymmetry. Rats were individually put into a glass cylinder (20 cm diameter, 34 cm height) and were video recorded for 5 minutes and until they touched the cylinder wall with their
forelimbs 20 times. The recordings were analyzed by an investigator who was not aware of the identity of the rats. The data are presented as the following formula: (Left touch)/(Right touch+Left touch+Both touch). - Neuromuscular strength was tested with a wire hang test. The mouse was placed on a wire mesh, waved gently so that the mouse gripped the wire, and then inverted. Latency to fall was recorded with a 15 minutes cut-off time.
- Neuromuscular strength was tested with a two limb wire hang test. The rat was placed on a wire string, waved gently so that the rat gripped the wire. Latency to fall was recorded with a 10 minutes cut-off time.
- The Ugo Basile 47650 - Mouse NG rotarod treadmill (Ugo Basile) was used to assess fine motor coordination and balance. Rotarod performance is measured on a rotating rod as the mice must walk forward to avoid falling off a continuously rotating cylinder (Carter et al. 1999; Jones and Roberts 1968). Pre-training consisted of 4 consecutive trials at low rotational speed of 20 rpm. Two trials were measured on a rod that accelerates from 0-50 rpm, and the average time on the rod for each mouse was used for data analysis. Time on the rod was used to assess fine motor coordination and balance.
- When placed in a clear cylinder, rats will engage in exploratory behavior, including rearing. During rearing behavior, the forelimbs will contact the wall of the cylinder. For this test, the rat was placed in a clear plexiglass cylinder (height = 30 cm, diameter = 20 cm) for 3 minutes. The test was conducted under low red-light conditions and video-recorded, and during video playback, the number of rears was quantified. To be classified as a rear, the animal had to raise forelimbs above shoulder level and make contact with the cylinder wall with either one or both forelimbs. Removal of both forelimbs from the cylinder wall and contact with the table surface was required before another rear was scored. This test has been successfully used previously to assess behavioral deficits in the rats receiving subcutaneous or intravenous rotenone.
- 24 hours before testing, all animals were habituated to the testing apparatus for 10 minutes (50 cm box, 40 cm high). The day after, animals were introduced to the objects: first, two identical objects were placed in the box, and mice were allowed to explore objects for 5 minutes. The same procedure continued until 5 mice were done. The entire phase for 5 mice lasted 30 minutes. Immediately after, these 5 mice were tested in the same order as before. Animals were introduced to two different objects, one familiar object and one novel object that the mice never encountered. Mice were allowed to explore objects for 5 minutes and then removed from the box. At all phases, after each mouse was removed from the box, the box was sterilized with alcohol. Sample and novel objects and their locations were counterbalanced across animals. Each trial was videotaped, and time and frequency spent with each object was measured using Noldus EthoVision XT 11.5 (Noldus information Technology, The Netherlands).
- Values shown in the Figures are presented as mean +/- SEM. P values for determination of the statistical significance of differences were calculated by means of paired, two-tailed Student’s t test, two-tailed Mann-Whitney U or Wilcoxon’s rank-sum tests, one-way ANOVA with a post hoc Dunnet’s or one-way ANOVA with Tukey’s post test.
- A human Fab/scFv library with a repertoire from over 110 individuals and diversity of 1×1011 was screened against recombinant modified human alpha-synuclein (PFF and oligomers). Use of this library allows for the identification of combinations of variable heavy and variable light chains that are not found together in any of the 110 individuals. High-affinity binders were selected by 3 rounds of bio-panning in which 42 positive clones were identified (
FIG. 1 ) and sequenced. From sequencing data, 6 clones were identified with unique variable regions. These 6 clones, namedFab 1 toFab 6, were subsequently expressed in E. coli in large scale as a Fab antibody format (50 KDa). Following Nickel column purification, the Fabs were analyzed by SDS-gel, and their protein concentrations were determined. - A standard ELISA assay was performed using alpha-synuclein PFFs as the coating protein. As shown in
FIG. 2 , Fabs 1 (PMS208), 3 (PMS210), 4 (PMS211), and 5 (PMS212) bound to the coating protein in a concentration dependent manner. However, Fabs 2 (PMS209) and 6 (PMS213) did not show binding under these assay conditions. - Three selected unique clones (PMS208, PMS210 and PMS212) were cloned to a mammalian expression vector as a scFv conjugated to human IgG1 Fc format (scFv-Fc). GGGGS × 3(SEQ ID NO:47) linker was used to link between the variable regions from heavy (VH) and light (VL) chains (
FIG. 4 ). - PMS208 showed high affinity binding to alpha-synuclein PFF’s and oligomers seen in surface Plasmon resonance (Biacore SPR system, GE Healthcare Life Sciences) and ELISA assays in scFv-Fc format (
FIGS. 6 and 7 ), to both human and mouse alpha-synuclein PFF/oligomers. For human aSyn, see materials and methods (Preparation of alpha-synuclein PFFs). For mouse monomers, mouse alpha-synuclein gene was cloned into a mammalian expression vector with his-tag, and HEK293T cells were transfected with the vector to express mouse synuclein his-tag protein and then purified in His-trap column (FPLC). - PMS208 was cloned and expressed as single chain variable fragments (scFv) with a molecular weight of 25 KDa. The GSSSS × 3 (SEQ ID NO:47) linker was used to link the variable regions from heavy (VH) and light (VL) chains. PMS208 was expressed with and without his-tag for tests.
- The main component of pathological lesions (almost 90%) in patients with Parkinson’s Disease (PD) is extensively phosphorylated at α-syn serine 129 (pS129 α-syn), which may play a critical role in synucleinopathy pathogenesis. Phosphorylation at Ser129 can regulate α-syn fibril formation and enhance α-syn toxicity both in vitro and in vivo. Although trace levels of phosphorylated α-syn are detectable in normal brains, nearly all α-syn accumulated within Lewy bodies in Parkinson disease brains is phosphorylated on serine 129 (Ser-129). Phosphorylated α-syn can be secreted from neuronal cells and can be seen in the serum and CSF of PD patients.
- Human serum derived from PD patients and human CSF derived from Lewy Body Dementia (DLB) or PD patients were immunoprecipitated with PMS208-Fc to determine its ability to bind endogenous human alpha-synuclein. Three different amounts of PMS208-Fc (50 µg, 10 µg, and 5 µg) were able to immunoprecipitate α-syn from PD patients sera and DLB/PD patients CSF (
FIGS. 7A and 7B ). Samples were stained with a commercial anti-human α-syn (FIG. 7A , left panel) and anti-human phosphorylated (Ser-129) α-syn (FIG. 7A , right panel andFIG. 7B ). Human recombinant PFF immunoprecipitation with PMS208-Fc was done as positive control for α-syn binding (FIG. 7A , left panel andFIG. 7B ) and negative control for serine 129 α-syn phosphorylation (there is no phosphorylation in serine 129, seen inFIG. 7A , right panel andFIG. 7B ). - The cytotoxicity of a-syn fibrils and oligomers was assessed on differentiated human neuroblastoma SH-SY5Y cells using the 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (
FIGS. 9A-C ). Fibrillar a-syn and a-syn oligomers had a toxic effect on cells in low concentrations as seen by the cell viability assay (FIGS. 9A-C ). Incubation of PFF a-syn in the presence of increasing concentrations of PMS208, showed increase in cell viability in a dose dependent manner, while no affect was seen in the presence of sham (80R) (FIG. 8A ). Incubation of a-syn oligomers in the presence of increasing concentrations of PMS208, showed high increase in cell viability in concentration of 10 ug/ml (~76%) and similar slight increase in 6ug/ml, 4ug/ml and 1ug/ml concentrations of PMS208 (~35%). PMS208 concentration of 0.2 ug/ml had no effect in cell viability (FIG. 8B ). Human PD brain extracts (1:1000 in PBS) had a toxic affect on cells compared to control extracts (data not shown). PMS208 was able to protect cells as evidenced by increasing cell viability as seen inFIG. 8C . - PMS208 (scFv) was able to bind avidly its target alpha-synuclein in a number of human brain (striatum, cortex) PD, DLB, and control extracts seen in Western blot staining (
FIGS. 10A and 10B ), demonstrating its ability to recognize modified forms of α-syn in multiple patients with synucleinopathies. - Microglia is one of the major cell types which are involved in the inflammatory responses in the central nervous system (CNS) that appear to contribute to neuroinflammation in PD pathogenesis. This pro-inflammatory local state is evident by expression of tumor necrosis factor-α (TNF-α; TNFa), interleukin-1β (IL-1β), and interferon-gamma (IFN-γ) in the midbrain of PD patients which strongly suggest the involvement of immune components in PD pathogenesis.
- The scFv form of PMS208 down-regulates (in a dose dependent manner) a panel of pro-inflammatory cytokines (TNF-α, IL-6) produced by microglia after exposure to PFF, whereas Fc containing anti-aSyn antibodies up-regulate these same panel of proteins (
FIGS. 11E and 11F ). Monocytes range from 10 - 30% of human PBMCs, these cells move into tissues throughout the body where they differentiate into macrophages and dendritic cells. They serve three main functions in the immune system: antigen presentation, phagocytosis, and cytokine production.FIGS. 11A-C shows that PMS208 down-regulates (in a dose dependent manner) pro-inflammatory cytokine TNF-α produced by human peripheral blood macrophages after PFF or oligomers alpha-synuclein exposure compared to Fc containing anti-aSyn antibodies which up-regulate TNF-α mRNA and protein levels (FIGS. 11E and 11F ). - One of the main functions of macrophages and microglia in the immune system is phagocytosis thereby facilitating clearance of debri. They can also serve as antigen presenting cells that promote T cell mediated cellular immunity. Recently, it has also been shown that PD patients exhibit a systemic autoimmune response to α-syn modified forms further attesting to the role of inflammation in the pathogenesis. Activation of microglia by dying neurons or by various forms of α-syn, as well as T cells, could result in a vicious circle of neuroinflammation and neurodegeneration that is self perpetuating and drives the progression of PD. Flow cytometry was used to measure PFF/oligomers conjugated to Alexa fluor 488 (PFF-488/Oligo-488) cellular uptake (calculated by relative geomean fluorescent intensity (gMFI)) (
FIGS. 11A-11F ). - Flow cytometry analysis shows that PMS208 in scFv format attenuates mouse and human macrophages cellular uptake of PFF conjugated to Alexa fluor 488 (relative gMFI ~60) compared to cells with PBS treatment (relative gMFI ~590) seen in
FIGS. 12A and 12B .FIGS. 11C-F shows that PMS208 in scFv format attenuates mouse microglia cellular uptake of PFF (FIG. 11C ) and oligomers (FIG. 11D ) conjugated to Alexa fluor 488 (FIGS. 11C and 11D ) in a dose dependent manner, whereas Fc containing antibodies does not (FIGS. 11E and 11F ). - Mice were injected with human a-syn PFF into the striatum (with and without PMS208 treatment) to examine in vivo neuroinflammation.
- The scFv form of PMS208 down-regulated a panel of pro-inflammatory cytokines and up-regulated anti-inflammatory genes produced in mice brain after 72 hours of exposure to human PFF (
FIGS. 12A and 12C ) or oligomers (FIGS. 12B and 12D ) alpha-synuclein.FIG. 12A shows that PMS208 significantly down-regulates IL-6, IL-12, and INFγ pro-inflammatory cytokines mRNA expression levels after PFF exposure.FIG. 12B shows that PMS208 significantly down-regulates TNFa and INFγ pro-inflammatory cytokines mRNA expression levels after oligomers exposure. Whereas,FIG. 12C shows that PMS208 significantly up-regulates Arg1 (Arginase 1) and Chi313 (Ym1) mRNA expression levels after PFF exposure.FIG. 12D shows that PMS208 significantly up-regulates Arg1 and Chi313 mRNA expression levels after oligomers exposure. - α-synuclein aggregated forms act as antigenic epitopes and drive helper and cytotoxic T cell responses in patients with Parkinson’s disease. To determine whether α-syn pff/oligomers were recognized by T cells, HLA class I type and HLA class II responses were assayed. IFNγ was used as a representative cytokine to detect CD8+HLA class I and CD4+ T helper 1 (Th1) class II T cells, and IL-5 was used as a representative cytokine secreted by CD4+T helper 2 (Th2) class II T cells. Peripheral blood mononuclear cells (PBMCs) from patients with Parkinson’s disease were stimulated for 14 days (PFF/oligomers at 10 µg/ml, diluted 1:1 every 3-4 days). These cultures were then stimulated with α-synuclein PFF/oligomers (25 µg/ml) with and without PMS208 (15 µg/ml) and Interferon-γ (IFNγ) or interleukin-5 (IL-5) responses were measured by colour enzyme-linked immunospot (ELISPOT) assay, enabling quantification of responsive T cells.
- Fourteen (14) days of α-synuclein oligomers PBMCs stimulation compared to un-stimulated PBMCs (PBS) increased the number of IL-5 secreted cells when re-exposed to α-synuclein oligomers (
FIG. 13A ), indicating a prominent CD4+Th2 phenotype. The addition of PMS208 (5 ug/ml and 2ug/ml) to α-synuclein oligomers managed to tune down by half the autoimmune response as seen inFIG. 13A . PBMCs response to the α-synuclein PFF after 14 days of PFF stimulation increased twice the number of IFNγ secreted cells (FIG. 13C ) compared to un-stimulated PBMCs (PBS), indicating a prominent CD8+ HLA class I and CD4+T helper 1 (Th1) class II T cells phenotype. The addition of PMS208 (5ug/ml) to α-synuclein PFF tuned down the autoimmune response. - Aggregation of misfolded proteins is a feature common to many neurodegenerative diseases. Parkinson’s Disease is a progressive movement disorder which is characterized neuropathologically by the presence of intra-neuronal Lewy Bodies (LB) and Lewy Neurites (LN). Misfolded and aggregated alpha-synuclein (fibrillar alpha-synuclein) is major component of LB’s and LN’s.
- Misfolded proteins are rich in β-sheet structures with a high tendency to form long fibrillar aggregates known as amyloid deposits. β-structures are harder to degrade than α-helixes (main conformation of native proteins), which explains why amyloid deposits cannot be removed by the proteasome system. The aggregation of misfolded proteins is believed to occur when hydrophobic residues exposed at the surface of proteins interact with other misfolded proteins. Human recombinant alpha-synuclein monomers can be driven to aggregate by constant shaking (orbital shaker) 1000 rpm at 37′C for 7 days (
FIG. 14 ). As seen inFIG. 14 , PMS208 (aSyn+PMS208 7.5ug/ml and aSyn+PMS208 15ug/ml) has the ability to inhibit alpha-synuclein aggregation (measured by Thioflavin T aggregated protein staining assay), whereas alpha-synuclein without PMS208 (aSyn+PBS) aggregates. Alpha-synuclein monomers were measured at each time point for reference (monomer). - Evidence suggests that many neurodegenerative diseases involve spreading aggregation of specific proteins through the nervous system, potentially via a prion-like mechanism. Prion proteins propagate by auto-catalytic conversion of native, nonpathogenic forms of the protein expressed in several types of human cells, into misfolded pathological conformation. In prion disease, the pathological conformation is the primary infectious agent that propagates using a mechanism called “seeding/nucleation,” where misfolded pathological form of the protein acts like a seed that recruits and converts soluble protein into aggregates of native-nonpathogenic protein, which form polymers. As prions grow and spread, they interfere with the function of the nervous system, resulting in progression of the disease in affected patients.
- Synucleinopathies are typified by pathologically aggregated alpha-synuclein in specific neuronal (e.g., Parkinson’s Disease and Dementia with Lewy Bodies) or glial (e.g., Multiple System Atrophy) populations where cell loss occurs. In this model, the ability of PMS208 to abrogate PFF seeding was tested. Small seeds of PFFs generated from recombinant α-syn were added directly to primary neurons with and without PMS208. These seeds of PFFs induced recruitment of endogenously expressed α-syn into abnormal, phosphorylated, insoluble and ubiquitinated aggregates. The formation of these aggregates from endogenous a-syn in primary neurons derived from wild-type, nontransgenic mice follows an initial lag phase of 2-4 days, which are then seen in the SDS extract of neuronal cells (insoluble protein) in the nitrocellulose membrane immunostaining (
FIG. 15 upper panel - 2% SDS Pellet). PMS208 was able to abrogate endogenous alpha-synuclein aggregation by inhibiting the human PFF prion-like mechanism (Red arrow; PFF+PMS208-upper panel). Higher levels of alpha-synuclein are seen the SDS extract after human PFF “seeding” without PMS208 (PFF-upper panel). - Causes of sporadic PD remain unknown. Epidemiological studies suggest that exposures to pesticides, metals and solvents are contributing risk factors. In general, most sporadic cases are believed to stem from a combination of environmental exposures and individual genetic susceptibility. Several useful animal models of PD exist, each with its own advantages and disadvantages. The rotenone model of PD provides certain advantages in modeling the pathogenesis of PD. In this model, systemic inhibition of mitochondrial complex I produces selective degeneration of the nigrostriatal dopamine system and reproduces key pathological features of clinical PD. Indeed, rotenone administration affects many of the pathogenic pathways including: oxidative stress, alpha-synuclein phosphorylation and aggregation and Lewy pathology, DJ-1 acidification and translocation, proteasomal dysfunction and nigral iron accumulation.
- Daily intraperitoneal injections of rotenone in natural oil (olive oil) were done for 12 days in 20 animals. 4 animals were injected with natural oil only as a control group. Animals were treated by intranasal (i.n.) administration of PMS208 (~40 ug/kg) and PBS as sham at
day FIG. 16A ). PMS208 i.n. treatment was able to significantly reduce loss of weight as shown inFIG. 16A (Rotenone + PMS208) at days 9-12. Animals were placed in a clear cylinder to quantify rearing behavior (forelimbs contact with the wall of the cylinder). Animals treated i.n. with PMS208 were able to minimize decrease in rearing behavior (FIG. 16B ; rotenone+PMS208) as seen in sham treated animals (FIG. 16B ; Rotenone+sham) atday 12 compared today 0. - An ideal model would replicate most, if not all, of the behavioral and pathologic characteristics of PD. Traditional models of PD include neurotoxin models, such as 6-hydroxydopamine or MPTP, to lesion dopamine neurons of the SNpc (substantia nigra pars compacta). These models can successfully predict the efficacy of dopaminergic-based therapeutics to alleviate motor symptoms. However, many compounds that showed neuroprotection in the neurotoxin models have failed in clinical trials. Toxin models did not sufficiently take into account the contribution of pathologic α-synuclein. The progressive time course of the α-synuclein models has provided interesting data suggesting that synaptic abnormalities in the striatum precede neurodegeneration. One of the greatest advantages of the rAAV-a-synuclein model is that α-synuclein can be expressed in dopaminergic neurons of the SNpc for long periods of time (a cell population particularly vulnerable in PD). Expression of the human wild-type a-synuclein leads to progressive loss of dopaminergic neurons in the SNpc, and loss of dopamine terminals in the striatum. Showing significant defects in motor behavior. The rapid early loss of striatal dopamine function seen in the rAAV-a-synuclein model replicates the pattern seen in human disease. Furthermore, neuroinflammation is one of the most robust phenotypes found by rAAV-a-synuclein over-expression, and replicates many features seen in human PD. These changes include early activation of microglia, increased pro-inflammatory cytokine expression, increased adaptive and innate immune responses, and infiltration of lymphocytes before cell loss. This inflammatory induction is caused by over-expression of a-synuclein, and not the virus itself, because control mice injected with rAAV-green fluorescent protein (GFP) do not show neuroinflammatory responses. The increase in inflammation likely contributes to neurodegeneration. Thus, targeting signaling in the inflammatory pathway may provide a therapeutic target that can prevent the progression for PD.
- Testing neuromuscular strength,
FIG. 17A shows that 6-8 weeks post intra-striatal injections of rAAV-a-synuclein in rats, reduced their latency to fall (+ AAV-aSyn + PBS; ~3.5 sec) in a wire hang test compared to sham injected animals (- AAV-aSyn + PBS; ~15 sec). Intranasal repeated treatments of PMS208 (twice a week) in rats post intra-striatal injections of rAAV-a-synuclein were able to attenuate motor dysfunction by significantly increasing the animals latency to fall (+ AAV-aSyn + PMS208 (50 ug/kg); ~9:00sec). It is important to note that rAAV-a-synuclein is typically unilaterally injected because tests of asymmetric motor behavior can be easily quantified (tests rely on asymmetry in motor behavior produced by unilateral losses of dopamine neuron function). The cylinder test is one of the tests that also measures asymmetry in use of forelimbs. In this experiment, rats had intrastriatal injections of AAV-a-synuclein (unilaterally) in the right hemisphere.FIG. 17B shows a decrease in left paw use of AAV-a-synuclein injected animals (+ AAV-aSyn + PBS) compared to sham (- AAV-aSyn + PBS; ~8% increase). PMS208 i.n. treatment (5ug/kg) was able to increase left paw use of AAV-a-synuclein injected animals (+ AAV-aSyn + PMS208; ~7%). - Sonicated fibrils made from recombinant a-synuclein, when added to primary cultured neurons or injected into the striatum or other brain areas, can produce robust formation of inclusions that resemble Lewy bodies and Lewy neurites found in diseased brains. Thus, this model of PFF injection allows investigation of the impact of misfolded α-synuclein on the neuronal function and consequent phenotypes, and determination of whether preventing inclusion formation can reverse these phenotypes. Similar to rAAV-a-synuclein models, inducing inclusion formation with protein fibrils is advantageous because transgenic over-expression of human α-synuclein is not required. Inclusion formation occurs in neurons from hippocampus, cortex, and midbrain and other brain regions, and thus the impact of these aggregates on diverse neuronal populations can be examined. Regardless of the injection site, α-synuclein inclusions form at the injection site and appear in brain areas distant from the site of injection. In this model, defects occur well before any neuron death, suggesting that neuronal dysfunction emerges in response to abnormal α-synuclein very early before neurodegeneration begins. This is important in light of the development of novel techniques showing the presence of a-synuclein aggregates at a very early stage in brains of patients with PD and dementia with Lewy bodies.
- As shown in
FIGS. 18A and 18B , mice were evaluated for their latency to fall 12 weeks post intra-striatal mouse a-syn PFF injections. Wire hang was used to test neuromuscular strength. Animals injected with mouse PFF and i.n. treated with PBS (FIG. 18A ; + mouse PFF + PBS; ~8:30 min) had significantly lower latency than animals injected with PBS and treated i.n. with PBS used as control (- mouse PFF + PBS; ~12:00 min). PMS208 i.n. treated animals showed significantly increase in their latency to fall (+ mouse PFF + PMS208 (320 ug/kg); ~12:00 min) compared to untreated animals (+ mouse PFF + PBS; ~8:30 min). The rotarod treadmill was used to assess fine motor coordination and balance in treated mice. Three different concentrations of i.n. treatment of PMS208 (16 ug/kg, 80 ug/kg, and 320 ug/kg) increased significantly mice latency to fall (+ mouse PFF + PMS208; ~120 sec) compared to untreated animals with mouse PFF intra-striatal injections (+ mouse PFF + PBS; ~50 sec).FIG. 18C shows cognitive decline of mouse PFF injected animals (+ mouse PFF + PBS) compare to PBS injected controls (- mouse PFF + PBS) measured by their preference to a novel object. Above 50% (FIG. 18C ), animal preference is for the novel object (less cognitive decline). Intranasal treatment with PMS208 (+ mouse PFF + PMS208 (320 ug/kg); ~65%) significantly improved cognitive decline compare to untreated animals (+ mouse PFF + PBS; ~45%). The experiment was done in 50 animals, 10 animals per group (n = 10). -
FIG. 19 shows that animals injected with adeno-associated virus expressing human aSyn (AAV-aSyn) develop extensive and significantly greater loss of TH+ neurons in SN pars compacta (SNc) andstriatum 6 weeks post injections as seen in tyrosine hydroxylase immunostaining of brain coronal slices (FIG. 19 - middle panel; right hemisphere (RH)). PMS208 given intra-nassaly (i.n. - twice a week) decreases loss of TH+nigral neurons induced by AAV-aSyn in rats (FIG. 19 - right panel). There is no loss of TH+neurons seen in sham injectedanimals 6 weeks post injections (FIG. 19 - left panel). Human alpha-synuclein levels in coronal rat brain slices was confirmed by immunostaining. - Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
- All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
-
TABLE 1 Additional Sequences SEQ ID NO in ST25 sequence listing filed in parent U.S. App. No. 17/255,776 Description of Sequence Sequence: 5 CDR2 L2 - PRT WAS 11 CDR2 LC - DNA tgggccagc
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/054,457 US20230340091A1 (en) | 2018-06-27 | 2022-11-10 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690733P | 2018-06-27 | 2018-06-27 | |
PCT/IB2019/055461 WO2020003203A1 (en) | 2018-06-27 | 2019-06-27 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
US202017255776A | 2020-12-23 | 2020-12-23 | |
US18/054,457 US20230340091A1 (en) | 2018-06-27 | 2022-11-10 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/255,776 Continuation US11512125B2 (en) | 2018-06-27 | 2019-06-27 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
PCT/IB2019/055461 Continuation WO2020003203A1 (en) | 2018-06-27 | 2019-06-27 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230340091A1 true US20230340091A1 (en) | 2023-10-26 |
Family
ID=68985534
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/255,776 Active 2039-07-27 US11512125B2 (en) | 2018-06-27 | 2019-06-27 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
US18/054,457 Pending US20230340091A1 (en) | 2018-06-27 | 2022-11-10 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/255,776 Active 2039-07-27 US11512125B2 (en) | 2018-06-27 | 2019-06-27 | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Country Status (3)
Country | Link |
---|---|
US (2) | US11512125B2 (en) |
EP (1) | EP3814375A4 (en) |
WO (1) | WO2020003203A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
US11512125B2 (en) | 2018-06-27 | 2022-11-29 | Mor Research Applications | Antibodies for the treatment of synucleinopathies and neuroinflammation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2949666B1 (en) | 2008-12-19 | 2018-12-19 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
UA118441C2 (en) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US11512125B2 (en) | 2018-06-27 | 2022-11-29 | Mor Research Applications | Antibodies for the treatment of synucleinopathies and neuroinflammation |
-
2019
- 2019-06-27 US US17/255,776 patent/US11512125B2/en active Active
- 2019-06-27 EP EP19826024.2A patent/EP3814375A4/en active Pending
- 2019-06-27 WO PCT/IB2019/055461 patent/WO2020003203A1/en unknown
-
2022
- 2022-11-10 US US18/054,457 patent/US20230340091A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3814375A4 (en) | 2022-07-13 |
WO2020003203A1 (en) | 2020-01-02 |
EP3814375A1 (en) | 2021-05-05 |
US20210214429A1 (en) | 2021-07-15 |
US11512125B2 (en) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6999421B2 (en) | Anti-sortilin antibody and how to use it | |
JP2022081543A (en) | Anti-trem2 antibodies and methods of use thereof | |
US20230340091A1 (en) | Antibodies for the treatment of synucleinopathies and neuroinflammation | |
JP5930502B2 (en) | Methods of providing disease-specific binding molecules and targets | |
US20190345237A1 (en) | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor | |
JP5398545B2 (en) | Methods of providing disease-specific binding molecules and targets | |
JP2024009818A (en) | Anti-siglec-7 antibodies and methods for use thereof | |
US20190336598A1 (en) | Methods for modulating inflammasome activity and inflammation in the lung | |
CN111356701B (en) | Anti-alpha-synuclein antibodies and uses thereof | |
TW201739761A (en) | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof | |
EA020508B1 (en) | Sp35 ANTIBODIES AND USES THEREOF | |
JP2011527338A (en) | How to promote neurogenesis | |
TWI717848B (en) | Uses of antibody for treating neurodegenerative diseases | |
US20240309082A1 (en) | Compounds and methods targeting interleukin-34 | |
KR20110128273A (en) | Osteoarthritis treatment | |
JP7458049B2 (en) | Autoimmune disease treatment agent | |
TW202334210A (en) | Compounds and methods targeting interleukin-34 | |
TW202334212A (en) | Compounds and methods targeting interleukin-34 | |
TW202334211A (en) | Compounds and methods targeting interleukin-34 | |
WO2011105527A1 (en) | Nerve growth promoter | |
BR122024012949A2 (en) | ANTIBODIES TARGETING INTERLEUKIN-34, COMPOSITIONS COMPRISING THEM, USES THEREOF, COMBINATIONS, NUCLEIC ACIDS, VECTORS, CELLS, PROCESSES FOR PREPARING ANTIBODIES, AND METHOD FOR DETERMINING THE LEVEL OF HUMAN IL-34 IN A BODY FLUID |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MOR RESEARCH APPLICATIONS, ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FASSLER, MICHAEL;GEORGE, JACOB;REEL/FRAME:063166/0824 Effective date: 20210325 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MOR RESEARCH APPLICATIONS LTD., ISRAEL Free format text: CHANGE OF ADDRESS;ASSIGNOR:MOR RESEARCH APPLICATIONS LTD.;REEL/FRAME:065667/0333 Effective date: 20231019 |
|
AS | Assignment |
Owner name: MOR RESEARCH APPLICATIONS LTD., ISRAEL Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 63166 FRAME: 824. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:FASSLER, MICHAEL;GEORGE, JACOB;REEL/FRAME:067569/0576 Effective date: 20210325 |